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Papua New Guinea is known as “the land of the unexpected” or the land of “a million 
different journeys”, as advertised by the tourism promotion authorities. PNG, how the 
country is called by the locals, is also the land of a billion stories to be told. Rich in culture, 
in languages as well as in different people and landscapes, this country has more to offer 
than one can describe in a single book. The story to be told here focuses on tuberculosis, 
which is still one amongst the top killer diseases in Papua New Guinea. 
 

Contents  I 
Table of contents 
Tables and figures ........................................................................................................................................... V 
Abbreviations .................................................................................................................................................. VI 
Acknowledgements ................................................................................................................................... VIII 
Summary ........................................................................................................................................................... XI 
Zusammenfassung ..................................................................................................................................... XIV 
Sotpela toksave pepa belong sik Tubakolosis .............................................................................. XVIII 
1 Introduction ............................................................................................................................................. 2 
1.1 Mycobacterium tuberculosis ..................................................................................................... 2 
1.2 Burden of disease ........................................................................................................................... 3 
1.3 Tuberculosis - The disease ......................................................................................................... 5 
1.3.1 Transmission and immunology ....................................................................................... 5 
1.3.2 Symptoms ................................................................................................................................. 6 
1.4 Disease prevention and control................................................................................................ 7 
1.4.1 Prevention ................................................................................................................................ 7 
1.4.2 Control ....................................................................................................................................... 8 
1.5 Diagnosis and treatment ............................................................................................................. 9 
1.5.1 Diagnosis .................................................................................................................................. 9 
1.5.2 Treatment .............................................................................................................................. 11 
1.6 Drug resistance and second-line treatment ..................................................................... 13 
1.7 Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis . 17 
1.7.1 Genotyping of Mycobacterium tuberculosis .............................................................. 17 
1.7.2 Genotyping methods ......................................................................................................... 17 
1.7.3 Evolution of the Mycobacterium tuberculosis complex ........................................ 21 
1.7.4 The impact of the bacterial genotype on TB infection and disease ................ 25 
1.8 Tuberculosis and Papua New Guinea .................................................................................. 27 
1.8.1 The country........................................................................................................................... 27 
1.8.2 The people and their genetic background ................................................................ 28 
1.8.3 The health system .............................................................................................................. 29 
1.8.4 The tuberculosis burden in Papua New Guinea ..................................................... 31 
1.8.5 The National Tuberculosis Program of Papua New Guinea ............................... 33 
2 Tuberculosis in Papua New Guinea: from yesterday until today ..................................... 36 
2.1 Introduction .................................................................................................................................. 37 
2.2 History ............................................................................................................................................. 38 
II  Contents 
2.3 Epidemiology ................................................................................................................................ 39 
2.3.1 Disease distribution: prevalence and incidence ..................................................... 39 
2.3.2 HIV/TB co-infection and risk factors .......................................................................... 43 
2.3.3 Drug resistance ................................................................................................................... 44 
2.3.4 Mycobacterium tuberculosis genotypes ..................................................................... 45 
2.4 Tuberculosis control .................................................................................................................. 47 
2.4.1 Prevention ............................................................................................................................. 47 
2.4.2 Detection/Diagnosis.......................................................................................................... 48 
2.4.3 Treatment .............................................................................................................................. 50 
2.5 Conclusion...................................................................................................................................... 51 
3 Rationale, aims and objectives ....................................................................................................... 54 
3.1 Active case detection approach ............................................................................................. 54 
3.1.1 Rationale ................................................................................................................................ 54 
3.1.2 Aim ........................................................................................................................................... 54 
3.1.3 Objectives .............................................................................................................................. 54 
3.2 Passive case detection approach........................................................................................... 55 
3.2.1 Rationale ................................................................................................................................ 55 
3.2.2 Aim ........................................................................................................................................... 56 
3.2.3 Objectives .............................................................................................................................. 56 
4 Methods .................................................................................................................................................. 57 
4.1 Study sites ...................................................................................................................................... 57 
4.1.1 Active case detection in sentinel sites ........................................................................ 57 
4.1.2 Passive case detection in provincial hospitals ........................................................ 58 
4.1.3 Tuberculosis situation in the study areas ................................................................. 59 
4.2 Study design and sample collection ..................................................................................... 60 
4.2.1 Active case detection......................................................................................................... 60 
4.2.2 Passive case detection ...................................................................................................... 61 
4.3 Sample processing and diagnosis ......................................................................................... 64 
4.4 Genotyping of Mycobacterium tuberculosis ..................................................................... 66 
4.4.1 Drug resistance genotyping ........................................................................................... 66 
4.4.2 Mycobacterium tuberculosis strain genotyping ...................................................... 66 
4.4.3 Whole genome sequencing ............................................................................................. 67 
4.5 Quality assurance ........................................................................................................................ 68 
4.6 Database and data analysis ..................................................................................................... 69 
4.7 Ethics................................................................................................................................................ 69 
4.8 Research collaborators ............................................................................................................. 69 
Contents  III 
5 What role can active case detection play in the control of tuberculosis in Papua New 
Guinea? ............................................................................................................................................................. 72 
5.1 Abstract ........................................................................................................................................... 73 
5.2 Background ................................................................................................................................... 73 
5.3 Methods .......................................................................................................................................... 75 
5.3.1 Study sites ............................................................................................................................. 75 
5.3.2 Inclusion criteria and sample collection ................................................................... 76 
5.3.3 Diagnosis and sample processing ................................................................................ 77 
5.4 Results ............................................................................................................................................. 78 
5.4.1 Sausi, Usino Bundi District, Madang Province ........................................................ 78 
5.4.2 East-Cape, Alotau District, Milne Bay Province ...................................................... 80 
5.5 Discussion ...................................................................................................................................... 80 
5.6 Conclusion...................................................................................................................................... 82 
6 Diversity of Mycobacterium tuberculosis and drug resistance between different 
provinces of Papua New Guinea ............................................................................................................. 84 
6.1 Abstract ........................................................................................................................................... 85 
6.2 Introduction .................................................................................................................................. 85 
6.3 Results and discussion .............................................................................................................. 88 
6.3.1 Study population characteristics ................................................................................. 88 
6.3.2 Genotyping ............................................................................................................................ 89 
6.3.3 Drug resistance ................................................................................................................... 95 
6.4 Conclusions .................................................................................................................................101 
6.5 Methods ........................................................................................................................................102 
6.5.1 Study sites and patient characteristics ....................................................................102 
6.5.2 Sample processing and drug susceptibility testing .............................................102 
6.5.3 Genotyping of Mycobacterium tuberculosis ............................................................103 
6.5.4 Drug resistance genotyping .........................................................................................103 
6.5.5 Statistical analysis ............................................................................................................104 
6.5.6 Ethical approval ................................................................................................................104 
7 Additional data on the genetic background of Mycobacterium tuberculosis ..............105 
7.1 Subtyping of lineage 1 and lineage 4 samples ...............................................................105 
7.2 Phylogenies based on whole genome sequencing .......................................................106 
8 Individual-level predictors of smear positivity in people with chronic cough living in 
Goroka, Papua New Guinea.....................................................................................................................112 
9 Non-tuberculous Mycobacteria – baseline data from three sites in Papua New 
Guinea .............................................................................................................................................................116 
9.1 Abstract .........................................................................................................................................117 
9.2 Introduction ................................................................................................................................117 
IV  Contents 
9.3 Methods ........................................................................................................................................118 
9.4 Results ...........................................................................................................................................119 
9.5 Discussion ....................................................................................................................................119 
10 General discussion ........................................................................................................................124 
10.1 Drug resistance ......................................................................................................................124 
10.2 Mycobacterium tuberculosis strain diversity ............................................................126 
10.3 Clinical considerations .......................................................................................................129 
10.3.1 Risk factors .....................................................................................................................129 
10.3.2 Non-tuberculous Mycobacteria ..............................................................................130 
10.4 Methodological issues .........................................................................................................131 
10.4.1 Sample size development and culture recovery ..............................................131 
10.4.2 Study site setup .............................................................................................................135 
10.4.3 Transmission dynamics .............................................................................................135 
10.5 Implications ............................................................................................................................136 
10.5.1 Provincial level ..............................................................................................................136 
10.5.2 Regional/global level ..................................................................................................137 
10.6 Outlook .....................................................................................................................................137 
11 References ........................................................................................................................................142 
Appendix 1: Flow charts laboratory procedures ...........................................................................157 
Appendix 2: Laboratory SOPs ................................................................................................................160 
Appendix 3: Primer tables ......................................................................................................................169 
Appendix 4: Additional data ...................................................................................................................170 
Appendix 5: Complementary co-authored publications .............................................................172 
Curriculum vitae .........................................................................................................................................187 
Tables and figures  V 
Tables and figures 
Table 1.1: Anti tuberculosis drugs, their targets and their mode of action. ......................... 12 
Table 1.2: Most common mutations associated with drug resistance against TB 
treatment drugs ............................................................................................................................................ 16 
Table 2.1: Administrative History of Papua New Guinea ............................................................ 40 
Table 4.1: Contextual study site characteristics and TB burden estimates. ........................ 60 
Table 4.2: Enrolment and study set up in the different study sites of the passive case 
detection survey............................................................................................................................................ 63 
Table 5.1: Population characteristics of the screened population aged 15 years or older 
and the enrolled study patients with chronic cough ...................................................................... 79 
Table 6.1: Characteristics of study population for each study site. ......................................... 89 
Table 6.2: Univariate and multivariate logistic regressions for the risk of an infection 
with a Beijing strain of lineage 2. ........................................................................................................... 94 
Table 6.3: Observed phenotypic drug resistance per study site............................................... 96 
Table 6.4: Univariate and multivariate logistic regressions for the risk of drug 
resistance. ......................................................................................................................................................100 
Table 7.1: Lineage 1 and lineage 2 subtyping results .................................................................106 
Table 8.1: Univariate logistic regression to assess associations between patient 
characteristics, signs/symptoms with smear positivity .............................................................113 
Table 8.2: Logistic regressions for the analysis of associations of common risk factors 
with smear positivity ................................................................................................................................115 
 
Figure 1.1: Cell wall of Mycobacterium tuberculosis ....................................................................... 3 
Figure 1.2: Estimated global incidence rates, 2012 .......................................................................... 5 
Figure 1.3: Spoligotyping and the direct repeat locus of the Mycobacteria chromosome.
 ............................................................................................................................................................................. 19 
Figure 1.4: Evolutionary scenario of the Mycobacterium tuberculosis complex ................. 22 
Figure 1.5: Phylogeny of MTBC ............................................................................................................. 24 
Figure 1.6: Whole genome sequencing based phylogeny of MTBC ......................................... 25 
Figure 1.7: Map of Papua New Guinea including provincial borders and the countries 
geographical location. ................................................................................................................................. 28 
Figure 1.8: The current and the future health system structure of PNG. .............................. 31 
Figure 1.9: Photographs of tuberculosis awareness posters of the National TB Control 
Program ............................................................................................................................................................ 35 
Figure 4.1: Location of study sites in PNG. ........................................................................................ 57 
Figure 5.1: Map of Papua New Guinea ................................................................................................ 76 
Figure 6.1: Mycobacterium tuberculosis lineage composition for each study site. .......... 91 
Figure 6.2: Spoligotypes for the observed lineages ....................................................................... 92 
Figure 6.3:  Overview of genes/gene regions sequenced and mutations observed. ........ 99 
Figure 7.1: Maximum-likelihood topology of lineage 2 related strains (Beijing family).
 ...........................................................................................................................................................................109 
Figure 7.2: Maximum-likelihood topology of lineage 4 related strains (Latin American 
Mediterranean family)..............................................................................................................................110 
Figure 7.3: Maximum-likelihood topology of lineage 1 related strains. ..............................111 
Figure 10.1: Flow chart of sample collection for genotyping. .................................................133 
 
VI  Abbreviations 
Abbreviations 
ACD Active Case Detection 
AFB Acid Fast Bacilli 
ALO Alotau 
APH Alotau Provincial Hospital 
AUS Australia 
BCG Bacille Calmette-Guérin 
CI Confidence Interval 
CPHL Central Public Health Laboratory 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CXR Chest X-ray 
DNA Deoxyribonucleic acid 
dNTP deoxyribonucleoside triphosphate 
DOTS Directly Observed Treatment short-course Strategy 
DR Drug Resistance 
DST Drug Susceptibility Testing 
EMB Ethambutol 
ETH Ethionamide 
FDC Fixed Dose Combination 
GFATM The Global Fund to fight AIDS, Tuberculosis and Malaria 
GGH Goroka General Hospital 
GKA Goroka 
GTC Goroka TB Clinic 
HIV Human Immunodeficiency Virus 
HLA Human Leukocyte Antigen 
IMR Institute of Medical Research 
INH Isoniazid 
IQR Inter Quartile Range 
LAM Latin American Mediterranean 
LSP Large Sequence Polymorphisms 
MAG Madang 
MAP Madang Province 
MBP Milne Bay Province 
MDR Multi Drug Resistance 
MGH Modilon General Hospital 
MGIT Mycobacterium Growth Indicator Tube 
MIRU Mycobacterial Interspersed Repetitive Units 
Mtb Mycobacterium tuberculosis 
MTBC Mycobacterium tuberculosis Complex 
NDoH National Department of Health 
NTM Non-tuberculous mycobacteria 
NTP National Tuberculosis Control Program 
OR Odds Ratio 
Abbreviations  VII 
PAS Para-Amino-Salicylic Acid 
PCD Passive Case Detection 
PCR Polymerase Chain Reaction  
PGG Principle Genetic Group 
PMGH Port Moresby General Hospital 
PNG Papua New Guinea 
PPD Purified Protein Derivate 
PZA Pyrazinamide 
QMRL Queensland Mycobacterium Reference Laboratory 
RD Region of Difference 
RFLP Restriction Fragment Length Polymorphism 
RMP Rifampicin 
RRDR Rifampin Resistance Determining Region 
SIT Shared International Type 
SNP Single Nucleotide Polymorphisms 
STR Streptomycin 
Swiss TPH Swiss Tropical and Public Health Institute 
TB Tuberculosis 
TST Tuberculin Skin Test 
VNTR Variable Number of Tandem Repeats 
WGS Whole Genome Sequencing 
WHO World Health Organisation 
XDR Extensively Drug Resistant 
ZN Ziehl Neelson 
 
VIII  Acknowledgements 
Acknowledgements 
I am greatly indebted to a number of people without whom this work would not have 
been possible. First and foremost I would like to thank my main supervisor Prof. Hans-
Peter Beck. Through his and Ingrid Felger’s support during my work as a scientific 
associate in 2006/2007 I gained the confidence to start my PhD. I am very grateful to 
Hans-Peter for giving me the opportunity to conduct this interesting work, for his great 
scientific and personal support, for interesting discussions that kept me looking beyond 
my own nose, and for his friendship. I am also indebted to Prof. Sébastien Gagneux for 
warmly welcoming me into his group, for the great support and the valuable inputs for 
my work. I very much appreciated the scientific discussions during the lab meetings and 
journal clubs through which I learned a lot about TB.  I would also like to thank Prof. 
Peter Siba for welcoming me as a member of the PNG IMR family and for supporting me 
throughout the study. Right at the beginning of my PhD Prof. Marcel Tanner facilitated 
and financed my attendance at a conference, where I could establish contacts to other 
TB scientists around the globe. I wish to thank him for his support and for his 
enthusiastic spirit that is so encouraging and makes Swiss TPH a very welcoming place 
with an inspiring atmosphere. One of the contacts I made during that conference was 
Prof. Thomas Dick. I would like to thank him for becoming part of my thesis committee 
and supporting me. Special thanks also to Dr. Ian Riley for sharing all the great stories, 
for his valuable inputs and for having inspiring discussions. Thank you!  
 
During my time in Papua New Guinea I met a lot of great people who made my stay 
enjoyable and unforgettable. Thanks to everybody who supported me in one way or the 
other. I would like to thank the communities of Sausi, East-Cape, Goroka, Alotau and 
Madang for participating in our studies! Tenkyu tru! I would also like to thank the health 
authorities from Eastern Highlands, Milne Bay and Madang for their approval and for 
establishing contact to health facilities. Thanks also to World Vision Goroka for helping 
us with patient follow up. Many thanks to the staff of Sausi H/C, East-Cape H/C, Gurney 
H/C, Goroka General Hospital, the Goroka TB clinic, Alotau Provincial Hospital and 
Modilon General Hospital; our studies would not have been possible without their 
support. Many thanks go to Dr. Kilagi Vanuga and Dr. Ruben Kamus for patient 
Acknowledgements  IX 
management and for clinical assistance. Special thanks to Patrick Vahin for allowing us 
to use the hospital lab for our work, and to Christopher Mokavelaga for the great 
collaboration. Great thanks also to Dr. Evelyn Lavu from CPHL for supporting us with 
microscopy training and in various other occasions. 
I would like to express my gratitude to the TB study teams and all other PNG IMR staff 
who supported us. I received great support from Dr. Suparat Phuanukoonnon, who 
kindly welcomed me into the TB team and assisted me in many ways. Many thanks also 
to Dr. Paul Harino who managed the TB lab in Madang and took care of the clinical 
management of the study patients from that study site. I am indebted to Kua Ulka, John 
Forova, Agnes Agi, Korai Millan, Beverlyn Warigi and Adam Bill, for conducting patient 
interviews, sample collection and sample processing in Goroka, Alotau and Madang. 
Thanks to the Bacto and STI team members Dr. Andrew Greenhill, Mition Yoannes, 
Mama Audrey, Carlton Guwada, Mathew David and Pamela Toliman for their assistance 
in various aspects of our TB work. Many thanks to the MalCon team for the constant 
assistance and support. Susan Paul, Amelia Koata, Lydia Petrus, Leonard Vavana, Birunu 
Nivio, Albert Sie, John Samatoe, Nelson Koata, Samson Gene and Henry Kote conducted 
sample collection and study interviews during our active case detection surveys and 
made me feel comfortable during our field work trips. Thank you so much! I will also 
never forget the great time I had with Korai Millan and Livingston Tavul when we 
shared an apartment in Alotau for a while. Thanks for looking after me. I would also like 
to thank George Koki for his support in many occasions, including translations of patient 
consent forms into tok pisin. Special thanks to him, Lilah Tol, Debbie Kisa and Lincoln 
Timinao for the tok pisin translation of the summary of this thesis. Many thanks also to 
Elsie Billam for the help with data entry.  
 
I also wish to thank the QMRL staff for culturing and DST, and for all the valuable inputs 
on sample processing and microscopy. Special thanks to Robyn Carter, Dr. Sushil Pandey 
and Dr. Christopher Coulter for the collaboration and all the support.  
 
During my time in Basel I appreciated being part of the MolPar group and to connect 
with the MolDia group. I always felt welcome and enjoyed the great scientific and 
personal discussions we had in many occasions. Thank you! Special thanks go to Marie 
Ballif, Natalie Hofmann, Maira Bholla and Oliver Dietz. As my predecessor, Marie paved 
X  Acknowledgements 
the way for my work and encouraged me with her interest and support. I thank her for 
sharing experiences and investing time to assist me, I really appreciated that. Many 
thanks also to Natalie for her constant smile, encouragement and friendship. Oli and 
Maira were “at the final stage of the PhD-buddies”, thanks so much for your support!  
I received great support from the TB unit and associated team members at Swiss TPH. I 
wish to thank all of them for always having an open door and ear for me, for supporting 
me in the lab and by answering my questions. I enjoyed the great scientific discussions 
and just having a good time. Thank you so much! I am indebted to Julia Feldmann for 
doing all the BSL 3 work for me, for introducing me to the genotyping methods and for 
being a friend. Many thanks also to Damien Portevin for assistance and inspiring 
discussions, David Stucki and Daniela Brites for their support with WGS, for the 
phylogenies and for providing valuable inputs to my work. I thank them for their time 
and patience in so many occasions. I am grateful to Liliana Rutaihwa for many scientific 
discussions and for being a wonderful friend. Thank you! 
 
I am grateful to all the support staff at Swiss TPH. Special thanks to Dr. Christian 
Schindler for statistical support, to Christine Walliser and Susi Gyoerffy for their help in 
many occasions, to Kurt Walliser for making our office greener and let it snow inside the 
building. Many thanks to everybody else at Swiss TPH for being valuable friends and 
colleagues and for contributing to the great time I had at the institute.  
 
Last but not least I want to deeply thank my family and friends for their constant 
support! Special thanks to my dear parents, to my siblings Nadeshna, Jonas and Tobias, 
to Ruth and Lukas for the continuous encouragement and for accepting that we were 
away for four years. And most of all, my deepest thanks to Manuel for always being at 
my side, for the scientific inputs and assistance, for the endless support, patience and 
encouragement and for always believing in me! Thank you so much! With the help of all 
of you I successfully completed my thesis. Thank you!  
 
Financial support 
This work has received financial support from the Stanley Thomas Johnson Foundation and the 
Medicor Foundation, Lichtenstein. The Swiss Society of Tropical Medicine and Parasitology and the 
Basler Stiftung für Experimentelle Zoologie provided financial support to attend conferences.
Summary  XI 
Summary 
With an estimated one third of the global population being infected with latent 
tuberculosis (TB) and 8.6 million people developing active TB in 2012, this infectious 
disease remains a major global health concern. Increasing drug resistance (DR) and the 
HIV pandemic are further challenges to the control of the disease.  
Mycobacterium tuberculosis (Mtb) is responsible for most of the TB cases in humans. For 
a long time it was thought that only environmental factors and the host immune status 
are the driving forces of TB transmission. Recently, evidence of the influence of the 
bacterial genetic background on transmission and disease outcome is increasing. Clinical 
samples from around the globe are required to further analyse the impact of the 
complex interactions of drug resistance, bacterial and host genetics, as well as 
environmental and social factors on TB epidemiology and individual patient 
management. 
 
Even though Papua New Guinea (PNG) is one of the high TB burden countries in the 
South Pacific, not much data on the local epidemiology of TB exists. Apart from the 
urgent need to fill such evidence gaps, the country also provides an interesting platform 
for TB research, considering its population genetic diversity and its isolation in the past. 
The presented project aimed at providing baseline data about the molecular 
epidemiology of tuberculosis from specific sites in PNG, including drug resistance and 
the population structure of Mtb. 
 
Between July and December 2010, active TB case detection surveys were conducted in 
the catchment area of two health centres in PNG: around Sausi health centre in Madang 
Province and around East-Cape health centre in Milne Bay Province. Each household in 
the catchment area was screened for people with chronic productive cough aged 15 
years and above. Of household members with chronic productive cough not having 
received TB treatment yet, three sputum samples were collected. Subsequently, samples 
were analysed by light microscopy to diagnose pulmonary TB by detecting the presence 
of acid fast bacilli. Around Sausi, 24 so far undetected pulmonary TB cases were 
identified, whereas in East-Cape only one additional case was found, reflecting the 
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differences in the performance of the control program between different sites in PNG. 
Active case detection as a complementary case detection approach turned out to be a 
useful tool to increase the case detection rate in certain areas, but appeared unsuitable 
to investigate the prevalence of drug resistance and the genetic background of Mtb. 
However, operational limitations did not allow obtaining better estimates on the real 
burden of TB in the country in the frame of our study.   
 
From November 2010 to July 2012, passive case detection was conducted in three 
provincial hospitals of PNG: Modilon General Hospital in Madang Province, Goroka 
General Hospital in Eastern Highlands Province and Alotau Provincial Hospital in Milne 
Bay Province. Three sputum samples were collected from TB suspects aged 15 years and 
above and subsequently analysed by light and fluorescent microscopy. Furthermore, the 
level of drug resistance as well as the genetic background of M. tuberculosis strains was 
determined and findings compared between sites. Of 225 passive case detection samples 
grown in culture, 212 samples could successfully be tested for drug susceptibility. 
Overall, 10.8% (23/212) strains were found to be resistant to at least one of the first-
line drugs streptomycin, rifampicin, isoniazid, pyrazinamide or ethambutol. Differences 
between study sites in any type of DR were marginal and ranged from 10% to 12%. 
Multi-drug resistant (MDR) TB was found in 2.8% (6/212) of cases, the highest 
percentage of MDR TB being found in Alotau (4.6% compared to 2.2% in Madang and 
1.8% in Goroka). These results show a significant amount of DR TB being present in all 
three sites investigated. It is therefore crucial to make diagnosis of DR TB and second-
line treatment more widely available in the country to decrease the delay of diagnosing 
DR TB as well as the duration of possible transmission and to avoid further DR 
development.  
 
Genotyping of Mtb could successfully be conducted of 147 samples. These strains could 
be classified into three of the so far seven known lineages of Mtb: 75/147 (51.0%) of 
samples belonged to lineage 4 (European-American lineage), 67/147 (45.6%) to lineage 
2 (East-Asian lineage) and 5/147 (3.4%) to lineage 1 (Indo-Oceanic lineage). All three 
lineages were detected in all three sites, but the individual lineage compositions varied 
significantly between sites (p<0.001). In Madang, lineage 4 was the most prevalent 
(76.6%), whereas in Alotau lineage 2 was dominant (84.4%). In Goroka, a trend towards 
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a higher prevalence of lineage 2 (60.5%) was found, but the difference between lineage 
2 and lineage 4 was not statistically significant and not as high as in Alotau. Lineage 1 
was generally only rarely found (5/147). The overall lineage composition found in PNG 
is similar to what can be observed globally: modern lineages (e.g. lineages 2 and 4) have 
more successfully spread around the globe and are more prevalent than ancient lineages 
(e.g. lineage 1). Further molecular subtyping by large sequence polymorphisms, 
Luminex based SNP-typing and whole genome sequencing revealed that a single 
introduction of lineage 2 into PNG with a subsequent clonal expansion is most probable, 
whereas for lineages 4 and 1, several introductions are likely. All three lineages appear 
to have undergone, to a certain degree, PNG-specific evolution. 
 
The present study is the first directly comparing DR and Mtb genotyping data between 
different sites of PNG, discovering the presence of significant differences in DR 
prevalence and Mtb lineages. However, the reason for these observed differences has yet 
to be determined.  The questions about how and from where TB was introduced into 
PNG in the first place, and about details on transmission dynamics of TB remain to be 
answered. 
 
Besides Mtb, also non-tuberculous mycobacteria (NTM) could be detected in a few 
sputum samples of study patients. NTM were detected in 4% (9/225) of sputum samples 
grown in culture. Five of these turned out to be samples containing NTM only, the 
detected species being Mycobacterium fortuitum, Mycobacterium terrae and 
Mycobacterium intracellulare. Four isolates contained both, Mtb and Mycobacterium 
avium or Mtb and Mycobacterium intracellulare, respectively. To our knowledge this is 
the first study describing the presence of NTM in PNG. 
 
A key component of the National TB Program should be the detection and continuous 
monitoring of DR TB to stop transmission. Our data emphasizes the need of a GeneXpert 
system for DR diagnosis and monitoring in each province of PNG. Priority should be 
given to those provinces with an increased proportion of DR TB such as Milne Bay 
Province. In addition, an in-country capacity to perform TB culturing and DST is urgently 
required. Implementing both recommendations could assist in achieving a reduction of 
time to diagnosis of DR TB and consequently decrease the risk of MDR TB transmission. 
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Zusammenfassung 
Nach Schätzungen der Weltgesundheitsorganisation ist ein Drittel der Weltbevölkerung 
mit latenter Tuberkulose (TB) infiziert und 8.6 Millionen Menschen sind in 2012 an 
klinisch aktiver Tuberkulose erkrankt. Damit stellt diese ansteckende Krankheit noch 
immer ein grosses Problem der öffentlichen Gesundheit dar. Zusätzlich erschweren die 
steigende Anzahl medikamentenresistenter Fälle und die HIV Pandemie die 
Bemühungen die Krankheit unter Kontrolle zu bringen.  
 
Die Tuberkulose im Menschen wird meistens vom Bakterium der Spezies 
Mycobacterium tuberculosis (Mtb) verursacht. Erst vor Kurzem wurde erkannt, dass 
neben Umweltfaktoren und dem menschlichen Immunsystem auch der genetische 
Hintergrund der Bakterien einen Einfluss auf die Übertragung und auf die Entwicklung 
der Krankheit hat. Weltweit gesammelte klinische Proben sind von grosser Bedeutung 
für die Erforschung der komplexen Zusammenhänge zwischen der 
Medikamentenresistenz, den genetischen Faktoren sowohl der Bakterien als auch des 
Menschen, der Umwelt- und sozialen Faktoren und deren Einfluss auf die Epidemiologie 
der Tuberkulose. 
 
Papua Neuguinea (PNG) gehört zu den Ländern im Südpazifik mit einer hohen 
Tuberkuloserate. Trotzdem sind kaum Daten zur Epidemiologie der Krankheit in diesem 
Land vorhanden. Abgesehen davon, dass diese Datenlücke dringend gefüllt werden 
muss, bietet PNG durch seine enorme Populations-Diversität und die lange Isolation in 
der Vergangenheit eine vielseitige Forschungsplattform. Das Ziel des hier präsentierten 
Projekts war es, Grundlagenforschung zur molekularen Epidemiologie der Tuberkulose 
in definierten Studiengebieten zu betreiben, mit den Schwerpunkten 
Medikamentenresistenz und Populationsstruktur von Mtb.  
 
Zwischen Juli und Dezember 2010 wurde im Rahmen einer Studie im Einzugsgebiet von 
zwei Gesundheitszentren aktiv nach Tuberkulosefällen gesucht. Bei den beiden 
Gesundheitszentren handelte es sich um das Gesundheitszentrum in Sausi in der 
Madang Provinz und um das in East-Cape in der Milne Bay Provinz. In den betreffenden 
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Gebieten wurden die Bewohner jedes Haushaltes im Alter von 15 Jahren oder älter über 
chronische Hustenleiden mit Auswurf befragt. Von Patient mit einem solchen Leiden 
wurden daraufhin drei Auswurf Proben gesammelt. Die Diagnose von 
Lungentuberkulose wurde mittels Lichtmikroskopie durchgeführt, bei der die Präsenz 
von säurefesten Stäbchenbakterien im Auswurf nachgewiesen wird. Im Einzugsgebiet 
des Sausi Gesundheitszentrum wurden so 24 Tuberkulosefälle entdeckt, im 
Einzugsgebiet des East-Cape Gesundheitszentrum jedoch nur ein einziger Fall. Diese 
Zahlen wiederspiegeln die Unterschiede in der Durchführung des nationalen 
Tuberkulose-Kontrollprogramms in verschiedenen Gebieten von Papua Neuguinea.  
 
Die Strategie neben passivem Detektieren auch noch aktiv nach Fällen zu suchen stellte 
sich als sehr nützlich für die Erhöhung der Falldetektionsrate heraus, war aber 
ungeeignet für die Untersuchung von Medikamentenresistenz und des genetischen 
Hintergrunds  von Mtb.  Leider war es durch finanzielle Einschränkungen nicht möglich 
im Rahmen dieser Studie eine bessere Einschätzung der eigentlichen 
Tuberkulosesituation des Landes zu erhalten.  
 
Von November 2010 bis Juli 2012 wurde eine Studie zur passiven Falldetektion an drei 
Provinz-Krankenhäusern in PNG durchgeführt: am Modilon General Hospital in der 
Madang Provinz, am Goroka General Hospital in der Eastern Highlands Provinz und am 
Alotau Provincial Hospital in der Milne Bay Provinz. Drei Auswurf Proben wurden von 
jedem Tuberkulose-Verdachtsfall im Alter von 15 Jahren oder älter gesammelt und 
anschliessend mittels Lichtmikroskopie und Fluoreszenzmikroskopie untersucht. Des 
Weiteren wurden die Medikamentenresistenz und der genetische Hintergrund der 
isolierten Mtb Stämme analysiert und die Resultate der drei Studiengebiete miteinander 
verglichen.  
 
Von 225 Proben die durch passive Falldetektion gesammelt worden und in Kultur 
gewachsen sind, konnten 212 Proben erfolgreich auf Medikamentenresistenz getestet 
werden. Total waren 10.8% (23/212) resistent gegen mindestens eines der 
untersuchten anti-Tuberkulose Medikamente Streptomycin, Rifampicin, Isoniazid, 
Pyrazinamid oder Ethambutol.  Die Unterschiede der allgemeinen Tuberkulose-
Medikamentenresistenz zwischen den Studiengebieten waren gering und lagen 
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zwischen 10% und 12%. Multiresistente Tuberkulose wurde in 2.8% (6/212) der Fälle 
entdeckt, der höchste Anteil davon in Alotau (4.6% verglichen mit 2.2% in Madang und 
1.8% in Goroka). Diese Resultate beweisen, dass es in allen drei untersuchten Gebieten 
medikamentenresistente Tuberkulose gibt. Um solche Fälle frühzeitig zu erkennen und 
die mögliche Verbreitung einzudämmen, ist es äusserst wichtig die Diagnose resistenter 
Tuberkulose und wirksame Medikamente dagegen im ganzen Land besser zugänglich zu 
machen.   
 
Die Mykobakterien von 147 Proben konnten erfolgreich genotypisiert werden. Diese 
Stämme konnten in drei der sieben Hauptabstammungslinien klassifiziert werden:  
75/147 (51.0%) der Stämme gehörten zur Linie 4 (Europäisch-Amerikanische Linie), 
67/147 (45.6%) zur Linie 2 (Ost-Asiatische Linie) und 5/147 (3.4%) zur Linie 1 (Indo-
Ozeanische Linie). Alle drei Linien wurden in allen drei Studiengebieten gefunden, 
allerdings in signifikant unterschiedlichen Verhältnissen (p<0.001). In Madang war Linie 
4 die meist vorhandene Linie (76.6%), in Alotau jedoch Linie 2 (84.4%). In Goroka 
konnte ebenfalls ein Trend zu einer höheren Präsenz der Linie 2 (60.5%) festgestellt 
werden,  allerdings war der Unterschied zwischen Linie 2 und 4 deutlich geringer als in 
Alotau und nicht statistisch signifikant. Stämme der Linie 1 wurden allgemein selten 
gefunden (5/147).  Im Ganzen gleicht die Zusammensetzung der Abstammungslinien 
der Zusammensetzung die auch global beobachtet wird: sogenannte moderne Linien 
(zum Beispiel Linien 2 und 4) konnten sich erfolgreicher verbreiten und sind global 
stärker vertreten als die älteren Linien (zum Beispiel Linie 1). Mittels molekularer 
Subtypisierung basierend auf sogenannten large sequence polymorphisms, SNPs und 
durch Genom Sequenzierung konnte festgestellt werden, dass Linie 2 wahrscheinlich ein 
einziges Mal nach PNG gebracht worden war und sich danach klonal ausgebreitet hat. 
Für Linie 4 und Linie 1 sind mehrere Einführung allerdings wahrscheinlicher. Alle drei 
Linien scheinen einen gewissen Grad an PNG-spezifischer Evolution durchgemacht zu 
haben. Die hier beschriebene Studie ist die erste die Medikamentenresistenz und Mtb-
Genotypisierungsdaten zwischen mehreren Gebieten in PNG direkt vergleicht und 
signifikante Unterschiede darin aufzeigt. Die Gründe für diese Unterschiede müssen 
jedoch erst noch ermittelt werden. Die Fragen über das Wie und das Woher von TB in 
PNG und Fragen zur Übertragungsdynamik der Krankheit bleiben unbeantwortet.  
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In 4% (9/225) der Proben die in Kultur gewachsen sind, wurden neben Mtb auch nicht-
tuberkulöse Mykobakterien (NTM) gefunden. Fünf dieser Proben enthielten nur NTM, 
gehörend zu den Spezies Mycobacterium fortuitum, Mycobacterium terrae und 
Mycobacterium intracellulare. Vier weitere Proben enthielten sowohl Mtb wie auch M. 
avium oder M. intracellulare. Unseres Wissens ist dies die erste Studie die die Existenz 
von NTM in PNG beschreibt.  
 
Die kontinuierliche Detektion und die Beobachtung von Medikamentenresistenz sollte 
eine Schlüsselkomponente des nationalen TB Kontrollprogramms sein. Nur so kann 
deren Übertragung gestoppt werden.  Unsere Daten betonen die Notwendigkeit eines 
GeneXpert Systems für die Diagnose und die Beobachtung von Medikamentenresistenz 
in jeder Provinz von PNG. Priorität sollte denjenigen Provinzen zukommen, die eine 
erhöhte Proportion an resistenter TB aufweisen, wie zum Beispiel Milne Bay Provinz. 
Zusätzlich ist ein Labor für die Kultivierung von Mtb innerhalb des Landes unabdingbar. 
Die Einführung beider Empfehlungen würde dabei helfen Medikamentenresistenzen 
früh zu erkennen und folglich auch dabei deren Übertragung zu verringern.  
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Sotpela toksave pepa belong sik Tubakolosis  
Long yia tu tausen na tuelf (2012) klostu tu billion pipal long wanwan hap long dispel 
graun oli gat sik TB, tasol oli no soim olosem oli gat dispel sik, na tu klostu naen million 
pipal oli bin kisim sik wantaem sik TB. Dispela sik i kimapim bikpela hasua o wari long 
helt bilong planti manmeri long planti hap long dispela graun. Namba bilong ol laen we 
oli save kisim marasin bilong sik TB na ino wok long bodi bilong ol i wok long go antap 
tru na tu sik HIV i wok long strong tu. Hastave na i had long kontrolim dispela sik TB. 
Binatang Maikobektiriam tubakolosis o (Mtb) i as bilong klostu olgeta sik TB we isave 
kamapim sik long ol manmeri na ol pikinini tu. Longpela taim nau tingting olsem 
samting bilong dispel graun tasol na samting we pasin bilong em i strong em oli save 
mekim sik TB i kalap igo ikam. Wok painim aut long wanem binatang na husat ol lain oli 
ken kisim sik TB na spredim na wanem samting iken kamap i wok long kamap strong 
nau. Ol stadi long ol sampal oli save kisim long ol TB klinik long olgeta hap long dispela 
graun ol dokta na saintis bai oli galasim long kisim save long hau marasin bilong sik TB 
ino save wok long planti long ol sik manmeri. 
Papua Niu Gini o (PNG) em wanpela bilong ol kauntri long Saut Pasipik we hevi bilong 
sik TB i antap tru, tasol inogat planti ol gutpela rekod long ol kainkain binatang oli save 
kamapim sik TB istap. PNG em wanpela intaresting peles long wokim wok painim aut 
long sik TB becos kauntri i pulap long ol kainkain as peles manmeri, kalsa, pasin, 
tokpeles na bilip na tu becos ol manmeri bilong taim bilong tumbuna oli no bin save go 
long we, o marit longwe long peles oli bin karim ol long en o banis bilong ol. Oli bin save 
poret long birua, posin na tambaran. Wok bilong nau em bilong kamapim sampela save 
long pasin bilong dispela binatang bilong TB oli kolim Maikobetiriam tubakolosis long ol 
hap oli makim pinis long PNG. 
Namel long mun Julai na Disemba long yia 2010 strongpela wok painim aut long sik TB 
oli bin wokim insait long tupela hap we tupela helt senta istap klostu long en insait long 
PNG: harere long Sausi helt senta insait long Madang Provins na klostu long Est – Kep 
helt senta insait long Milnibei Provins. Ol manmeri krismas bilong ol olsem wanpela ten 
paip (15) na antap insait long wanwan haus insait long hauslain klostu long helt senta 
we oli bin gat strong pela kus na spet long longpela taim oli bin testim ol. Ol manmeri 
long wanwan haus silip we oli bin gat kus long planti mun, ol wokman i bin kisim tripela 
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spet sampal na oli galasim ol dispela spet sampal long galas oli kolim long maikraskop 
long traim painim wanpela strongpela TB binatang oli kolim asid fast basilai we isave 
kamapim palmonari TB. Insait long Sausi, tupela ten po (24) manmeri we bipo oli no 
paim olosem oli gat palmonari TB, taim oli testim ol, oli painim olsem oli bin gat dispel 
palmonari TB. Long Est-kep oli bin painim wanpela (1) tasol. Emi soim olsem olgeta 
samting ino wankain long ol narapela hap insait long PNG. Wei oli usim long painim sik 
TB emi nambawan tru na bai oli usim gen long sampela hap insait long kauntri. Tasol 
emi hat yet long kisim mak bilong hevi bilong TB insait long kauntri na tu long painim 
hevi long TB marasin we ino save daonim sik na wok strong bilong binatang Mtb. 
Long mun Novemba long yia 2010 igo long mun Julai 2012, painim aut bilong sik TB oli 
bin wokim long tripela provinsal haus sik insait long PNG: Modilon Genaral Haus Sik 
long Madang Provins, Goroka Genaral Haus Sik insait long Esten Hailans Provins na 
Alotau Provinsal Haus Sik insait yet long Milni Bei Provins. Tripela spet sampal oli bin 
kisim long ol lain oli bin tingting strong olsem oli gat TB. Em long ol laen, krismas 
wanpela ten paip (15) yia na igo antap mo. Oli galasim ol dispela spet long maikraskop 
na oli painim olsem mak bilong marasin ino wok na sitorong bilong M. tubakolosis oli 
painim na oli bungim ol risal wantaim na sikelim namel long ol dispela ol narapela hap. 
Tu handret na tupela ten paip (225) sampal oli bin groim long laboratri, tu handret na 
ten tu (212) sampal oli bin inap long testim long painimaut sapos marasin igat strong 
long kilim binatang bilong TB. 10.8 pesen (10.8%) o tupela ten tri aut long tu handret na 
ten tu (23/212) ol kain binatang isave kamapim TB oli painim olsem ol marasin olsem 
streptomaisin, rifampisin, isonaisid na pairasinamaid oretambutol bai oli nonap strong 
long daonim ol dispela binatang bilong TB. Taem ol dispela marasin ino inap long 
daonim sik TB, oli kolim dispela TB olsem multi drug resistant TB o MDR. Long ol 
manmeri we oli bin stadim ol, oli painim olsem klostu tri pesen (2.8%) o six pela lain aut 
long tu handret na tentu (6/212) oli bin gat multi drug resistant TB (MDR)TB. Lukluk 
namel long ol stadi heria ino bin wan kain. Namba bilong drug resistant TB i bin stap 
namel long ten (10) na tualf pesen (12%), tasol namba bilong MDR TB long Alotau i bin 
sut igo atap tru, klostu long paip pesen 4.6%) we long Madang namba i bin tu 
pesen(2.2%), na Goroka i bin go daon long wan poin heit pesen (1.8%). Dispela ol 
kandim o resalt  emi soim olsem igat planti moa Drug resistant TB o DR TB istap long 
dispela tripela hap oli bin painim aut long en.Olsem na emi gutpela long mekim wok 
painim aut long DR TB na namba tu hap long tritmen long olgeta hap insait long kauntri 
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long daonim isisi ol wok painim aut long DR TB, na tu taime we sik i ken kalap igo long 
narapela manmeri na long havirisim kamap mo long DR. 
Strongpela pasin wok long lukluk igo insait long binatang bilong MTB iken win sapos oli 
karim wok igo insait long wan hundred na popela tenseven (147) grup bilong binatang 
bilong TB. Yumi ken sikelim ol dispela grup igo long tripela bilong ol sevenpela grup 
bilong binatang bilong MTB yumi save pinis long en: lain 4, (em ol waitsikin belong 
Amerika) laen 2 (em ol lain belong Est Asia) na laen 1 (em  ol lain wan solwara wantaim 
PNG. Ol dispela tripela laen MTB oli bin painim long Goroka, Madang na Alotau. Tasol 
wanwan hap laen ino bin wankain namel long ol peles. Long Madang, laen 4 i bin klostu 
long heiti pesen(76.6%), tasol laen 2 i bin kam strong turu long Alotau (84.4%).Na insait 
long Goroka laen 2 i bin planti turu(60.5%), tasol lukluk namel long laen 2 na laen 4 long 
insait long dispela hap ino bin go antap tumas. Laen 1 ino save kamap tumas. Taim oli 
bin galasim wan handret na po pela ten seven sampal oli bin lukim olsem paip pela tasol 
i bin gat laen wan (5/147). Antap long olgeta kain kain laen oli painim long PNG emi wan 
kain tu oli save lukim long ol narapela hap long dispela graun: ol niupela laen (olsem 
laen 2 na laen 4 ikamap gut mo long olgeta hap long dispela graun na i pulap mo long ol 
laen bilong bipo bipo turu (kain olsem laen 1). Natu sampela galasim wok i bin soim 
olsem ating laen 2 em wanpis i kam kamap long PNG na bihain emi bin go nabaut, lukluk 
long laen 4 na 1 i soim olsem tupela i bin kam kamap wan o tu o planti taim. Ologeta 
tiripela laen ya i soim olsem oli bin go tru bikpela senis long sampela kain mak, we i 
soim olsem oli bin kamap long taim bipo bipo an ino nau tasol. 
Dispela stadi em fest pela stadi long lukluk steret namel long binatang bilong TB isave 
kamapim banis long marasin na ol save bilong ol liklik famili bilong binatang bilong TB 
long ol wanwan ples bilong wok painim long PNG, na i soim olsem igat planti kaen laen 
insait long banis long marasin na liklik ol famili bilong TB binatang istap. Tasol as bilong 
ol dispela ino wan kain lukluk i mas gat ansa, na askim nau em olsem wanem, na TB i bin 
kam long wanem hap turu na i kam kamap long PNG long pestaim turu, na tu long save 
bilong kalap igo ikam bilong TB. Dispela ol askim emi mas gat ol ansa. 
Wanpela moTB binatang i stap paswantaim binatang bilong mtb em oli kolim non-
tuberculous mycobacteria (NTM) dispela TB binatang em oli nap painim long ol spet 
sampal bilong ol sik lain we oli bin stap long stadi. NTM oli bin painim insait long (4%) o 
long naen pela spet sampal aut long tu handret na tupela ten paip (9/225) oli bin wok 
long en long laboratori. Paip pela oli painim aut olsem ol sampal igat NTM TB binatang 
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tasol. Oli painim olsem ol TB binatang ikam long famili bilong Mycobacterium fortuitum, 
Mycobacterium terrae na Mycobacterium intracellulare. Po pela sampal i bin gat Mtb na 
Mycobacterium avium or Mtb na Mycobacterium intracellulare bung wantaim. Long save 
bilong mipela dispela stadi emi pes pela stadi long diskraibim stap bilong NTM insait 
long PNG. 
Ki wok pasin ol lain long Nasanal TB program oli mas wokim em long painim aut na 
kontiniu long lukluk klostu long DR TB long stopim binatang long kalap igo ikam long ol 
manmeri. Long ol as panim aut mipela i toktok or soim pinis antap, Alotau em i antap mo 
long namba bilong MDR TB taim oli makim wantaim ol narapela provins oli bin wokim 
painim aut wok long en. Mipela i tok strong long saplaim Alotau Provinsal Haus Sik long 
wanpela masin bilong ol yet long galasim ol binatang bilong TB. Na tu long strongim ol 
wok manmeri insait long kantri long wok grovim TB na DST insait long ol laboratori. 
Dispela wok i mas kamap hariap. Stat long wok long dispela tupela bikpela toktok em 
iken halivim long sotim taim long luksave long DR TB na tu bainap long daonim pasin 
bilong MDR TB long kalap namel igo ikam long ol manmeri.   
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1 Introduction 
1.1 Mycobacterium tuberculosis 
Mycobacterium tuberculosis (M. tuberculosis), first discovered by Robert Koch in 1882, is 
a rod-shaped, aerobic, immobile bacterium belonging to the family of Mycobacteriaceae.  
M. tuberculosis is a member of the Mycobacterium tuberculosis complex (MTBC), formed 
by several mycobacterial species which are the causing agents of tuberculosis (TB) in a 
variety of hosts: M. tuberculosis, M. africanum, M. canetti (all three causing TB in 
humans), M. microti (infecting voles), M. bovis (mainly infecting cattle), M. pinnipedi 
(found in seals and sea lions), M. caprae (infecting sheep and goats) and the vaccine 
strain Bacillus Calmette-Guérin (BCG) (Smith et al. 2006b). The different bacterial 
strains of the MTBC are closely related, sharing a similarity at the nucleotide level of 
99.9% (Brosch et al. 2002; Sreevatsan et al. 1997) but exhibit strong host specificity.  
 
M. tuberculosis (Mtb) is responsible for most of the TB cases in humans. Important 
characteristics of Mtb are the high guanine-cytosine content of its DNA, a long 
generation time (dividing only every 12 – 24h under favourable conditions) and the 
special cell wall Mtb shares with all Mycobacteria (Barrera 2007). This cell wall is built 
of highly cross-linked peptidoglycans and mycolic acids (Figure 1.1), rendering the 
bacteria highly hydrophobic and acid-fast (i.e. they cannot be decolorized with acid-
alcohol), the latter still widely utilized for the diagnosis of tuberculosis by light 
microscopy Ziehl-Neelson (ZN AFB) staining (Barrera 2007; Steingart et al. 2006b). The 
lipid rich cell wall furthermore forms a permeability barrier building the basis for the 
intrinsic resistance of Mtb to many antibiotics (Nguyen and Pieters 2009). 
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Figure 1.1: Cell wall of Mycobacterium tuberculosis 
Source: Park et al. 2000 (Park and Bendelac 2000) 
 
1.2 Burden of disease 
Tuberculosis and humans co-exist already for a long time, the latest estimations 
suggesting this co-existence to date back 70’000 years (Comas et al. 2013). Physical 
proof of the bacteria in humans was found for example in 9000 year old human remains 
near Haifa, Israel (Hershkovitz et al. 2008) and in Egyptian mummies dating back to 
1550 – 1080 BC (Nerlich et al. 1997).  However, tuberculosis reached epidemic heights 
in Europe and North America only much later - in the 18th/19th century - which declined 
again with the introduction of sanatoria and chemotherapy, only to re-emerge in the late 
1980s early 1990s, fuelled by the emerging HIV pandemic and increasing drug 
resistance (Daniel 2006; Porter and McAdam 1994).  
 
In 1993 World Health Organisation (WHO) declared tuberculosis to be a global 
emergency. As a consequence, the Directly Observed Treatment Short course (DOTS) 
strategy was developed and a few years later the Stop TB Partnership was formed (see 
chapter 1.4.2).  
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Tuberculosis remains a major health problem throughout the world to this day. A third 
of the global population is infected with TB and 8.6 million people developed TB 
resulting in 1.3 million deaths in 2012 (World Health Organization 2013b). The majority 
of TB cases worldwide are found in South-East Asia (29%), Africa (27%) and the 
Western Pacific region (19%), with the 22 highest TB burden countries accounting for 
82% of the globally notified TB cases, with India and China alone making up 39% of it 
(Figure 1.2). Tuberculosis is affecting more men than women, but is nevertheless one of 
the three leading causes of death in women, especially among HIV positive people (WHO 
2013).  All age groups are affected by the disease, but the highest peak of cases is found 
in the economically productive age group (World Health Organization 2013b). TB in 
children has been neglected for a long time, as they do not represent the most infectious 
cases. However, children are an indicator for ongoing transmission and in 2012, children 
accounted for 6% of all TB cases detected (World Health Organization 2013b). 
 
To reduce the global TB burden, the Stop TB Partnership has formulated several targets 
to be reached by 2015, which are following the Millennium Development Goals (Stop TB 
Partnership and World Health Organization 2010; United Nations 2005). Although the 
global mortality rate has been reduced by 45% and the prevalence by 37% since 1990, 
several of these targets of the Stop TB Partnership - for example the target of reducing 
the prevalence of active TB by 50% - will probably not be met by 2015, as especially in 
the African and European (former Soviet Union countries) regions, mortality and 
prevalence numbers remain high (World Health Organization 2013b). The high numbers 
of latently infected people, the HIV pandemic and the increasing drug resistance are also 
challenging the reach of the target of the Stop TB partnership to eliminate TB as a public 
health problem by 2050 (Stop TB Partnership and World Health Organization 2010). 
Every year about 450’000 new multidrug-resistant (MDR) cases are detected, the global 
MDR rate has reached 3.6% in new cases in 2012 and already 92 countries have 
reported at least one extensively drug-resistant (XDR) TB case by now (WHO 2010; 
World Health Organization 2013b). Less than 25% of the globally estimated MDR cases 
are detected and only 50% of MDR TB cases starting chemotherapy are successfully 
treated. New drugs are urgently required to overcome the threads to current control 
efforts. 
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Figure 1.2: Estimated global incidence rates, 2012 
Source: Global Tuberculosis Report 2013, World Health Organisation (World Health 
Organization 2013b). 
 
1.3 Tuberculosis - The disease 
1.3.1 Transmission and immunology 
Tuberculosis is mainly transmitted through aerosols. Aerosols are small droplets 
containing bacteria, formed when a patient with active TB is coughing or sneezing. If 
these droplets are inhaled by another susceptible person (or animal), the bacteria enters 
the lung where they are phagocytosed by macrophages. In other words, Mtb needs to 
induce active disease in order to be transmitted. One person with active TB can on 
average infect 10-15 people over the period of one year (WHO 2013). However, the 
amount of bacilli present, their virulence, the state of health (co-infections, 
immunosuppression) and the age of a person as well as environmental factors such as 
adequate ventilation and exposure to sunlight (UV light) have a major influence on the 
infectiousness. Yet, theoretically, TB is infectious as long as there are viable bacteria in 
the sputum. If a patient is under treatment, it takes about four to eight weeks until 
sputum conversion, i.e. until no bacteria can be detected in their sputum any more (Chin 
2000). 
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As the first place of entry is the lung, the main phenotype of TB is pulmonary TB. 
Nevertheless, TB can affect all other parts of the body, called extrapulmonary TB. As in 
the case of extrapulmonary TB the bacteria are not coughed up, the patients are 
generally non-infectious, although they have developed clinical disease.  
 
Once the bacteria have entered the lung, they are engulfed by alveolar macrophages. M. 
tuberculosis can grow inside the macrophages by inhibiting the fusion of the phagosome 
with the lysosome, therefore preventing its own digestion. Granulomas are formed - 
aggregations of infected phagocytes (macrophages, neutrophils, monocytes and 
dendritic cells) and surrounding lymphocytes (B- and T-cells) (Ernst 2012). In principle 
three scenarios are then possible: First, the immune system is getting the upper hand 
and the bacteria are killed and eliminated entirely. Second, the bacteria are overcoming 
the immune system and multiply within the lung, causing development of clinical 
disease. Or third, there is a balance between the bacteria and the immune system, 
allowing the bacteria to remain in a dormant state (so-called latent TB). When a person 
is latently infected with TB, the infection remains clinically silent and the bacteria are 
not spread. In 90 – 95% of cases the bacteria remain in the latent state and never re-
activate. In the remaining 5-10% re-activation of the bacteria occurs after several years, 
leading to clinical disease, the so-called secondary TB (Schluger and Rom 1998). The 
described scenarios cannot be seen as clearly separate outcomes, but rather build a 
system with dynamic transitions, the direction of which are dependent on many host as 
well as bacterial factors (Barry, III et al. 2009). One reason for re-activation of latent TB 
to active disease is HIV co-infection. CD4+ T cells play a major role in the formation of 
granulomas, as they produce cytokines (e.g. IL-12 and IFN-γ) which are themselves the 
activating agents of the macrophages. As the level of CD4+ T cells is usually low with 
advanced HIV infection, HIV positive patients have an increased risk (up to 40-fold) of 
being infected with TB and of progression of an infection to disease (Brites and Gagneux 
2012; Nunn et al. 2005).  
 
1.3.2 Symptoms 
The most common symptom of TB is a persistent productive cough over several weeks, 
therefore serving as an indicator for TB in high endemic countries. It is often 
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accompanied by more unspecific symptoms such as fatigue, fever, night sweats, but at 
later stages also by weight loss, chest pain and breathing difficulties (WHO 2013). 
 
1.4 Disease prevention and control 
1.4.1 Prevention 
Strategies for the control of TB include preventative measures as well as treatment. The 
main strategy to prevent TB would be efficient vaccination. The only TB vaccine 
currently available is the Bacille Calmette-Guérin (BCG). BCG was discovered in the 
1920s and since then has widely been administered. BCG is an attenuated strain of M. 
bovis that has lost its virulence through the deletion of the region of difference RD1 
(Pym et al. 2002). The vaccine is not preventing TB infection, but mainly protects against 
the dissemination of the disease from the lung to other organs and throughout the whole 
body. However, BCG induced protection varies strongly between different geographical 
areas (from 0% up to 80% protection against pulmonary TB (Fine 1995)), especially in 
adults, and is therefore administered mainly to children. Additionally, as BCG is a life 
vaccine, it harbours the risk of BCG induced TB disease in immune-compromised 
patients. Therefore, new vaccines overcoming these limitations are urgently required. 
Currently, 14 vaccine candidates are in clinical trials, including whole-cell 
mycobacterium candidates as well as BCG recombinants and viral-vectored or adjuvant 
subunit vaccines (i.e. a specific vaccine antigen is combined with a substance to enhance 
the antigen-specific immune response) (Claydan et al. 2013). 
 
Strategies to reduce TB infection rates should include interventions reducing risk factors 
in a population. Such risk factors include poor living and working conditions increasing 
the level of transmission (e.g. overcrowded and poorly ventilated rooms as for example 
in prisons) or immune response affecting factors such as HIV co-infection, diabetes, 
smoking or alcohol abuse (Lonnroth et al. 2009).  
 
Once infection has occurred it is important to reduce the risk of progression to active 
disease. One third of the world’s population is estimated to be infected with latent TB 
(World Health Organization 2013b). Preventive treatment with isoniazid (INH) for 9 
months has been shown to significantly reduce the risk of progression to active disease 
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(Wilkinson 2000). More recently a combination of INH and rifapentine for a reduced 
duration of 3 months has been suggested to treat latent TB (Sterling et al. 2011) in high 
risk groups such as HIV positive patients or children with a parent with active 
tuberculosis. Besides the difficulties of differentiating latent TB from active TB 
(American Thoracic Society 2000; Centers for Disease Control and Prevention (CDC) 
2000), another problem arises with the fact that the definition of latent TB is not that 
simple: latently infected people include people who have entirely cleared infection as 
well as patients infected with replicating bacteria but absence of clinical signs. There is 
still no sensitive test to determine if a bacterium is dead or just in an inactive, non-
growing state (Barry, III et al. 2009). This leads to major challenges for the development 
of new drugs active against dormant bacteria, and a regimen with a reduced duration for 
only a few weeks (Barry, III et al. 2009) and probably makes it impossible to successfully 
eliminate latent TB in the near future.  
 
1.4.2 Control 
Prevention of TB is generally difficult and strict control measurements are therefore 
indispensable. High case detection rates at an early stage as well as prompt and effective 
treatment are of uttermost importance in order to reduce time of infectiousness and 
therefore possible transmission. Active screening of people with increased risk – for 
example HIV positive people, household contacts of TB patients and health workers - 
can strongly improve detection rates. Furthermore, active case detection (ACD) where 
health workers are routinely visiting the community looking for individuals with chronic 
productive cough and encouraging them to be tested for TB, has been proven to be an 
effective tool to increase detection rates in various studies (Sekandi et al. 2009; Zenner 
et al. 2013).  
 
The directly observed treatment short-course strategy (DOTS) is the WHO 
recommended and internationally accepted public health intervention for TB case-
finding (diagnosis through quality-assured bacteriology) and cure and incorporates 
several control aspects: access to quality diagnosis, access to quality treatment with 
standardized short course chemotherapy and uninterrupted supply of TB drugs, as well 
as political commitment to sustained and increased funding are the most important 
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components of that strategy (World Health Organization and The Stop TB Partnership 
2006). DOTS has been endorsed by WHO in 1994 (World Health Organization 1994) 
followed by DOTS-plus in 1999, which is focusing on MDR-TB case management with 
second-line drugs. DOTS is part of the Stop TB Partnership, established in 1998 as a 
network of several public and private organizations, countries, governments and donors 
to reach the overall goal of the partnership to drastically reduce the global TB burden by 
2015 following the Millennium Development Goals (StopTB Partnership 2014; Stop TB 
Partnership and World Health Organization 2010; World Health Organization and The 
Stop TB Partnership 2006). 
 
1.5 Diagnosis and treatment 
1.5.1 Diagnosis 
In order to detect TB cases, suitable diagnostic tools are required. In developing 
countries with a high TB burden, acid fast bacilli Ziehl-Neelson (ZN AFB) direct smear 
microscopy (see Box 3, chapter 4.3) as well as Chest X-ray (CXR) are still the main 
diagnostic methods used. Although the sensitivity of microscopic methods has been 
improved, for example through an NaOCl (“bleach”) based sputum concentration 
method (Angeby et al. 2000) or fluorescent microscopy (Steingart et al. 2006a), 
microscopy still only detects a relatively low percentage of infections, especially in HIV 
positive patients and children who are often sputum smear negative, if they can produce 
a sample at all. On the other hand, as in high endemic areas the amount of AFB not 
belonging to the MTBC will be negligible, microscopy is quite specific, fast and 
inexpensive and detects the most infectious patients (Steingart et al. 2006b).  Culturing 
Mtb remains the gold standard of diagnosing tuberculosis as it is much more sensitive 
than microscopy. Nevertheless, besides taking several weeks until a result becomes 
available, culturing has the drawback that it is not feasible for many countries as no 
culturing suitable facility is available, therefore also not allowing for culture based DST. 
Many other diagnostic methods using various approaches for the detection of TB have 
been developed over the past decades. Such methods include nucleic acid amplification 
based assays (e.g. GenoType MTBDRplus 2.0, Hain Lifescience, Germany) blood based 
assays for antigen detection (e.g. Interferon gamma release assays such as T-SPOT TB 
test, Oxford Immunotec, UK) as well as non-molecular methods (e.g. TB-LAM lateral flow 
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test, Alere, US). Many other methods are furthermore in the development pipeline 
(Claydan et al. 2013). However, there is often the problem that also these methods are 
not suitable for resource poor settings as they are expensive and highly technical 
equipment is required. In addition, a positive result in some cases cannot clearly 
distinguish between active and latent TB. For latent TB usually tuberculin skin tests 
(TST) were used, but due to cross-reactions with non-tuberculous mycobacteria (NTMs) 
and BCG vaccination they became widely unusable (American Thoracic Society 2000; 
Centers for Disease Control and Prevention (CDC) 2000). 
 
With the increasing thread of drug resistance (DR), drug susceptibility testing (DST) is 
necessary to ensure successful treatment. Culturing of MTBC is required for detailed 
subsequent DST with for example the BACTECTM Mycobacteria Growth Indicator Tube 
960 system (Becton Dickinson, US), but obviously the limitations for developing 
countries remain. In 2010 WHO endorsed the Xpert® MTB/RIF (Cepheid) which detects 
MTBC and simultaneously screens for rifampicin (RMP) resistance by amplifying the 
81bp rifampin resistance determining region (RRDR) of rpoB (see chapter 1.5). As the 
prevalence of RMP monoresistance is usually low, RMP resistance is used as a marker 
for MDR TB (Felmlee et al. 1995; Franzblau et al. 1998). It furthermore has been shown, 
that INH monoresistance (which is not detected by Xpert® MTB/RIF) does only have a 
very limited impact on detecting additional MDR TB cases and can therefore be 
neglected (Denkinger et al. 2014). Xpert® MTB/RIF is a fast, simple to use and both, 
sensitive as well as specific method (Hillemann et al. 2007) and can therefore be used 
for pre-screening of MDR TB suspects, especially in countries with limited or no 
possibilities to conduct culture based DST.  Despite its advantages, the machine is 
expensive, therefore making it difficult to implement in resource poor countries. 
Additionally, the all-in-one cartridge strategy strongly limits possible trouble shooting 
and individual improvement of input material such as DNA extraction. Details about the 
comparison of Xpert® MTB/RIF to other diagnostic methods, especially in childhood TB 
can be found in Bholla, M. 2014 (Maira Bholla 2014). 
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1.5.2 Treatment 
With the discovery of streptomycin (STR) as a component active against TB in 1944, the 
era of chemotherapy was heralded. The discovery and addition of isoniazid (INH) to the 
TB treatment regimen followed in 1952 (Zhang 2005). With the further amendment of 
ethambutol (EMB) and rifampicin (RMP) to the cure in 1970, treatment duration could 
drastically be reduced from formerly 18 -24 months down to nine months. Treatment 
duration further dropped to 6 months when finally pyrazinamide (PZA) was included 
into the regimen in 1980 (Almeida da Silva and Ainsa 2007). The usual treatment course 
currently recommended by WHO consists of a two months intensive phase of a 
combination of four antibiotics daily: INH, RMP, EMB and PZA (Box 1).  In this phase, the 
bacilli are relatively quickly killed and the patient becomes non-infectious and the 
symptoms usually disappear. The intensive phase is followed by a longer lasting 
sterilizing phase, the so-called continuation phase. It lasts for four to six months and 
includes daily or 3 times weekly intake of two of the first-line drugs used in the 
preceding phase, mostly RMP and INH (World Health Organization 2009b). In case of a 
category II case (Box 1), STR is added to the standard regimen. The main first-line TB 
drugs and their mode of action are summarized in Table 1.1. WHO recommends the use 
of fixed-dose combinations (FDC) in which all the drugs are combined in a defined dose 
in a single tablet. This reduces the pill burden and therefore increases compliance to the 
regimen (WHO 2013). 
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Table 1.1: Anti tuberculosis drugs, their targets and their mode of action. 
Drug Name 
Effect on Bacteria and  
Mechanism of Action Drug Target Comment 
Rifampicin 
bactericidal; inhibition of 
RNA synthesis 
RNA polymerase β 
subunit encoded by 
rpoB 
Active against 
actively growing 
as well as slowly 
metabolizing non-
growing bacteria 
Isoniazid 
bactericidal; inhibition of 
cell wall mycolic acid 
synthesis 
Acyl carrier protein 
reductase encoded 
by inhA; multiple 
other targets 
Prodrug, 
activation through  
KatG required 
Streptomycin 
bactericidal; Inhibition of 
protein synthesis 
Small 30S ribosomal 
subunit: S12 protein 
(encoded by rpsL) 
and 16S rRNA 
(encoded by rrs) 
Contraindicative 
during pregnancy 
Ethambutol 
bactericidal; inhibition of 
cell wall arabinogalactan 
synthesis 
Arabinosyl 
transferase encoded 
by embCAB   
Pyrazinamide 
bacteriostatic/ 
bactericidal; Disruption 
of membrane transport 
and energy depletion 
Membrane energy 
metabolism  
Active only in acid 
pH and more 
active at low 
oxygen or 
anaerobic 
conditions; 
prodrug activated 
by PZase/ 
nicotinamidase 
encoded by pncA 
Ethionamide 
bacteriostatic; Inhibition 
of mycolic acid synthesis 
Acyl carrier protein 
reductase encoded 
by  
inhA  
Prodrug, activated 
by the enzyme 
EthA 
Quinolones 
bactericidal; inhibition of 
DNA synthesis 
DNA gyrase encoded  
by gyrA 
Examples: 
moxifloxacin, 
gatifloxacin 
Kanamycin,  
Capreomycin 
Amikacin 
bactericidal; inhibition of 
protein synthesis 
16S rRNA 
(encoded by rrs) 
Injectables, used 
in second-line 
treatment  
Adapted from Zhang 2005 (Zhang 2005) 
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Sources of information: World Health Organisation (WHO 2010; World Health Organization 
2009b; World Health Organization 2013a). 
 
1.6 Drug resistance and second-line treatment 
One of the biggest threats to current TB control efforts is the emerging drug resistance 
(DR). DR against some of the first-line drugs emerged very soon; it was monitored 
already in the 1960s. DR can either be classified as primary DR – i.e. the strain is already 
resistant at the time of infection– or acquired DR, which refers to a primarily susceptible 
strain developing DR under treatment. Reasons for acquired DR are manifold; 
behavioural factors such as poor treatment compliance of patients or inadequate 
treatment supervision by health personnel, or health system related factors as for 
First-line TB drugs
Second-line TB drugs
Pansusceptible TB
Monoresistant TB
Poly drug-resistant TB
Multi drug-resistant TB
Extensively drug-resistant TB
Cured
Treatment completed
Treatment Failure
Died
Defaulted/Lost to follow-up
Relapse
Drugs Duration Drugs Duration
Category I 
(Category III)*
All new TB patients, defined as never having taken 
TB treatment before  or for less than 1 month
RMP
INH
EMB
PZA
2 months, daily
(FDC)
RMP
INH
4 months, daily
(FDC)
Category II
All retreatment cases (relapse, treatment after 
default, treatment after failure); 
RMP
INH
EMB
PZA
STR
3 months, daily
(FDC)
__________
2 months, daily
RMP
INH
EMB
5 months, daily
(FDC)
Category IV MDR-TB cases, failures
18 - 24 months
second-line treatment with 
fluoroquionolones and 
injectibles
Definitions
Treatment Outcome
Types of Resistance
Box1: Definitions, Categories and Regimens of TB Treatment 
Category and Regimens
DefinitionCategory
A TB patient previously declared cured or treatment completed and is again diagnosed with sputum 
smear or culture positive tuberculosis
*Category III patients are defined as category I patients but with a thrice a week instead of daily treatment regimen. 
This treatment category classification is no longer recommended by WHO as it can increase DR levels in undetected MDR 
cases if repeatedly put on Cat egory II treatment. However,  in countries with no readily available DST and or second-line 
treatment the above classifications are still used.
Isoniazid (INH), rifampicin (RMP), ethambutol (EMB), parazinamid (PZA), streptomycin (STR)
Fluoroquinolones (e.g. moxifloxacin) and the injectible drugs amikacin, kanamycin, capreomycin
Susceptible to all 5 first-line TB drugs
Resistant to a single drug of the first-line treatment
Resistant to more than one of the first-line treatment drugs (other combinations than INH and RMP)
Resistant to at least RMP and INH, the two main first-line treatment drugs
MDR TB with additional resistance to a fluoroquionolone and to at least one of the second-line 
injectible drugs (amikacin, kanamycin and/or capreomycin)
A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who was 
smear- or culture-negative in the last month of treatment and on at least one previous occasion.
A TB patient who completed treatment without evidence of failure BUT with no record to show that 
sputum smear or culture results in the last month of treatment and on at least one previous occasion 
were negative, either because tests were not done or because results are unavailable.
Intensive phase Continuation phase
Drug Regimen and Duration
A TB patient whose sputum smear or culture is positive at months 5 or later during treatment
A TB patient who dies for any reason before starting or during the course of treatment
A TB patient who did not start treatment or whose treatment was interrupted for 2 consecutive months 
or more
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example poor treatment quality or erratic drug supply. Also pharmacokinetics and 
pharmacogenomics such as contraindications between drugs (e.g. anti-TB and HIV 
treatment (Weiner et al. 2005)) or the metabolizer phenotype of a patient leading to 
sub-clinical concentrations of drugs need to be considered (Garcia-Martin 2008; 
Ramachandran et al. 2013). 
 
As the prevalence of multi-drug resistant (MDR) and extensive drug resistant (XDR) TB 
are rising worldwide (see chapter 1.2), it is crucial to find new ways to treat TB. Second-
line treatment drugs used to treat DR TB (Box 1) are not only more expensive than first-
line drugs, they furthermore need to be taken for 18-24 months and also more often lead 
to serious side effects (Caminero et al. 2010; Gandhi et al. 2010).  
 
A major achievement in TB drug development was the approval of a new drug to treat 
MDR-TB in 2012. Bedaquiline is a bactericidal drug which can now be used to treat MDR 
TB when there are no other options available anymore. As bedaquiline has only been 
tested in a Phase IIb trial so far, WHO has issued only “interim policy guidelines” for the 
moment (World Health Organization 2013b). Many other drugs are currently in the 
pipeline, but for some - for example moxifloxacin which is part of the REMoxTB regimen 
currently in phase III - there is already the problem of pre-existing DR as the antibiotic 
has already been prescribed to treat other bacterial diseases (Claydan et al. 2013). These 
challenges are worrisome as they increase the risk that TB will one day become an 
incurable disease.  
 
In Mtb there are no plasmids conferring DR. Mtb acquires DR in a stepwise manner by 
sequential accumulation of chromosomal mutations (Heym et al. 1994; Ramaswamy and 
Musser 1998). Several such mutations in different M. tuberculosis genes have been 
identified and found to be associated with DR of the bacteria. The most frequently found 
DR associated mutations in clinical samples are listed in Table 1.2. For example, the gene 
rpoB coding for the β-subunit of the RNA polymerase of Mycobacteria is the target of 
RMP. The most important point mutations in the rpoB gene found to be associated with 
RMP resistance are located in an 81bp rifampin resistance determining region (RRDR) 
(Ramaswamy and Musser 1998; Telenti et al. 1993). These mutations can be detected in 
95% of RMP resistant cases and are therefore used as markers for RMP resistance in 
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diagnostic tools such as the Xpert® MTB/RIF (Cepheid) or MTBDRplus  (Hillemann et al. 
2006; Hillemann et al. 2007).  
 
For a long time it was believed that DR TB would rather stay locally contained than 
readily transmit, as in the absence of drug pressure DR bacteria are usually less fit than 
their susceptible counterparts (Keshavjee and Farmer 2012). As shown over the last 
years this seems not to be entirely true in the case of TB, as multiple MDR-TB outbreaks 
and primary DR (i.e. patient to patient transmission) have been reported (Muller et al. 
2012). Positive selection on specific DR associated mutations or the acquirement of 
fitness restoring compensatory mutations have been shown to impact on the 
transmission of DR strains, rendering them as fit as, or even fitter than their susceptible 
counterparts (Muller et al. 2012). Mutations in the ahpC promoter region have been 
found to compensate for loss of function or reduced function of the KatG peroxidase 
caused by INH DR associated mutations in katG (Gagneux et al. 2006a), and rifampicin 
resistant strains were found to often harbour compensatory mutations in rpoC (Comas 
et al. 2012; De Vos et al. 2013). The latter are not only associated with a specific RMP 
resistance conferring rpoB mutation, but also with a specific genetic background of Mtb 
(De Vos et al. 2013), pointing at a complex system of interactions (e.g. epistasis) 
between DR mutations, compensatory mutations and the genetic background of the 
bacteria (Borrell and Gagneux 2011).   
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Table 1.2: Most common mutations associated with drug resistance against TB treatment drugs 
Drug 
Genes 
affected  
Most common  
mutations  
Comments 
RMP rpoB 
D516N,A,E,G,V,Y,F  
H526F,N,D,Y,S,T,L,P,R,G,C,Q 
S531L, F, Y, W, C, Q [1,2]  
Besides rare mutations outside that 
region, most common mutations in 
rpoB are found in the 81bp 
rifampin resistance determining 
region: codons 507 - 533 (27 amino 
acids)  
INH katG 
S315T,R [2](Zhang and Yew 
2009)  
Mutations in katG leads to non-
activation of INH; mutations in katG 
associated with high INH resistance 
INH 
promoter 
region of 
mabA/inhA 
operon 
C -15 T 
C -8 T [3]  
Mutations lead to overexpression 
of the drug target; mutations in the 
inhA promoter region are 
associated with low INH resistance 
INH ahpC ahpC promoter region [4, 5]  
Compensatory mutations for INH 
resistance associated mutations in 
katG 
STR rrs 
Mutations in the  
530 loop and  
around region 915 [2, 3]   
STR rpsL 
K88R, Q, M, T 
K43R, T [1, 3]    
STR gidB 
Mutations scattered over the 
whole gene [6] 
Mutations in gidB lead to low level 
STR resistance  
EMB 
 embB 
(embCAB 
operon) 
M306I,V  
G406S,D,A  
Q497R,K [3,7] 
65% of clinical isolates resistant to 
EMB have mutations in the embCAB 
operon 
PZA pncA 
Mutations scattered over the 
whole gene [2]  
M. bovis is intrinsically resistant to 
PZA due to a characteristic  
mutation in pncA 
FQ gyrA D94A,Y,N,H,F,G,V  [1,2] 
Most common mutations 
associated with resistance to 
fluoroquinolones are found in the 
quinolone resistance determining 
region (320bp in gyrA and 375 bp 
in gyrB) 
AMK  
KM rrs 
Mutations around position  
1400  
These mutations are associated  
with high resistance to both drugs 
*Mutations are given as amino acid changes at codon positions, except for the mutations 
in gene rrs and in the promoter regions.  
RMP = Rifampicin; INH = Isoniazid; STR = Streptomycin; EMB = Ethambutol; PZA = 
Pyrazinamide; FQ = Fluoroquinolones; AMK = Amikacin; KM = Kanamycin 
References: [1] = Sandgren et al. 2009; [2] = Zhang and Yew 2009; [3] = Ramaswamy 
and Musser 1998; [4] = Gagneux et al. 2006c; [5] = Muller et al. 2012; [6] = Okamoto et 
al. 2007; [7] = Plinke et al. 2010 
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1.7 Molecular epidemiology and genetic diversity of Mycobacterium 
tuberculosis 
1.7.1 Genotyping of Mycobacterium tuberculosis 
In order to tackle a deadly disease like TB, transmission dynamics need to be 
understood, disease outbreaks need to be identified and associations between disease 
phenotypes, disease outcomes and genotypes of the pathogen need to be investigated. 
Genotyping is the essential tool to address these and related questions. Depending on 
the discriminatory power and the rate of change of the marker, genotyping can be used 
to explore the evolution and phylogeny of the bacteria or it can help to distinguish 
between recent outbreaks (on-going transmission reflected through clusters of strains 
with an identical genotype) and reactivation of old infections (unique genotypes) (Kato-
Maeda et al. 2011; Malik and Godfrey-Faussett 2005). This information can assist 
national programs in establishing specific disease control strategies in a certain area. In 
low-endemic countries, reactivation of latent infections often outnumbers cases from 
recent transmission and is often found in immigrants. This points at a well-functioning 
TB program within the country, and the focus of the control program should mainly be 
put on the detection of latent infection and the consideration of preventive treatment in 
high risk groups (Nguyen et al. 2004).  
 
In addition, the mounting evidence of MTBC genotype influencing the disease phenotype 
(Coscolla and Gagneux 2010) (discussed below), emphasizes the importance of 
genotyping in tuberculosis. Understanding host-pathogen interactions might allow 
predicting disease outcome in the future, and therefore need to be taken into account for 
drug and vaccine development. Unfortunately, genotyping can still not be conducted in 
many resource poor countries which also tend to be the countries with the highest 
burden of TB.  
 
1.7.2 Genotyping methods 
For a long time methods used to distinguish between different MTBC or between 
different M. tuberculosis strains were based on phenotypic typing methods such as 
morphology (WILL et al. 1951), bacteriophage typing or drug susceptibility typing 
(Schurch and van Soolingen 2012). Although some of these methods were successfully 
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used to analyse outbreak strains, they nevertheless were not highly discriminatory and 
in the case of the drug susceptibility typing also not based on stable markers (Schurch 
and van Soolingen 2012). In tuberculosis research, molecular epidemiology started to be 
successfully used in the early 1990s (Malik and Godfrey-Faussett 2005) and several 
different genotyping methods using different markers with variable discriminatory 
power became available within a relatively short period of time. The classical 
genotyping method usually used to genotype bacteria - the classical multilocus sequence 
typing based on few housekeeping genes - is not informative in the case of MTBC as for 
monomorphic bacteria with a lack of recombination this method does not have a 
sufficient resolution (Achtman 2008). Most genotyping methods used for MTBC are 
based on mobile or repetitive elements (Comas et al. 2009). Depending on what the goal 
of genotyping in a specific project is, the suitable method with the best marker has to be 
chosen. For molecular epidemiology for example, the marker should be highly 
discriminatory to distinguish between two unrelated strains but it should still be stable 
enough to recognize related strains. For phylogenetic analysis on the other hand, 
markers need to be robust and not be prone to homoplasy (Kato-Maeda et al. 2011). 
Often several methods are combined to reach a combination of both. Different 
genotyping methods, their markers, limitations and advantages are reviewed in (Kato-
Maeda et al. 2011). Below, a few of these methods are described in detail. 
 
1.7.2.1 IS6110-RFLP 
In the early 1990s the DNA fingerprinting method based on detection of the insertion 
sequence IS6110 by restriction fragment length polymorphism (RFLP) (van Embden et 
al. 1993) became the first gold standard for genotyping of MTBC (Comas and Gagneux 
2009). This method is based on the differences of the distribution and the copy number 
of IS6110 between different strains and has a high discriminatory power. On the other 
hand, the method does not only require a facility to culture MTBC, but furthermore, 
technical equipment such as thermocyclers for polymerase chain reactions (PCR) and a 
x-ray film developing facility are required, making it less suitable for resource poor 
settings. Additionally, the method is less suitable for strains with a low IS6110 copy 
number and results are difficult to be compared between laboratories (Kato-Maeda et al. 
2011) (Barnes and Cave 2003).  
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1.7.2.2 Spoligotyping 
In 1997, the so-called spacer oligonucleotide typing – or short “spoligotyping” – was 
developed (Kamerbeek et al. 1997), a method based on the direct-repeat locus of the 
Mycobacteria chromosome (Hermans et al. 1991). This locus shows considerable strain-
to-strain polymorphisms: the clustered regularly interspaced short palindromic repeats 
(CRISPR) are separated by 35-41 base pair spacers whose sequences are well conserved 
between different Mtb strains (Figure 1.3). On the other hand, the patterns of these 
spacers (the presence or absence of a specific spacer) differ between strains and can 
therefore be used as a genotyping marker. The advantage of spoligotyping over IS6110-
RFLP typing is that it is fast and cheap and can be performed directly on clinical isolates. 
On the other hand, spoligotyping is based on repetitive DNA elements which are prone 
to homoplasy and the method has only limited discriminatory power (Barnes and Cave 
2003; Kamerbeek et al. 1997).  
 
 
Figure 1.3: Spoligotyping and the direct repeat locus of the Mycobacteria chromosome. 
DR= direct repeat (in this Figure only); source: (Kamerbeek et al. 1997) 
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1.7.2.3 MIRU-VNTR 
The MTBC genomes contain mycobacterium interspersed repetitive units (MIRUs), 
tandem repeats scattered over several intergenic regions. Forty one such MIRU loci have 
been identified in the Mtb H37Rv chromosome (Supply et al. 1997; Supply et al. 2000). 
Several of these loci were found to vary in the copy number as well as in the length of 
the repeats, the polymorphism used in the MIRU-VNTR typing method. PCR 
amplification of the flanking regions of different MIRUs and subsequent visualization on 
a gel, allow to determine the copy number of repeats at each locus (Kato-Maeda et al. 
2011). The discriminatory power of MIRU-VNTR typing depends on the number of loci 
analysed. For phylogenetic analyses a set of 24 loci has been suggested (Supply et al. 
2006), whereas for epidemiological studies - except for the discrimination of unrelated 
Beijing strains (Alonso et al. 2010; Iwamoto et al. 2007) - 15 loci are sufficient. 
Compared to IS6110-RFLP typing, 24 loci MIRU-VNTR typing has a higher 
discriminatory power, but it is prone to homoplasy, similar to spoligotyping (Comas et 
al. 2009). If the automated capillary sequencer approach (Supply et al. 2001) is used, 
results are highly reproducible (Kato-Maeda et al. 2011), but it also comes with much 
higher costs compared to the classical method based on agarose gels (Kato-Maeda et al. 
2011).   
 
1.7.2.4 Regions of difference and single nucleotide polymorphism typing 
In 1998 the full genome sequence of Mtb became available (Cole et al. 1998). This 
opened the door for comparative genomic approaches. Over the following years 
microarray based studies identified and studied large sequence polymorphisms (LSPs), 
so-called regions of difference (RD) (Behr et al. 1999b; Gordon et al. 1999; Tsolaki et al. 
2004).  Based on the presence or absence of specific RDs, different Mtb strains can be 
distinguished (e.g. through PCR amplification and subsequent gel electrophoresis 
analysis). Three specific RDs - RD142, RD150 and RD181 - were found to distinguish 
four monophyletic subgroups of the so-called Beijing clade (Tsolaki et al. 2005). These 
markers are still widely used to subtype this family of strains (Aleksic et al. 2013; 
Hanekom et al. 2007b; Kong et al. 2006). RDs are phylogenetically informative and led to 
the demonstration of the phylogeographic population structure of Mtb (Gagneux et al. 
2006b) (see chapter 1.6.3). 
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Single nucleotide polymorphisms (SNPs) are also very robust markers for phylogenetic 
analyses and, compared to LSPs, can be used to analyse actual genetic distances. With 
the increasing availability of affordable whole genome sequencing (WGS), SNPs will 
probably increasingly become the genotyping marker of choice, especially for 
monomorphic bacteria such as Mtb (Achtman 2008).  A recently developed SNP-based 
method (Stucki et al. 2012) allows to classify a strain into one of 6 of the 7 main human 
associated lineages of MTBC (Comas et al. 2013) by six independent TaqMan real-time 
PCR assays. This method is fast and robust, but requires a real-time PCR machine, which 
makes it less suitable for resource poor countries. Additionally, by classifying strains 
into main lineages, the assay is useful for confirmation of rough phylogenetic 
information but clearly not suitable for establishing the chain of transmission within a 
population.  
 
1.7.3 Evolution of the Mycobacterium tuberculosis complex  
The different strains of the MTBC are extremely homogenous (99.9% similarity on 
nucleotide level) with little or no horizontal gene transfer (Hirsh et al. 2004; Supply et al. 
2003) and therefore referred to as genetically monomorphic (Achtman 2008). The 
commonly accepted hypothesis states that the common ancestor of the MTBC 
underwent clonal expansion, developing into different strains with different specific 
host spectra after a bottleneck somewhere between 15’000 and 35’000 years ago 
(Brosch et al. 2002; Gutierrez et al. 2005; Smith et al. 2006a; Sreevatsan et al. 1997). 
However, the increasing availability of different genotyping methods in the early 1990s 
did not only allow to gain deeper insight into the evolution of MTBC and to the 
recognition that it harbours a higher genetic variability than previously thought - it also 
led to many different subgroupings of the bacterial strains, with partially congruent 
results but nevertheless, without a clearly defined and consistent nomenclature until 
now (reviewed in (Coscolla and Gagneux 2010)). For example in 1997, Sreevatsan et al. 
(Sreevatsan et al. 1997) differentiated M. tuberculosis (Mtb) into three principle genetic 
groups (PGG) based on the different combinations of two alleles of the genes katG and 
gyrA. Based on their findings, a recent global dissemination of Mtb was assumed 
(Sreevatsan et al. 1997). However, this view was challenged in 2002 when the so-called 
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M. tuberculosis deletion 1 (TbD1) was discovered, distinguishing Mtb into “ancient” (no 
deletion of TbD1) and “modern” (TbD1 deleted) (Brosch et al. 2002). Together with 
findings from extracted Mtb DNA from human remains from before the 18th century, 
these results pointed at a much older existence of Mtb than previously believed. Brosch 
et al. furthermore detected M. bovis – and all the other animal adapted strains - to exhibit 
many more deletions in their chromosome compared to Mtb (Figure 1.4). In the absence 
of horizontal gene transfer, this reduction in genome size suggests that TB has not – as 
previously thought - originated in animals and been transmitted to humans, but rather 
the other way around (Brosch et al. 2002; Smith et al. 2009).  These findings were later 
supported by a study of Gutierrez et al., who proposed the common ancestor of MTBC to 
be the so-called M. prototuberculosis, comprised in the smooth tubercle bacilli, to which 
also M. canetti belongs and which – compared to the rest of the MTBC - show clear signs 
of recombination and are thought to be pre-bottleneck ancestors of today’s MTBC 
strains (Gutierrez et al. 2005). In the following years, studies grouped Mtb into different 
clades based on spoligotyping (Filliol et al. 2003) and into different SNP cluster groups 
(SCG) based on whole genome comparisons (Filliol et al. 2006; Gutacker et al. 2006).   
 
 
Figure 1.4: Evolutionary scenario of the Mycobacterium tuberculosis complex 
Source: (Müller 2010), adapted from (Brosch et al. 2002). 
Loss of 26 
spacers 
present in 
M.canetti 
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Around the same time, a phylogeography of Mtb based on LSPs could be established, 
showing an association between specific Mtb strains and a particular geographic region 
(Gagneux et al. 2006b; Hirsh et al. 2004). The different Mtb strains were grouped into 6 
main lineages, named after the geographic region they were associated with. In 2008 
Hershberg et al. (Hershberg et al. 2008) analysed 89 genes of a global collection of 108 
MTBC strains which confirmed the previous phylogeography of Gagneux et al., as well as 
the distinction of Mtb into modern and ancient strains. The analysis further revealed a 
higher genetic diversity for the human adapted MTBC strains than so far believed and 
found genetic drift and human demography to be the driving forces of its evolution, 
leading to the proposition of an “out-of-and-back-to-Africa” scenario (Hershberg et al. 
2008). Figures 1.5 and 1.6 show the phylogeny constructed by Gagneux et al. (Gagneux 
et al. 2006b) based on LSPs and the latest phylogeny of MTBC based on WGS, congruent 
with the previous one from Hershberg et al. (Hershberg et al. 2008) but including the 
recently detected lineage 7 (Comas et al. 2013; Firdessa et al. 2013).  
 
The proposed out-of-Africa scenario is further supported by recent findings of Comas et 
al. (Comas et al. 2013): the analysis of 259 MTBC whole genome sequences and the 
comparison of the formed phylogeny to human mitochondrial genomes revealed that 
MTBC probably already existed about 70’000 years ago, co-evolving with humans and 
spreading with the big human out of Africa migration waves.  
  
 
Figure 1.5: Phylogeny of MTBC 
Phylogeny based on large sequence polymorphisms (regions of difference); source: (Gagneux et al. 2006b).
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Figure 1.6: Whole genome sequencing based phylogeny of MTBC  
Phylogeny based on whole genome sequencing, including lineage 7; source: (Comas et al. 
2013). 
 
1.7.4 The impact of the bacterial genotype on TB infection and disease   
Until the early 1990s, it was believed that host and environmental factors are shaping 
TB disease and the genetic background of Mtb was generally neglected. However, the 
sub-grouping of Mtb into PGGs (Sreevatsan et al. 1997) and the finding that specific 
lineages of Mtb are associated with geographic regions and have adapted to its host, 
opened the door to a new era in TB research (Gagneux et al. 2006b; Hirsh et al. 2004). 
Over the following years, the impact of the genetic background of Mtb on TB disease 
dynamics was increasingly researched and mounting evidence was found. Although 
many results cannot directly be compared as different typing methods were used, it 
nevertheless could be shown that different strains of Mtb vary in virulence and 
pathogenicity and are associated with different disease outcomes (reviewed in (Coscolla 
and Gagneux 2010; Gagneux and Small 2007; Malik and Godfrey-Faussett 2005)). 
Lineage 4 for example has been found to more often cause pulmonary disease than 
extrapulmonary TB (Caws et al. 2008; Thwaites et al. 2008). Lari et al. on the other hand 
found an association between the Central Asian clade (belonging to lineage 3) and 
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extrapulmonary TB (Lari et al. 2009). A more recent study investigated the association 
of drug resistance, drug resistance associated mutations and the genetic background of 
Mtb (Fenner et al. 2012). Fenner et al. (Fenner et al. 2012) showed that INH resistance in 
lineage 1 was correlated with a mutation in the inhA promoter rather than with 
mutations in katG (see chapter 1.5). However, most studies investigated the Beijing 
family of lineage 2 and its impact on disease outcome. This strain family has been 
reported to be associated with many different factors as for example drug resistance and 
MDR (Fenner et al. 2012; Ghebremichael et al. 2010; vanRie et al. 1999), as well as with 
HIV co-infection (Brites and Gagneux 2012; Caws et al. 2006; Middelkoop et al. 2009). 
De Jong et al. furthermore found an association between Beijing strains of Mtb and a 
faster progression to active disease compared to M. africanum, when following up 
household contacts of TB cases in The Gambia (de Jong et al. 2008). Taken together, the 
Beijing strain and generally the modern strains of Mtb have more successfully spread 
around the world than ancient lineages (Gagneux and Small 2007). Portevin et al. 
(Portevin et al. 2011) observed that modern lineages elicit a lower inflammatory 
response (lower production of pro-inflammatory cytokines, e.g. IL-6, TNF-α) than 
ancient lineages. A delayed onset of the adaptive immune response (activation of 
antigen specific CD4+ T cells) due to a lower inflammatory response will prolong the 
duration of the progressive growth state of the bacteria. This advantage for the pathogen 
might result in faster transmission and disease progression (Manca et al. 2004; Portevin 
et al. 2011).  Portevin et al. proposed the hypothesis that modern lineages might be 
better adapted to the current situation of an increased host population  and density, and 
therefore faster transmission and progression to active disease, compared to ancient 
lineages which are probably better adapted to low host densities and therefore long-
lasting latency periods (Portevin et al. 2011).  
 
In summary, all these studies confirm that the genetic background of Mtb has a strong 
clinical impact, and that host and pathogen have adapted to each other. The question if 
this adaptation has a real “reciprocal” character, as per definition required for co-
evolution (Gagneux 2012; Woolhouse et al. 2002), remains to be answered. Only a few 
studies have so far investigated the combination of both, host and pathogen genetic 
background (Caws et al. 2008; Herb et al. 2008; van Crevel et al. 2009). All these studies 
found an association with a human genetic polymorphism and a specific lineage of 
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MTBC, further supporting a longstanding co-evolution between host and pathogen 
(Coscolla and Gagneux 2010).  
 
1.8 Tuberculosis and Papua New Guinea 
In order to understand how a disease enters and spreads within a population, the 
population itself and its surrounding needs to be taken into account. In the following, 
Papua New Guinea and its population are described.  
 
1.8.1 The country  
Papua New Guinea (PNG) is an independent country in the south-western Pacific Ocean, 
occupying the eastern half of the island of New Guinea and numerous offshore islands. 
The country is divided into four geographical regions and 22 provinces: Momase Region 
(comprising Morobe, Madang, East and West-Sepik/Sandaun provinces), Highlands 
Region (Simbu, Eastern Highlands, Enga, Jiwaka, Hela, Southern Highlands, and Western 
Highlands provinces), Papua or Southern Region (Central, Gulf, Milne Bay, 
Northern/Oro, Western/Fly provinces and the National Capital District, Port Moresby), 
and Islands Region (East and West New Britain, Manus, New Ireland provinces and the 
Autonomous Region of Bougainville) (Figure 1.7). 
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Figure 1.7: Map of Papua New Guinea including provincial borders and the countries 
geographical location. 
SH= Southern Highlands; WH= Western Highlands; CH= Chimbu (Simbu); EH= Eastern 
Highlands; NCD= National Capital District. 
 
1.8.2 The people and their genetic background 
PNG has a population of about 7 million people (National Statistical Office 2000) 
speaking over 800 indigenous languages and forming at least as many traditional 
societies, which makes PNG one of the most diverse countries on Earth (Lewis 2009). 
Over 80% of the population lives in rural areas living from subsistence farming 
(National Statistical Office 2000). 
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The genetic population structure of PNG has extensively been studied in the past, based 
on linguistics or archaeological evidences, but also with the help of genetic markers such 
as human leukocyte antigen-typing (Bugawan et al. 1999; Main et al. 2001) or 
mitochondrial DNA (mtDNA) typing (Easteal et al. 2005; Stoneking et al. 1990). Different 
language groups were often used as basis to determine the origin of populations, and 
inferences concerning the genetic variability between and within these groups were 
made (Kirk 1992). For example Friedlaender et al. (Friedlaender et al. 2008) studied the 
genetic relationship of Pacific Islanders, including PNG, and found a small (<20%) 
ancestry with Polynesians and Micronesians in Austronesian-speaking island 
populations (in PNG namely on Bougainville and New Britain), but none in Papuan-
speaking groups (Friedlaender et al. 2008). However, shaped by migration, founder 
effects, genetic drift and natural selection with fluctuating magnitudes of each 
contributing factor over specific time periods, an intermixture of the different 
populations occurred, making a clear separation of language or genetic groups 
impossible (Serjeantson et al. 1992). Nevertheless, there is an overall consensus that 
Austronesian-speaking coastal populations elicit a higher heterogeneity compared to 
highlands populations in PNG which comprise only non-Austronesian-speaking groups, 
and reflect an ancient population related to Australian aborigines (Friedlaender et al. 
2008; Main et al. 2001) (see chapter 2).  
 
1.8.3 The health system  
With the Organic Law on Provincial Government 1976, the PNG health system was 
decentralized and the responsibility over the rural health services was handed over 
from the National Department of Health (NDoH) to the provincial and local governments 
(Day 2009). The PNG health services are currently organized in seven different levels 
(see Figure 1.8), following a primary health care concept with health centres serving as 
main operational units. Per 10’000 people there is about one health centre, further 
supported by aid posts and sub-centres in more remote areas and a referral system 
consisting of district hospitals, provincial referral hospitals (one per province) and the 
national referral hospital in the capital Port Moresby (PNG National Department of 
Health 2011). In the PNG health system, churches play an important role: subsidized by 
the Government, churches/missions manage about 46% of facilities and 52% of service 
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delivery in rural areas of PNG (PNG National Department of Health 2011; World Health 
Organization and National Department of Health PNG 2012). 
 
The responsibility for policy and program making, medical supply into the country and 
the management of the referral hospitals lies with the national Government, whereas  
the remit of the provinces includes the implementation of the programs and guidelines 
and the management of the complete rural health service (World Health Organization 
and National Department of Health PNG 2012). The PNG health system is therefore 
mainly working through the public sector. The much smaller contribution of the private 
sector consists of facilities in the mining sector, some private clinics and doctors as well 
as traditional healers (PNG National Department of Health 2011).  
 
K. Wari stated in 1974 (Wari K and Wigley S.C. 1974): “To the Melanesian, all causal 
occurrences which affect his life are due in his opinion to benign or malignant 
influences”. These believes in which craft and black magic often render people 
inaccessible to the real cause of a disease, leading them to first seek help from 
traditional healers and in some cases even to never taking medication against a disease 
at all (Wari K and Wigley S.C. 1974). Traditional healers therefore play an important role 
as facilitators between the community and the health system and were recognized as 
such by the establishment of a national office for traditional medicine within the NDoH 
and the Traditional Task Force in 1999 (World Health Organization and National 
Department of Health PNG 2012). 
 
The quality decline or even decay of many rural health centres, difficulties in the 
coordination between health centres and the provincial hospitals (drug supply, patient 
referral, financial issues) due to the separate administration, as well as the general lack 
of resources have created major challenges to the health system of PNG. To address 
these issues, a 40 years strategy – Health Vision 2050 - has been developed, aiming at 
bringing all health facilities – including the provincial hospitals – under the single 
control of a provincial health authority. At the same time, rural health services should be 
restored and the formation of community health posts and regional specialist hospitals 
promoted (Figure 1.8) (National Department of Health 2010; World Health Organization 
and National Department of Health PNG 2012). 
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Figure 1.8: The current and the future health system structure of PNG. 
Adapted from the Papua New Guinea National Health Plan 2011 – 2020 (National 
Department of Health 2010). 
 
1.8.4 The tuberculosis burden in Papua New Guinea 
Tuberculosis is the third highest cause of morbidity and mortality in PNG (PNG National 
Department of Health 2011). Just recently the top 20 research priorities of the Papua 
New Guinea national health agenda were published, including research on the 
prevalence and determinants of TB and drug resistant TB (Viergever et al. 2014). This 
reflects the acknowledgment of TB still being a major health problem in the country. A 
consistent rise of TB in PNG could be observed over the last 30 years: in 1984 the PNG 
National Department of Health reported an incidence rate of 98/100’000 population 
(Tirumalachar M.A. 1985), 14 years later the incidence rate had already reached about 
140/100’000 population (Levy et al. 1998) and the latest WHO estimates for PNG’s TB 
incidence rate show that it has more than doubled since (World Health Organization 
2013b). For the year 2012 WHO reported an estimated TB incidence rate of 
348/100’000, a prevalence rate of 541/100’000 and 3900 TB related deaths for PNG. If 
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these numbers are compared to the numbers of Cambodia, one of the countries with the 
highest burden in the region (411/100’000 incidence and 764/100’000 prevalence rate 
in 2012), and to Australia with the lowest number of estimated cases in the region 
(6.5/100’000 incidence and 8.8/100’000 prevalence rate in 2012), it becomes clear that 
PNG is amongst the countries with the highest TB burden in the Western Pacific Region 
(World Health Organization 2013b).  Of the reported cases, 8277 were extrapulmonary 
cases, which is 3 times higher than the reported smear positive pulmonary cases (2862). 
However, most of the notified cases (9195 cases) were actually either smear negative or 
the method used for diagnosis was unknown (World Health Organization 2013b). It 
needs to be considered though, that the WHO estimates for PNG are based on records of 
a few health facilities only and the accuracy of the reported figures is unclear. In a 
recently published paper, a TB incidence of 1290/100’000 was calculated for Kikori, 
Gulf Province per year (Cross et al. 2014). This would be even higher than the estimated 
incidence rate of 1000/100’000 in South Africa in 2012 (World Health Organization 
2013b). 
 
The MDR estimates additionally reflect that PNG is not only a high TB burden country in 
its region, but has also a high estimated MDR ratio in comparison to the global average: 
with 4.9% MDR in new cases in 2012, PNG lies above the global average of 3.6%. 
Additionally, PNG became one of the countries having to report even XDR TB in 2012 
(McBryde 2012; Setepano 2012).  
 
Already in 1974 it had been noted that there was a high percentage of TB patients that 
were defaulting and absconding from TB treatment (Wari K and Wigley S.C. 1974). This 
problem has not been eliminated; PNG has still reported worrying numbers of defaulters 
in 2012: 19% of the registered cases had defaulted, which makes PNG the country with 
the highest amount of defaulters in the region (World Health Organization 2013b). 
 
The highest number of registered cases is found in the National Capital district 
(1065/100’000 in 2010) (PNG National Department of Health 2011). This does probably 
not only result from environmental factors present in big cities compared to rural areas, 
but registration and detection rates are probably higher compared to more remote areas 
due to the more readily available technical equipment for diagnosis through the Central 
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Public Health Lab, localized in Port Moresby. On the other hand, Western Province has 
been reported to have an about 1.5 times higher TB prevalence than the average 
estimates for the whole country (McBryde 2012). Even though PNG has been 
independent since 1975, there is strong interest from Australia in TB in the Western 
Province which is in close proximity to the Torres Strait Islands (TSI). It is from there, 
where multi-drug TB cases, even an XDR-TB case in 2012, entered Queensland, forming 
a major threat to the Australian TB control programs (Lumb et al. 2011; McBryde 2012). 
As intensive investigations on DR are rare for other provinces of PNG and generally 
difficult to obtain, direct comparisons are difficult and numbers from one province 
cannot be extrapolated to the whole country. 
 
1.8.5 The National Tuberculosis Program of Papua New Guinea 
PNG’s National Tuberculosis Programme (NTP) is run by the Disease Control Branch of 
the NDoH, which is accountable to the Public Health Executive Manager. The program is 
managed on three levels (National Department of Health et al. 2012):  
 
1. The national level, responsible for the establishment of protocols, registers and 
guidelines, for the organization and the realization of trainings of all involved 
parties as well as for budgeting and the whole DR monitoring and prevention.  
2. The provincial level, responsible for the implementation, coordination, 
management and supervision of the TB program, including DOTS, and for the 
distribution of drug supplies to facilities. 
3. The district level, responsible for initiating and monitoring diagnosis and 
treatment (depending on the level of the health facility by either referring 
patients or their samples to facilities equipped for TB diagnosis and patient 
management) as well as for informing and educating patients about TB. 
 
Diagnosis of TB is based on direct smear microscopy and – where possible - backed up 
by chest X-ray examination (National Department of Health et al. 2012). Since 1997, the 
NTP guidelines of PNG include DOTS (Levy et al. 1998). DOTS quality expansion and 
implementation was one of the main targets set by The Global Fund to Fight AIDS, 
Tuberculosis and Malaria (GFATM) Round 6 grant (Country Coordinating Mechanism of 
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PNG 2006). In PNG, TB treatment is free and guidelines are following the WHO 
recommendations (Box 1; chapter 1.4.3) (National Department of Health et al. 2012). In 
2012, DR surveillance based on Xpert® MTB/RIF started in five major cities of PNG 
(National Department of Health et al. 2012). The DR surveillance guidelines basically 
stipulate routine testing of sputum samples of DR TB suspects, and in case of confirmed 
rifampicin resistance, culture based DST at QMRL in Australia (National Department of 
Health et al. 2012). Other important aspects of the NTP are contact tracing, HIV testing 
(all TB patients should be offered Provider Initiated Counselling and Testing) and the so 
called Advocacy Communication Social Mobilization (ACSM) component. The latter aims 
to improve case detection and treatment adherence as well as the reduction of stigma 
towards TB patients. The strategy to achieve these aims is to create a platform of 
dialogue and communication between the community and the government, and to 
increase awareness about TB, its cause and its prevention through posters (Figure 1.9), 
flyers and public events (National Department of Health et al. 2012).  
 
The origin of TB in PNG is unknown. Did TB come together with the early human 
migration waves populating PNG about 50’000 years ago? Or is it more likely that the 
PNG population encountered the bacteria for the first time when German and British 
colonialists brought the disease with them at the end of the 19th century? These and 
related questions are discussed in the following chapter, describing details about the 
history, the epidemiology and the general situation of TB in PNG (chapter 2). 
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Figure 1.9: Photographs of tuberculosis awareness posters of the National TB Control 
Program 
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Summary 
Little is known about the situation of tuberculosis in Papua New Guinea despite its high 
TB burden, emerging drug resistance and rising HIV co-infection. This review gives an 
overview on the current situation of TB in PNG and identifies knowledge gaps that 
should urgently be addressed in the future.   
 
Keywords 
Mycobacterium tuberculosis; drug resistance; lineage typing; history; control; 
prevention 
 
2.1 Introduction 
In 1999 WHO declared a TB crisis in the Western Pacific Region (WPR) where the 
incidence accounts for 19% of the global burden. In 2012, 2.4 million TB cases were 
reported for the Region, with the highest incidence rate of 411/100’000 occurring in 
Cambodia. Although the incidence of MDR-TB cases is increasing in the WPR, the 
estimated overall TB incidence rate seems to have fallen over the last 20 years (World 
Health Organization 2013b). 
 
Papua New Guinea (PNG) has one of the highest tuberculosis (TB) incident rates in the 
Western Pacific Region (WPR) (348/100’000 population). The goal of 85% treatment 
success has been achieved in all high burden countries in the Region but PNG, where 
treatment success was only reported for 69% of cases in 2011 (World Health 
Organization 2013b). With a population of almost 7 million it was estimated that there 
were 25’000 new TB cases in PNG in 2012 and that the national prevalence was 39’000 
cases (World Health Organization 2013b). In 2006 PNG was held to be one of seven 
countries with a high TB burden in the Western Pacific Region and in 2011 PNG was 
reported to have a more than 10-times higher incidence rate compared to other pacific 
island countries (Viney et al. 2011). Furthermore, only in 2012 a country wide drug-
resistance (DR) survey in a few provinces started, the same year in which the first XDR 
TB case from PNG was reported (PNG National Department of Health 2011).  
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The land area of PNG is 462’840 km2 and approximately 80% of the 7 million people live 
in rural areas (PNG National Department of Health 2011). Tuberculosis is the 3rd highest 
cause of morbidity and mortality and the burden is rising.  Major factors are an 
inadequate treatment programme, an increase of DR, especially in Western Province 
(Gilpin et al. 2008), and an increase of people infected with HIV (PNG National 
Department of Health and PNG National AIDS Council Secretariat 2010).  
 
Unfortunately, the prevalence estimates of TB for PNG which were developed by WHO 
and are quoted above are mostly based on models and data sources for these are of 
uncertain validity as TB case estimates are derived exclusively from health facility 
records which are often of poor quality. The lack of national prevalence data on DR 
highlights the urgent need for information about the actual TB situation.  
This review aims to summarize information on TB in PNG. In order to understand the 
current situation, it is necessary to understand the history of TB introduction into PNG, 
its epidemiology, and to discuss current control strategies and the effectiveness of 
treatment. By using published research information and grey literature, probable 
knowledge gaps that need to be addressed could be identified. 
 
2.2 History  
When and how was TB introduced into PNG? Until recently, human infection with 
Mycobacterium tuberculosis (Mtb) was thought to date back to the Neolithic period, 
when humans first came into close contact with domesticated animals. Recent genetic 
evidence tough has now shown that TB in humans dates back as far as 70’000 years ago 
(Comas et al. 2013) suggesting that TB would have spread out of Africa with the first 
migrations of modern humans and thus would have come most probably to PNG with 
the early migration waves. The relevance for modern PNG is of likely host-pathogen co-
evolution between humans and Mtb in which host and bacterial genotypes influence 
disease phenotype (Caws et al. 2008; Gagneux 2012).  
 
It is commonly accepted that the first migrations into New Guinea occurred 40’000 to 
60’000 years ago when Australia and PNG formed one continent called Sahul. This 
explains a close genetic relationship between Australian Aborigines and PNG 
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Highlanders (Main et al. 2001). Human leukocyte antigen (HLA) typing and skeletal 
findings indicate that inhabitants from the Eastern Highlands district Goroka represent 
descendants of the oldest migration waves (Main et al. 2001; Reich et al. 2011). A second 
migration wave into PNG occurred around 3’500 years ago from Taiwan and through the 
Philippines. These Austronesians (a language family which is found throughout islands 
of Southeast Asia and the Pacific) settled along the coast and on the islands and later 
populated islands throughout the Pacific. It has been suggested that Austronesian-
speaking groups of PNG are more heterogenic than the non-Austronesian-speaking 
groups (e.g. highlands populations) (Main et al. 2001).  
 
2.3 Epidemiology  
2.3.1 Disease distribution: prevalence and incidence 
Dr. Wigley, the Specialist Medical Officer for TB in PNG during the late 1950s to early 
1960s described in detail how TB spread in PNG and how a first National TB Control 
Program was established (Wigley S.C. 1972; Wigley S.C. 1991). It is unknown whether 
TB was present in PNG when the Europeans started to arrive in any number in the late 
19th century, when missionaries and traders came to settle. Wigley, however, stressed 
the point that with the arrival of Europeans circumstances changed and conditions 
developed that favoured the spread of previously unknown diseases and of diseases that 
had been contained in small populations because of their comparative isolation.  
 
At the time of colonization in 1884 the Northern part of PNG was occupied by the 
German Trading Company, forming German New Guinea (GNG), and the Southern part 
has been ruled as British New Guinea (BNG) which in 1906 was transferred to Australia. 
In 1975 PNG became independent (the administrative history of PNG is summarised in 
Table 2.1) (Wigley S.C. 1972; Wigley S.C. 1991). The Germans and the Australians 
recruited national workers to the sugar cane fields in Samoa and Queensland, 
respectively, from 1869 until 1910. Living and working conditions were poor and 
reports suggested that workers brought back to their villages many diseases, and in 
Wigley’s opinion TB then began to spread through the country because of the associated 
movement of the population (Wigley S.C. 1972).  
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Table 2.1: Administrative History of Papua New Guinea 
Southeast New Guinea Northeast New Guinea 
1884 British New Guinea 
German New Guinea 
1906 
Australian Territory of Papua 
1914 Australian military administration 
1921 
League of Nations Mandated 
Territory administered by Australia 
1942 Military administration. Theatre of war 
1945 Provisional administration by Australia 
1949 
Permanent civil administration by Australia of the Territory of Papua and 
the United Nations Trust Territory of New Guinea 
1975 Independent State of Papua New Guinea 
1978 Organic Law establishing Provincial Government 
1995 Organic Law devolving health services to Provincial and Local government 
 
From 1914 onwards population studies using the tuberculin skin test (TST) were 
conducted, showing an increasing number of TB cases in Papua New Guineans which 
were more often serious or fatal than in expatriates (Clements FW 1936; Heydon 1937; 
Kersten H.E. 1915). Infections appeared first in young men and spread later to children 
and women, especially in those villages where people had been recruited to work on the 
sugar fields in Rabaul or outside of PNG. For example, Kersten (Kersten H.E. 1915) 
reported that between 1912 and 1913 none of 44 men from the upper Waria river 
(Morobe province), with no experience of plantation work, reacted to the von Pirquet 
test whilst 23% of 135 male adults from the lower Waria river, where many had worked 
on plantations, reacted positively to tuberculin. The results of such studies (Clements 
FW 1936; Heydon 1937; Kersten H.E. 1915) led to the building of an isolation hospital 
on an island near Port Moresby (Wigley S.C. 1990).  
 
Wigley summarized data from various reports for the German Colonial Office during the 
first 40 years of the 20th century which showed that the von Pirquet test, applied to all 
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new labour recruits in Rabaul, had an alarming increase of positive reactions over a 
period of only 5 years. A positivity rate of 5% in new recruits in 1920 increased to 
42.8% in 1921 and to 51.5% in 1925. By 1922, 20.7% of all deaths in Rabaul were 
attributed to TB and infection rates seemed to be strongly correlated with contact to 
expatriates through labour trade or missionaries (Wigley S.C. 1972). Tuberculin skin test 
surveys for the National TB Control Program were conducted from 1950 to 1966 and by 
1963, evidence of infection in all provinces of PNG was found (Wigley S.C. 1991). TB 
infection rates summarized in an undated monograph of Wigley (Wigley S.C. 1972) 
provide basic data for TB in PNG from 1950 through to Independence in 1975, although 
methods of data collection and information on Bacille Calmette-Guerin (BCG) 
vaccination is lacking. There were major differences in TB infection rates between 
coastal and highlands provinces. Infection rates ranged from 86.7% in Kavieng Town 
(New Ireland Province) and 81% on Sisiame Island (Western Province) to 0.2% in 
Kopiam village and 0.9% Laiagam villages (both Western Highlands Province), reflecting 
the impact of the long isolation of the highlands from the outside world. Between 1950 
and 1975 more studies reported TB infection rates obtained through various methods 
including Manteaux test, sputum smear examination and clinical examinations such as 
chest X-ray (CXR) (Mylius L.E. and Wigley S.C. 1971; NORTH and JAMIESON 1950). 
Although direct comparisons are difficult there appears to be little doubt that infection 
with TB increased in most provinces in PNG throughout this period. It is noteworthy 
that infections in relatively isolated regions were still found mostly in adult males. For 
example, between 1959 and 1966 in the Highlands Region infection rates in females 
were 0 to 2%, whereas in males they reached up to 12.5% (Wigley S.C. 1972). In less 
isolated regions higher infection rates were found in adults over 15 years regardless of 
gender and in settlements of Port Moresby active tuberculosis was almost equally 
present in children and adults (Mylius L.E. and Wigley S.C. 1971). Overall, the coastal 
population of PNG showed much higher TB infection rates than the highlands 
population, which seemed to have been free of TB until the 1950s, which supports again 
the hypothesis that occurrence of TB infections in the PNG population was dependent on 
the intensity of early contact with Europeans and the degree of urbanization.  
 
Wigley showed that 80% of the coastal population had a positive reaction to TST before 
BCG vaccination which increased to 85% after vaccination (Wigley S.C. 1972). In 
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contrast, only 1% of the highlands population reacted to TST before vaccination and 
only 10% subsequently after vaccination. The duration of skin test reactivity also varied 
and waned quickly in the highlands population whilst it stayed for several years in the 
coastal population (Bagshawe A. et al. 1989; Wigley S.C. 1974). Bagshawe et al. 
(Bagshawe A. et al. 1989) found almost no natural reaction to TST before vaccination in 
Karimui (Eastern Highlands Province) in the 1960s, but reactivity increased to 87.4% 3 
months after vaccination only to drop to 60.4% within 9 months. It has been speculated 
that short-lived reactivity to tuberculin was due to the lack of superinfecting non-
tuberculosis mycobacteria (NTM). Several studies suggested that almost no such 
infection occurred in the highlands, which could explain the low natural reaction rate 
(Bagshawe A. et al. 1989). This was further supported by a TST sensitivity study 
conducted by Brown et al. (Brown et al. 1981) in which also no reactivity to atypical 
mycobacterial antigens could be found. Still, it is yet unclear why these differences in 
reaction to tuberculin in different populations occur but genetic factors have been 
implicated in determining a TST reaction (Schurr 2011) and also influencing immune 
responses and memory to BCG (van den Biggelaar et al. 2009). In PNG with its human 
genetic diversity this could well play a role. 
 
After Independence in 1975, it was confirmed again that TB prevalence was higher in 
coastal sites than in the highlands. There was not only a difference in TB prevalence but 
TB presented itself with a different phenotype in the highlands (Kaupa L et al. 1982). 
Kaupa et al. reported that from 1980-81 only 23.2% (13/56) of all TB patients from the 
highlands presenting at Goroka General Hospital (GGH) had pulmonary TB, all others 
suffered from extrapulmonary TB. In comparison, 75% (2896/3809) of coastal patients 
suffered from pulmonary TB in 1979 (Kaupa L et al. 1982). There are limitations in the 
data since most extrapulmonary TB is diagnosed on clinical signs and not confirmed 
bacteriologically, but it is evident that less pulmonary and less post-primary cavitating 
TB was found in the highlands.  
 
The situation seems to be similar today and although case notifications reported in the 
National Strategic Plan are derived from only 9 of 20 provinces (PNG National 
Department of Health 2011), it remains that most TB cases in 2010 came from coastal 
areas and a high prevalence of extrapulmonary TB was reported from the highlands. 
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Whether this pattern remains and reflects the epidemic situation in the highlands, 
where people rarely have encountered the bacilli in childhood and hence develop at 
older age primary tuberculosis either in the lungs or disseminated needs to be further 
investigated.  
 
2.3.2 HIV/TB co-infection and risk factors 
In 2011 HIV prevalence in the adult population aged 15 to 49 years was estimated to be 
0.9% in PNG (PNG National Department of Health and PNG National AIDS Council 
Secretariat 2010); 9.8% of TB patients with known HIV status were HIV positive (World 
Health Organization 2013b). Seaton et al. (Seaton A. et al. 1996) reported in 1996 that 
56% of 67 enrolled HIV patients were diagnosed with TB at Port Moresby General 
Hospital (PMGH). This might have been overestimated since it was solely based on CXR 
for the diagnosis of pulmonary TB but nevertheless reflects the high level of co-infection.  
 
Other known risk factors for TB include malnutrition, smoking and diabetes (Dye et al. 
2011; Lin et al. 2007). Diabetes is known to increase the risk of TB 2-3 fold, and its 
prevalence is increasing in PNG. In five of 160 diabetes patients attending PMGH, 
pulmonary TB was diagnosed which gives an 11 fold higher annual incidence rate for TB 
in this group than had been estimated for the general population (Patel MS 1989). 
Chewing of betel nut is very common in PNG (areca nut, nut of the areca catechu palm, 
“buai”) and it has been shown to cause oral cancer and other oral diseases in humans 
(Gupta and Ray 2004). There has been growing concern that spitting of betel nut saliva 
could contribute to TB transmission but no study has yet investigated this nor has the 
impact on TB of alcohol consumption or smoking been studied in PNG. Similarly, no 
studies have investigated consequences of co-infections with helminths on the burden of 
TB in PNG, although there is a high prevalence of helminth infections and known effects 
of such co-infections on the immune response against TB (Salgame et al. 2013). 
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2.3.3 Drug resistance  
Only in 2012 did country-wide surveillance for DR commence in PNG and little 
information is available. There is no biosafety level three laboratory in PNG, thus sputa 
of suspected DR cases are sent to Australia for drug susceptibility testing (DST) (PNG 
National Department of Health 2011) leading to a significant delay in diagnosing 
patients and in initiation of appropriate second-line treatment. This increases the period 
in which transmission of resistant strains might occur. In 2012 the first XDR TB cases 
were reported (McBryde 2012). Most information on DR in PNG is obtained from 
Australia where migrants are screened either in the Torres Strait Islands cross-border 
region (Gilpin et al. 2008; Simpson et al. 2011), or migrants from PNG entering Australia 
by air (Simpson et al. 2006). Simpson et al. (Simpson et al. 2006) showed that all MDR-
TB cases detected in Far North Queensland between 1998 until 2002 were from PNG, 
and Lumb and colleagues from the Mycobacterium reference laboratory network (Lumb 
et al. 2011) reported that a substantial proportion of MDR-TB cases in Australia in 2008-
9 originated in Western Province, PNG (6/21 in 2008; 11/31 in 2009). Importantly, the 
majority of these MDR-TB cases seemed to be primary DR strains giving evidence for on-
going transmission of MDR-TB in PNG (Gilpin et al. 2008).  
 
Western Province has been estimated to be the province with the highest TB burden in 
PNG, with an estimated incidence 2-3 times higher than the national level (McBryde 
2012). From there the first PNG XDR TB case originated. Already in 2008 Gilpin et al. 
reported pre-XDR TB cases (MDR-TB also resistant to quinolones) from Western 
Province thus foreseeing the emergence of XDR TB (Gilpin et al. 2008). A study in 2012 
conducted in Madang Province in the north of PNG showed that 15.7% of 172 TB cases 
were resistant to at least one drug, and that 5.2% were MDR cases (Ballif et al. 2012b). 
Although these numbers cannot be extrapolated to the whole country they are alarming 
and add force to the fact that PNG urgently needs to address the MDR-TB problem. This 
is reinforced by data from the Central Public Health Laboratory (CPHL) of PNG from 
2011 where it was shown that 77% of 87 suspected drug resistant re-treatment cases 
(having received TB treatment for at least 1 month during a previous episode) were 
indeed resistant and of these 61% were MDR (PNG National Department of Health 
2011). Consequentially, there is an urgent need for drug resistance testing in PNG either 
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bacteriologically or by molecular means but also for monitoring drug quality, 
availability, and compliance to treatment. Improving the directly observed treatment 
strategy (DOTS) in PNG is not sufficient if drug resistance cannot be monitored 
simultaneously.  
 
Overall, the few available studies provide baseline information on DR for some 
provinces but no inferences can be drawn for PNG as a whole. Large differentials are to 
be expected because of regional variation in incidence, the general diversity of the 
population and because of variable quality in the implementation of the National 
Tuberculosis Control Program (NTP) which is a provincial responsibility. 
 
2.3.4 Mycobacterium tuberculosis genotypes 
Compared to other bacteria the Mycobacterium tuberculosis complex (MTBC) shows low 
genomic variability and very little horizontal gene transfer (Sreevatsan et al. 1997). 
Outcome of TB infections and transmission are determined by a range of factors which 
include host genotypes (Caws et al. 2008), socio-economic conditions, and bacterial 
genotypes (de Jong et al. 2008; Muller et al. 2012). With the advent of genotyping 
methods in the early 1990s various studies found associations between certain MTBC 
genotypes and disease pattern, differences in virulence of distinct strains, an association 
of drug-resistance with the so called Beijing family of strains (Coscolla and Gagneux 
2010).  
 
In addition, genotyping is used to identify outbreaks, to investigate transmission 
dynamics, and to determine the origin of the Mtb strains circulating in a population. 
Genotyping is the only means of determining whether a strain has been introduced into 
a country or population; robust phylogenetic markers for MTBC exist (Gagneux et al. 
2006b). Mtb can be separated into seven main lineages based on long sequence 
polymorphisms and these lineages have been found associated with specific geographic 
regions and human populations with differing incidence and risk for TB (Coscolla and 
Gagneux 2010; Yen et al. 2013). For example, Yen et al. showed that the indigenous 
population of New Zealand had a 6 to 18 times higher rate of TB than descendants of 
Europeans in New Zealand and that the lineage distribution differed significantly 
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between those two groups (Yen et al. 2013). Since Mtb is at least 70’000 years old and 
seems to have co-evolved and migrated with humans (Comas et al. 2013) one could 
speculate that TB was probably present in PNG before European contact. This leaves two 
options, either the disease had died out prior to the arrival of the Europeans due to small 
and isolated populations unable to sustain transmission, or, the “ancient TB” was 
sustained at a low frequency in some populations (e.g. in the highlands) but had been 
replaced by modern and more successful lineages in most populations with the arrival of 
Europeans. There is good evidence that “modern” strains show increased success and 
strain specific differences in virulence and progression to active disease (de Jong et al. 
2008) when compared to the “ancient” strains. It was reported for example, that the 
prevalence of M. africanum (ancient) which used to be the predominant strain in 
Cameroon has drastically decreased and seemed to be replaced slowly by a recently 
emerged strain family of lineage 4 (modern) between the 1970s and 2009 (Assam et al. 
2013; Niobe-Eyangoh et al. 2003). There is also little information available on Mtb 
lineage distribution in Melanesia or PNG. Aleksic et al. (Aleksic et al. 2013) found in 
Kiribati an almost equal distribution of Lineage 2 (East-Asian lineage) and Lineage 4 
(Euro-American lineage). Since no MDR had been detected, an association with a specific 
lineage could not be investigated.  
 
In PNG two studies involving Mtb genotyping were conducted. Gilpin et al. (Gilpin et al. 
2008) found that between 2000 and 2006 15 of 60 isolates from severely ill patients 
from Western Province living in the Torres Straits belonged to the Beijing-type of 
Lineage 2. Ballif et al. (Ballif et al. 2012a) investigated TB cases from Madang and found 
a similar proportion of Beijing strains and showed that 77% of the collected samples 
belonged to Lineage 4. It is however not possible to infer a genotype distribution in PNG 
as whole from such small samples representative of only two populations. Hence, it 
remains to be determined whether ancient strains are present in other parts of PNG, in 
particular in the more remote and isolated areas. Because disease phenotypes appear to 
be determined by bacterial genotypes and because of the differences in disease 
presentation between highlands and coast (Caws et al. 2008), (Kaupa L et al. 1982; Lari 
et al. 2006), we are currently addressing this question by conducting studies in the 
coastal area of Alotau (Milne Bay Province) and in the Goroka district (Eastern 
Highlands Province).  
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2.4 Tuberculosis control 
The first attempt at TB control in PNG was probably the establishment of an isolation 
hospital on Gemo Island in 1937 (Wigley S.C. 1990) but the first official National TB 
Control Program (NTP) based on modern chemotherapy was implemented in 1950 
(Levy et al. 1998; NORTH and JAMIESON 1950; Wigley S.C. 1991). A Tuberculosis 
Control Unit (TBU) of the Department of Health was formed which conducted mass 
examinations and determined TB prevalence in communities through mass miniature 
CXRs and TSTs. Subsequently, BCG vaccination was introduced and a mass vaccination 
campaign was conducted in the highlands (NORTH and JAMIESON 1950; Wigley S.C. 
1972). The control program also included school medical services, the establishment of 
a thoracic surgery program (Wigley S.C. 1990; Wigley S.C. 1991) and facilitated 
cultivation of mycobacteria (Becker A.A. 1961; Wigley S.C. 1990). It emphasized mobile 
patrols for surveillance rather than depending on passive diagnosis from within health 
facilities, and was coordinated in a highly centralized way. This changed drastically with 
the establishment of the Organic Law on Provincial Governments and Local Level 
Governments in 1977 and the New Organic Law in 1995 in which ‘the management and 
service delivery of rural health services’ were handed over from the National 
Department of Health (NDoH) to the provincial and local governments (Day 2009). This 
organisation remains in place until today and strongly affects the health service sector. 
Since the quality of a control program is dependent on the developmental state of a 
province it is difficult to extrapolate data from one province to the whole country. In this 
section we provide a short overview of various parts of the TB control program, namely 
prevention of TB, case detection and diagnosis, and treatment and management of TB 
patients.  
 
2.4.1 Prevention  
Because little TB was detected in the highlands in the late 1950s, it was thought that this 
population was at high risk of primary TB infection (Wigley S.C. 1972). Throughout the 
1960s BCG vaccine was therefore administered to all age groups in the highlands 
including adults (Kaupa L et al. 1982; NORTH and JAMIESON 1950). The country wide 
expanded program on immunization recommended a 3-dose regimen for BCG in 
children because of waning tuberculin reactivity (Balibaseka Bukenya G. 1987; Levy et 
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al. 1998) although WHO recommendation was only one dose at birth. This 3-dose 
strategy was kept for decades and only changed to one dose in the late 1990s. BCG 
vaccination remains part of the PNG NTP until today. 
 
Globally, the effectiveness of BCG varies in different populations and geographical 
regions (Fine 1995) and with its large human genetic diversity and its environmental 
differences, PNG could be expected to differ not only when compared to other countries 
but also between provinces. This becomes obvious since PNG neonates elicited a 
different immune reaction against atopic diseases compared to Western Australian 
neonates when primed with BCG (van den Biggelaar et al. 2009). For example, IFN-γ 
production in response to BCG was significantly enhanced in both study groups but to a 
much lower extend in PNG new-borns compared to Western Australian neonates. Other 
studies have examined BCG coverage and TST reactivity before and after vaccination in 
specific study sites (Brown et al. 1981; Mirou P. and Masere D 1983). There has however 
never been a study of the efficacy of BCG in PNG.  
 
2.4.2 Detection/Diagnosis 
For several decades in the early twentieth century, TB was diagnosed by TSTs such as 
the Manteaux test (Kersten H.E. 1915; Murtagh K. 1980; NORTH and JAMIESON 1950). 
From the mid 1930ties CXR also became available in PNG and physicians began to 
biopsy lesions to diagnose TB (Backhouse TC 1956; Woibun M. and Naraqi S. 1979). 
Sputum smear microscopy became available in hospitals in the post-war period and 
sputum culture became available in a few. Sputum smear microscopy was widely 
introduced in 1975 (Levy et al. 1998), and became the main diagnostic tool to control 
the spread of TB in the community (Spicer P.E. and Lucena G. 1998; Vanadevan T. 1979). 
Although CXR has a higher false positive rate than sputum smear microscopy (Borgdorff 
et al. 2002) it was - and is still today - widely used to diagnose pulmonary TB, 
particularly in sputum smear negative patients.  
 
Historically, it is not clear whether a case-finding approach and treatment at home was 
integrated into the PNG control program with limited success as described by Levy et al. 
(Levy et al. 1998), or, whether there was no definite and planned case finding strategy at 
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all until 1990 (Mondia 1990). In any case, in 1997 the internationally recommended 
DOTS strategy for the control of TB was being implemented in PNG (Levy et al. 1998). 
DOTS requires the health system to provide access to standardized treatment, to ensure 
drug intake for all TB cases, and to provide quality-assured sputum microscopy. 
However, more than 10 years after the introduction of DOTS to PNG, the coverage rate 
was only 51% in 2010 (PNG National Department of Health 2011). The case detection 
rate was the lowest in 7 high TB burden countries of the Western Pacific Region in 2007 
(van Maaren et al. 2007) and the cure rate was only 53% in 2011 (World Health 
Organization 2013b). It has been shown repeatedly that the most effective control 
strategy to decrease TB transmission would be to increase DOTS coverage (Hickson et 
al. 2012) and indeed, treatment success rates were 80% in 2010 in those provinces that 
had implemented DOTS, whereas the lowest rates were observed in provinces which 
had not yet introduced DOTS (PNG National Department of Health 2011). The increase 
of DOTS coverage was a priority of the National Strategic Plan 2006 to 2010 (PNG 
National Department of Health 2011) in which it was aimed to cover all 20 provinces 
and 80% of the population by the end of 2012. During that period the quality of DOTS 
coverage and case detection was questioned (Ongugo K et al. 2010) since apparently all 
provinces had introduced DOTS but only 69% of the population was being reached. 
Nevertheless, cure rates had drastically been improved with 80% of smear positive 
cases being successfully treated but there was still a poor performance in terms of drug 
supply and only 40% of facilities sent quarterly reports on TB as required by national 
guidelines (The Global Fund to fight AIDS Tuberculosis and Malaria and PNG National 
Department of Health 2006).  
 
In 1961 Becker reported culturing of M. tuberculosis in PNG (Becker A.A. 1961) but this 
has changed because of obvious safety reasons and at the present time Mtb culture 
cannot be performed within the country. All samples requiring culture and DST have 
still to be sent to the Queensland Mycobacterium Reference Lab (QMRL) in Brisbane, 
Australia. This way, only samples of suspected MDR-TB cases are sent and no systematic 
monitoring of resistance is being conducted. Improvement of diagnosis but also of rapid 
detection of MDR-TB cases is possible through the use of the Xpert® MTB/RIF (Cepheid) 
which has been introduced in few centralized places in PNG (PNG National Department 
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of Health 2011), but needs urgently to be introduced generally. However, DR other than 
RMP resistance cannot be identified by this approach.  
 
To significantly curb TB in PNG, case detection rates have to increase and the DOTS 
program must ensure compliance and access to accurate treatment. An active case 
detection study conducted in rural communities in Madang province between November 
2005 and March 2006 identified a substantial number of TB positive patients 
(Phuanukoonnon et al. unpublished). Reducing the number of non-identified infections 
would substantially reduce transmission but again requires diagnosis through quality 
smear microscopy and probably a changed health seeking behaviour. Xpert® MTB/RIF 
(Cepheid) could play an essential role here but its true value might only be assessed in a 
few years. 
 
2.4.3 Treatment 
The era of chemotherapy against TB started with Streptomycin (SM) in 1946 followed 
by Isoniazid (INH) in 1952 and Para-Amino-Salicylic Acid (PAS). The early treatment 
regimens in PNG consisted of an intensive phase with INH PAS and SM for three months 
and a maintenance phase of INH and PAS for 21 months. All Highlands patients were 
treated in coastal hospitals for the full two years to reduce chances of transmission in 
the highlands.  In the 1970s Thiacetazone was added and the total duration of treatment 
shortened (Jamieson D 1955). Compliance rates were then poor, but improved 
drastically with the introduction of the short course chemotherapy (SCC) in 1984 for 
children (Biddulph et al. 1987) and 1989 for adults (Levy et al. 1998) with a regimen 
including RMP and PZA reducing treatment duration drastically from 18 to 6 months. 
Jamieson et al. described in detail how the different presentations of TB were managed 
and treated in the 1950s before SCC (Jamieson D 1955) when surgery was conducted if 
chemotherapy was not an option. Ten years later surgery was still conducted if 
chemoprophylaxis failed but only in cases of spinal tuberculosis (Jamieson D 1955). 
Since 2007 TB treatment in PNG follows WHO recommendations consisting of a fixed 
dose combination (FDC) of 4 different drugs (Levy et al. 1998). Several studies showed 
an alarmingly high number of defaulters in PNG (Garner and Hill 1985; Levy et al. 1998; 
Ongugo K et al. 2010). This is influenced by health seeking behaviour, belief in sorcery, 
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lack of knowledge of the disease (Maibani G. et al. 2010; Wari K and Wigley S.C. 1974) 
but long distance to the closest health facility (Jamieson D 1955), social and financial 
pressure, the attitude and performance of health workers towards patients, and also 
limited drug supply are additional reasons (Wari K and Wigley S.C. 1974). To overcome 
this problem various approaches have been taken, such as out-patient treatment with 
regular and close supervision of the patients in the 60s and 70s (Wari K and Wigley S.C. 
1974; Wigley S.C. 1960). Garner et al. (Garner and Hill 1985) described methods that 
were tried in Aitape, Sandaun province which included patient participation (former 
patients talking about their experience), showing patients their microscopy slides or 
CXR films, reduction of out-patient treatment duration, and even threatening patients to 
withhold treatment after defaulting. These strategies seemed to have improved 
compliance but not all of them are feasible today. Instead, reliable drug supply, 
intensifying follow-ups, and thorough contact tracing would not only decrease the 
defaulter rate but also increase TB case detection. 
 
2.5 Conclusion 
Although more data have been compiled on TB in PNG over the last few years there is 
still no comprehensive description of the disease for the whole country. Importantly, all 
available data suggest a threat of increasing transmission, the advent of MDR and even 
of XDR-TB. Therefore comprehensive, accurate and timely data about the epidemiology 
of TB and prevalence of DR in PNG are an absolute priority. Although TB appeared to 
have been brought under control in the early 1970s (Wigley S.C. 1991) this was either 
overly optimistic or the situation has changed dramatically due to the emergence of DR 
and the epidemic of HIV/AIDS. Overall, reported cure rates are well below development 
goals for WPR and accuracy of diagnosis and DOTS coverage are well below 
international standards. 
 
PNG has been isolated for a long time from the outside world and some parts remained 
without contact even until the 1980ties. The human population with its vast genetic 
diversity and the limited outside interferences through human migration provide an 
ideal platform for TB research and its evolution. The emerging evidence that “modern” 
strains transmit more successfully than “ancient” lineages (Gagneux 2012) could well be 
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tested by genotyping samples from various sites in PNG, including remote sites, and thus 
might give insight into the evolution of M. tuberculosis in PNG. At the same time it would 
allow to explore differences in M. tuberculosis strains circulating in high or low incidence 
settings and in urban or rural settings. With this research addressing important 
evolutionary questions essential information of incidence, prevalence and degree of 
drug resistance for PNG could be obtained and thus would strengthen the TB control 
strategies in PNG for the benefit of the population of this country (Gilpin et al. 2008; 
Simpson et al. 2011).  
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Sputum sample processing, PNG IMR TB lab, Madang 2010 
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3 Rationale, aims and objectives 
3.1 Active case detection approach 
3.1.1 Rationale 
In Papua New Guinea (PNG), the current estimates of tuberculosis (TB) incidence are 
based on records from hospitals and health facilities. The numbers therefore only 
represent those cases that attended a formal health care facility while clinical cases that 
resort to traditional treatment or do for other reasons not seek formal health care, are 
not included in the current estimates. The numbers are considered to be an 
underestimation of the TB burden in the country but the prevalence of undetected TB 
cases in the community is unknown. Estimates of drug resistance are equally 
compromised by this lack of information, amongst other factors discussed in the 
introduction. To obtain a better estimation of the real TB burden in PNG and to 
complement previous findings on drug resistance and circulating Mycobacterium 
tuberculosis (Mtb) genotypes, an active TB case detection (ACD) survey was planned to 
be conducted in sentinel sites across the country. 
 
3.1.2 Aim  
The overall aim of this project was to contribute to a better understanding of the 
molecular epidemiology of TB in selected sites across the country, including the 
population based prevalence, the population structure of Mtb genotypes and the 
frequency of drug resistance. Active case finding could contribute to improved, locally 
adapted control strategies. 
 
3.1.3 Objectives 
The specific objectives of the study were as follows:  
 
1. To determine the prevalence of pulmonary tuberculosis in selected sentinel 
sites in Papua New Guinea 
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2. To assess and compare the Mycobacterium tuberculosis strain diversity and 
distribution in selected sites of Papua New Guinea 
 
3. To determine and compare the proportion of Mycobacterium tuberculosis 
resistant to standard tuberculosis treatment in selected sites across Papua 
New Guinea 
 
a. To determine the phenotypic drug resistance of each strain 
b. To investigate the drug resistance genotype of each phenotypically 
drug resistant strain  
 
4. To investigate the correlation between certain Mycobacterium tuberculosis 
genotypes and phenotypic drug resistance  
 
3.2 Passive case detection approach 
3.2.1 Rationale 
After the completion of the active case detection survey in the first two sentinel sites - 
one each in two different provinces- it became evident that the number of undetected TB 
cases in the community was lower than expected in the planning phase of the active case 
detection survey. The number of samples collected in the two sites was insufficient to 
draw a scientifically sound conclusion about the prevalence of drug resistance or the 
distribution of Mycobacterium tuberculosis genotypes in the respective locations (see 
chapter 5). As a consequence, three of the main study objectives (3.1.3 objectives 2-4) 
could not have been met. The extension of the survey to further sentinel sites, with the 
aim of obtaining at least sufficient aggregated data, was at that time compromised by 
delays in the establishment of those sites by the respective program (Hetzel et al. 2014). 
In order to compensate for the lacking number of samples, we complemented our study 
design with a passive case detection approach in three urban hospitals. For this purpose, 
we continued the sample collection of a previously established passive case detection 
study in Madang and established additional study sites in two further provinces. This 
allowed the comparison of the TB situation in different sub-populations of PNG, 
especially in the light of the distinct genetic background of the host populations. The 
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continuation of the ACD survey after the establishment of further sentinel sites was not 
possible due to financial restrictions.  
The resulting changes in the aim and objectives of the study are described below.  
 
3.2.2 Aim 
The overall aim of the project presented here was to contribute to the understanding of 
the epidemiology of TB in PNG, including drug resistance and the population structure of 
Mycobacterium tuberculosis. Molecular epidemiological investigations in three sub-
populations of PNG can provide relevant information for adapting control and 
monitoring strategies to the local context.  
 
3.2.3 Objectives 
 
1. To establish and maintain two new study sites and contribute to the 
maintenance of one existing site for the passive case detection of TB cases 
 
2. To assess and compare the Mycobacterium tuberculosis strain diversity and 
distribution in selected sites of Papua New Guinea 
 
3. To determine and compare the proportion of Mycobacterium tuberculosis 
resistant to standard tuberculosis treatment in selected sites across Papua 
New Guinea 
 
a. To determine the phenotypic drug resistance of each strain  
b. To investigate the drug resistance genotype of each phenotypically 
drug resistant strain  
 
4. To investigate the correlation between the Mycobacterium tuberculosis 
genotypes and the phenotypic drug resistance  
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4 Methods 
4.1 Study sites 
4.1.1 Active case detection in sentinel sites 
In order to obtain data from across Papua New Guinea (PNG), the active case detection 
(ACD) surveys (Box 2) were planned to be conducted in seven sentinel sites across the 
four regions of PNG. The sentinel sites were set up primarily for the impact evaluation of 
the Global Fund support to the National Malaria Control Program and comprised 
morbidity surveillance in a central health facility and demographic surveillance in its 
catchment area. The sites provided a platform for studies such as the one presented here 
to benefit from the already established contacts, available infrastructure and personnel. 
Two sites each were established in Southern, Momase and Islands Regions and one site 
in the Highlands Region (Figure 4.1) (Hetzel et al. 2014).  
 
Figure 4.1: Location of study sites in PNG. 
Black dots indicate sentinel sites (active case detection), black dots with a circle indicate sentinel 
sites where active case detection was actually conducted, and stars indicate sites of hospitals 
(passive case detection). Source: adapted from (Hetzel et al. 2014).  
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Due to delays in the establishment of the sentinel sites, particularly the demographic 
surveillance (Hetzel et al. 2014), active case detection surveys were restricted to two of 
the seven sites: around Sausi (Usino Bundi District of Madang Province) between July 
2010 and August 2010, and around East-Cape (Alotau District of Milne Bay Province) 
between November 2010 and December 2010.  
 
Box2: Sample collection strategies 
Definitions  
Active case detection TB cases are actively searched in the 
community 
Passive case detection TB cases are detected when they present to a health facility 
Sentinel site 
Purposely selected surveillance site (in this 
case a rural health centre and the villages in its 
catchment area) 
 
4.1.2 Passive case detection in provincial hospitals 
Passive case detection was conducted in three different provincial capitals - Goroka, 
Eastern Highlands Province; Alotau, Milne Bay Province and Madang, Madang Province – 
thus covering three of four regions of PNG. The selection of sites was based on the 
availability of required infrastructure (e.g. lab facilities with a biosafety cabinet) as well 
as on already established collaborations during our active case detection surveys.  
Sample collection was done in the following facilities: Goroka General Hospital, Eastern 
Highlands Province (from June 2011 to July 2012); Alotau Provincial Hospital and 
nearby Gurney Health Centre, Milne Bay Province (from July 2011 to July 2012) and 
Modilon General Hospital, Madang Province (from November 2010 to June 2012) 
(Figure 4.1). The study site in Madang had been set up in the frame of a previous TB 
cohort study, conducted from April 2009 to October 2010, assessing the level of drug 
resistance and exploring the different Mtb genotypes circulating in Madang (Ballif et al. 
2012a). Activities in this site could draw on the laboratory and office infrastructure and 
human resources of the Madang branch of the PNG Institute of Medical Research (PNG 
IMR). This study site was maintained and samples collected from November 2010 
onwards were included in the presented study. The other two sites were newly 
established in the frame of the presented work in order to compare the situation of drug 
resistance and circulating Mtb genotypes in three genetically and geographically distinct 
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sub-populations of PNG, with known differences in disease presentations and disease 
prevalence (see chapter 2). In Goroka, activities could build up on the laboratory and 
office infrastructure and human resources of the Goroka branch of PNG IMR, whereas in 
Alotau the facilities of the Alotau Provincial Hospital could be used.  
 
4.1.3 Tuberculosis situation in the study areas 
Up-to-date province-level information on the TB situation is not easily accessible and 
the following description therefore relies on several different data sources. Madang 
Province (MAP), Milne Bay Province (MBP) and Eastern Highlands Province (EHP) were 
the three sites where active and/or passive case detection was successfully conducted. 
According to the PNG National Health Plan 2011 – 2020, MBP had the highest TB burden 
(highest case detection rate) of the three study provinces in 2008, but nevertheless MBP 
did not report a markedly higher TB related death rate than the other two provinces 
(National Department of Health 2010). This probably reflects an improved system of 
case detection and patient management compared to the other two provinces. In 2010, 
the three study provinces had all implemented  DOTS and belonged to the five provinces 
of PNG with the highest treatment success (>80%) (PNG National Department of Health 
2011). Demographic data as well as TB prevalence estimates of the study sites are listed 
in Table 4.1 
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Table 4.1: Contextual study site characteristics and TB burden estimates. 
Study Sites Characteristics 
  
Eastern Highlands  
Province 
Milne Bay  
Province 
Madang  
Province Year 
Region Highlands Region Southern Region Momase Region   
Provincial Capital  Goroka Alotau Madang   
Altitude  (meters) 1515 15 12   
Population size 
region 3'001'598 1'302'887 1'795'474 2011 [1] 
Population size 
province 582'159 269'954 487'460 2011 [1] 
Tuberculosis Burden 
  
Eastern Highlands  
Province 
Milne Bay  
Province 
Madang  
Province 
Records 
from Year 
Case notification 
rate (new and 
relapse) 197/100'000 223/100'000 231/100'000 2010 [2] 
Newly detected 
sputum positive 
cases 
44  
(7/100'000) 
193  
(72/100'000) 
163  
(34/100'000) 2008 [3] 
Newly detected 
extrapulmonary 
cases 
192  
(46/100’000) 
207  
(101/100’000) 
161  
(56/100’000) 2008 [3] 
TB related deaths 
70  
(9/100'000) 
27  
(10/100'000) 
50  
(10/100'000) 2008 [3] 
Hospital 
admissions due to 
TB/province   
422  
(78/100'000) 
299  
(148/100'000) 
766  
(151/100'000) 2008 [3] 
HIV 
prevalence/region 
(%) 0.91 0.89 0.64 2011[4] 
References: [1]= GeoHive 2011; [2]= PNG National Department of Health 2011; [3] = National 
Department of Health 2010; [4]= National Aids Council Secretariat Papua New Guinea 2012 
If nothing else is indicated, values are numbers per province. As the information was obtained 
from different reports of different years, rates cannot directly be compared within a province. 
 
4.2 Study design and sample collection  
4.2.1 Active case detection 
In the two study sites Sausi and East-Cape, where the active case detection survey was 
successfully conducted, all households in the sentinel site catchment area were screened 
for persons aged 15 years or older with chronic productive cough (two weeks or 
longer). Study participants were enrolled following written informed consent and 
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questionnaire-based interviews were conducted with all enrolled study participants 
about the clinical presentation of this illness, previously diagnosed episodes and 
treatments of TB of the patient, and history of TB in the patients’ family. Demographic 
variables were also recorded. Information on previous TB diagnosis and treatment was 
used to classify patients into category I or category II (see Box 1 chapter 1). 
 
Three consecutive sputum specimens were collected: the first at enrolment, the second 
sample in the early morning on day two by the patient him/herself and the third sample 
during the follow up visit at the facility, also on day two.  Subsequently, these samples 
were stored at 4°C in a mobile gas fridge for 2-4 days until they could be transported to 
the laboratory for examination by light microscopy. 
 
All study patients (including suspect as well as confirmed TB cases) were registered into 
the National TB Program (NTP) following routine procedures. Patient management and 
treatment in case of a positive diagnosis were the responsibility of the staff of local 
collaborating health facilities following the National Department of Health (NDoH) 
standard TB treatment guidelines (see chapter 1.8.5). 
 
4.2.2 Passive case detection 
Patients aged 15 years or older with chronic productive cough (two weeks or longer) or 
other symptoms suggestive of pulmonary tuberculosis presenting at one of the study 
facilities were identified with the help of local health facility staff and invited to 
participate in the study. In all three sites, patients underwent routine procedures for 
suspected TB cases at the hospital/TB clinic (according to the national TB guidelines) 
such as sputum sample collection, patient registration and diagnosis by microscopy. 
Following written informed consent, patients were enrolled into the study and their 
sputum samples, which were collected by the hospital/clinic, were shared with the IMR 
study team. After a second microscopy examination by trained IMR laboratory 
technicians, the samples were processed and sent to the Queensland Mycobacterium 
Reference Lab (QMRL) in Australia for culture and drug susceptibility testing (DST) as 
described in detail in chapter 4.3. Within the time frame and the financial means of this 
study it was not possible to establish exactly comparable study environments in all three 
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sites. Sample collection and processing in the laboratory therefore had to be adapted to 
the local context, in particular to the local infrastructure, equipment and the availability 
of personnel. In Madang, PNG IMR had set up a research lab that also served as 
diagnostic lab for the TB clinic of the Modilon Hospital. The lab facilities used for the 
study in Madang were therefore an integral part of the national TB program. This eased 
the embedding of the research study into the routine procedures of the national control 
program and facilitated the availability of diagnostic results and treatment outcomes. In 
Goroka on the other hand, diagnosis was performed by the hospital and the TB clinic 
staff, respectively, and the remaining sample was handed over to the study team for 
second reads and sample processing for study purposes in the PNG IMR lab facilities 
located next to the hospital. Results of the different reads were shared between the 
hospital and the study team, and in case of inconsistencies of the overall result (positive 
versus negative), an additional sample was collected. In Alotau, the diagnostic read of 
the sample was also conducted by the hospital staff. As no PNG IMR lab facility was 
available on site, one trained PNG IMR staff was based at the hospital, using the hospital 
lab facilities to prepare additional microscopy slides as well as processing sputum 
samples. These additional slides as well as the samples were regularly sent to Goroka for 
inoculation and shipment of the samples to QMRL in Australia.  The details of the 
enrolment and sample handling procedures for each study site are summarized in Table 
4.2.  
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Table 4.2: Enrolment and study set up in the different study sites of the passive case detection 
survey. 
  Goroka Alotau Madang 
Hospital/Clinics 
Goroka General 
Hospital  
and Goroka TB Clinic 
Alotau Provincial 
Hospital  
and Gurney Health 
Centre 
Modilon General 
Hospital 
Study Duration June 2011 - July 2012 July 2011 - July 2012 
November 2010 - 
July 2012 
Enrolment 
procedure 
During first visit of 
patient before 
diagnosis (TB 
suspected) 
During first visit of 
patient before diagnosis 
(TB suspected) where 
possible, but mainly if 
confirmed positive for 
pulmonary tuberculosis 
Only if confirmed 
positive (based on 
CXR or AFB ZN 
microscopy)  for 
pulmonary 
tuberculosis  
Inclusion criteria 
Chronic cough (2 weeks or longer) or other symptoms suggestive for 
pulmonary TB patients aged 15y or older 
Exclusion criteria 
Patients who were not a resident of the catchment area  
Extrapulmonary TB patients 
Diagnostic 
microscopy read  
Hospital/clinic 
laboratory Hospital laboratory 
PNG IMR laboratory 
Madang  
(serving as hospital 
laboratory at the 
same time) 
Second read  
PNG IMR laboratory 
Goroka 
PNG IMR laboratory 
Goroka 
PNG IMR laboratory 
Madang 
PNG IMR 
personnel on site 
working for or 
assisting in the 
present study 
1 interviewer 
1 microscopist 
1 interviewer/lab 
technician 
1 Physician  
1 HEO + 2 nursing 
officers  
1 CHW 
1 driver 
2 scientific officers 
+ 1 lab technician  
Clinician  
TB physician of  
Goroka General 
Hospital 
TB physician of 
Alotau Provincial 
Hospital 
PNG IMR TB 
physician 
PNG IMR= Papua New Guinea Institute of Medical Research; HEO= Health Extension Officer; 
CHW= Community Health Worker; CXR= chest X ray; AFB ZN= acid fast bacilli Ziehl Neelson 
staining. 
 
All TB positive study patients were treated and managed at the respective hospital or 
clinic (routine procedure according to the NDoH standard TB treatment guidelines, see 
chapter 1.8.5). Since these patients were enrolled in the national TB control program 
through the study hospital prior to joining the IMR study, no additional measures were 
required to ensure patient treatment and follow-up. However, follow up cups (collected 
at months two, five and six after treatment start) were also included in the study and 
therefore processed and sent for culture, where available. 
64  4_Methods 
4.3 Sample processing and diagnosis 
The diagnosis of pulmonary tuberculosis in this study (for both, active as well as passive 
case detection) was based on acid fast bacilli (AFB) direct smear Ziehl-Neelson (ZN) 
staining microscopy (Box 3) which is the standard method used in the frame of the 
national TB program of PNG. Of each of the three sputum samples of a patient a direct 
smear for ZN staining was prepared. Smears for confirmatory diagnosis by fluorescent 
staining (Morse Stain; TB Fluorescent Stain Kit M, Becton, Dickinson and Company, USA) 
were prepared for a subset of samples in the case of ACD and for all samples in the case 
of PCD. Both staining procedures followed the respective manufacturer’s protocol (Box 
3). Subsequently, all three samples of the same patient were pooled into one cup. In the 
frame of PCD, about 1 mL of the pooled sample was removed for sodium hypochlorite 
(household bleach: NaOCl) inoculation and concentration by centrifugation for a 
subsequent additional sputum smear, as described by Angeby et al. (Angeby et al. 2004) 
(see appendix 2). The remaining (or in case of ACD the complete) sample pool was 
decontaminated with NaOH and after 20-30 minutes incubation, neutralized with H3PO4 
as described by Petroff (Petroff 1915) (see appendix 2). Subsequently, an additional 
post-decontamination smear for ZN staining was prepared. The remaining 
decontaminated sample pool was stored at -20°C. Of all pulmonary TB or thoracic TB 
positive patients, an aliquot of the decontaminated sputum samples (where available) 
was inoculated into Mycobacterial Growth Indicator Tubes (BACTECTM MGITTM 960 
system; BD, Franklin Lakes, NJ, USA) and sent in batches to QMRL for culture and drug 
susceptibility testing (DST). The MPT64 antigen immuno-chromatographic test (SD 
Bioline/BD) was used to determine if the grown AFBs belonged to the Mycobacterium 
tuberculosis complex (MTBC) (excluding BCG) or to the so called non-tuberculous 
mycobacteria. In case of the latter, further speciation (e.g. for M. fortuitum or M. 
intracellulare) was done with the GenoType® Mycobacterium CM line probe assay (Hain 
LifeSciences, Nehren, Germany). Both, the MPT64 test as well as the line probe assay, 
were conducted according to the manufacturer’s protocol. Only MTBC strains were 
subject to DST. Drug susceptibility testing was performed by the proportion method 
(Canetti et al. 1969). Drug concentrations used were as follows: 1.0µg/mL rifampicin, 
0.1 and 0.4µg/mL isoniazid, 5.0µg/mL ethambutol, 100µg/mL pyrazinamide and 
1.0µg/mL streptomycin. In case of multi-drug resistance detection the following drugs 
were tested in addition: 5.0 µg/mL kanamycin, 1.0µg/mL amikacin, 2.5 µg/mL 
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capreomycin, 2.0 µg/mL ofloxacin, 5.0 µg/mL ethionamide, 4.0 µg/mL p-aminosalicylic 
acid and 50.0 µg/mL cycloserine.  
 
Aliquots of successfully grown culture samples of Mycobacterium tuberculosis were 
stored in dubos broth, a prepared tubed medium for cultivation of mycobacteria 
(Becton, Dickinson and Company, Maryland, USA), and sent to the Swiss Tropical and 
Public Health Institute (Swiss TPH) in Basel, Switzerland for genotyping.  
 
Box 3: Microscopy staining methods and bacterial quantitation scale  
Staining procedure 
Staining steps 
Light microscopy Fluorescent microscopy 
Ziehl-Neelson Auramine/Rhodamine 
1. Heat-fixation of smear on microscopy slide 
2. Primary staining 
Carbol Fuchsin  
(heated)  
Auramine or  
Auramine/Rhodamine 
3. Decolourization  
Sulphuric acid  
(or other acid alcohol) 
Acid alcohol 
4. Counterstaining 
Methylene blue or  
Malachite green 
Potassium permanganate 
Bacteriological index: count  of bacteria on slide 
Ziehl Neelson 
(x1000) 
Auramine/Rhodamine 
(x450) 
Report 
 
No AFB per 100 fields 0 AFB negative 
1-9/100 fields 
observed count  
divided by 4 
Scanty positive (exact count) 
10-99/ 100 fields AFB positive 1+ 
1-10/fields AFB positive 2+ 
>10/field AFB positive 3+ 
AFB = Acid Fast Bacilli; Source of information: Tuberculosis 2007 (de Waard and 
Robledo 2007) 
 
For a proportion of samples DNA was extracted from culture by InstaGene Matrix (Bio-
Rad, Hercules, CA, USA) where the pellet of one bacterial colony resuspended in 1 ml of 
autoclaved water was mixed with 200 µl of InsteGene matrix, incubated at 56°C for 15-
30 min. and subsequently vortexed and heat killed at 100°C for 8 min. The supernatant 
was then used for molecular analyses. For most of the samples, DNA was obtained from 
heat kills, where 100 µl of Mtb inoculated into Dubos broth (prepared tubed medium for 
cultivation of mycobacteria; Becton, Dickinson and Company, Maryland, USA) were 
66  4_Methods 
mixed with 100 µl distilled water and subsequently inoculated at 90°C for 1 hour, 
centrifuged at full speed and the supernatant used for molecular analyses. For samples 
sent for whole genome sequencing, 100 µl of Mtb inoculated into Dubos broth were 
transferred into 10 ml of Middlebrook 7H9 broth (Becton, Dickinson and Company, 
USA). After 4-6 weeks of growth, 500 µl of that liquid culture were inoculated into fresh 
10 ml of Middlebrook  7H9 broth and incubated for another 3 weeks before DNA was 
extracted using the CTAB method as described by Ausubel et al. (Ausubel et al. 1994).  
 
4.4 Genotyping of Mycobacterium tuberculosis 
4.4.1 Drug resistance genotyping 
All phenotypically drug resistant samples of which DNA could be obtained were 
screened for DR associated mutations (see chapter 1.6). Ten genes known to be involved 
in mechanisms leading to resistance against common TB drugs were amplified and 
subsequently sequenced by Macrogen (The Netherlands) as described in chapter 6. 
Condon positions for resistance conferring mutations in rpoB are usually indicated as 
positions on the E. coli orthologous gene (Miller et al. 1994; Ramaswamy and Musser 
1998; Telenti et al. 1993), in which these mutations have extensively been studied (Jin 
and Gross 1988; McClure and Cech 1978). This reporting system is also used throughout 
the present thesis. Codon positions for all other genes are positions on the respective 
Mtb gene.  
 
4.4.2 Mycobacterium tuberculosis strain genotyping 
All isolates of which DNA was available were classified into the six main lineages by a 
single nucleotide polymorphism (SNP)-based TaqMan real-time PCR assay (Stucki et al. 
2012) and subsequently grouped into spoligo families by spoligotyping (Kamerbeek et 
al. 1997). Further subtyping was conducted based on regions of difference for all lineage 
2 samples (Tsolaki et al. 2005) as described in chapter 6 and with a SNP based 
fluorescent microsphere assay run on a Luminex flow cytometer for lineage 1 and 
lineage 4, respectively (Stucki et al. in preparation). Phylogenetically informative SNPs 
were determined through principle component analysis, genomic distance and large 
sequence polymorphisms of all SNPs obtained from 72 lineage 4 and 50 lineage 1 whole 
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genomes, respectively. With the help of these SNPs, ten lineage 4 (X, Haarlem, Ghana, 
Ural, Vietnam, LAM, Iran, Uganda, Cameroon and PGG3) (Stucki et al. in process) and six 
lineage 1 subtypes (L1.1, L1.2, L1.3, L1.4, L1.5 and L1.6 (Rutaihwa 2014)) can be 
distinguished.  
 
4.4.3 Whole genome sequencing  
Whole genome sequencing was carried out for ten selected lineage 2 typed strains, for 
seven Latin American Mediterranean (LAM) family strains of lineage 4 and for all lineage 
1 typed strains. Short read libraries were prepared using the Nextera® XT DNA sample 
preparation kit (Illumina, San Diego, USA) with inserts of 500 base pairs following  the 
manufacturer’s recommendations, and which were then paired-end sequenced 
(barcoded and multiplexed) on an Illumina MiSeq device. Before aligning, raw reads 
were trimmed using the Burrows-Wheeler Alignment tool (BWA 0.6.2) (Li and Durbin 
2009) to remove all bases with quality below 20. Short reads were then mapped to a 
hypothetical MTBC ancestral genome (Comas et al. 2010) and single nucleotide 
polymorphisms were called using SAMtools/BCFtools version 0.1.12a (Li et al. 2009) 
per strain. All variants called in this way were pooled, generating a non-redundant list of 
variable positions and annotated based on the H37Rv reference genome (Cole et al. 
1998). Variants called in repetitive regions in the genome (PE, PPE-PGRS genes, phages 
and insertions sequences) were removed. On a following step, this list of annotated non-
redundant variable positions was used for recovering again the genotype of each strain.  
In order to recover the phylogenetic position of the strains analysed, the information on 
their variants was pooled with that of other strains with available genomes and then 
used to build nucleotide alignments containing only variable positions across the 
complete genome. Phylogenetic trees were obtained using the model GTR implemented 
in RAxML with 1000 rapid inferences, followed by a thorough maximum-likelihood 
search (Stamatakis 2006) trough CIPRES (Miller et al. 2010). Genetic differences among 
strains were inferred by directly counting number of mutations using the software 
MEGA 5.05 (Tamura et al. 2011). 
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For the confirmation of mutations associated with drug resistance, bam files generated 
with SAMTools 0.1.18 (Li et al. 2009) were visualized with the Artemis Genome Browser 
and Annotation Tool of the Sanger Institute (Carver et al. 2012).  
 
4.5 Quality assurance 
The quality of the sputum smears, the staining and reading of the microscopy slides as 
well as the sample processing was crucial for the outcome of the diagnosis. Therefore, 
internal as well as external quality assurance procedures were implemented for both, 
the active as well as the passive case detection approaches. As an internal quality control 
of microscopy reads, all ZN stained slides and a sample of the bleach treated as well as 
fluorescently stained microscopy slides were double read in a blinded and independent 
way, either by the staff of the respective hospital (in Goroka and Alotau) or by a second 
microscopist within the study team (Madang and Goroka). In case of inconsistencies 
either a third independent read was conducted or additional sputum samples were 
collected. Additionally, an external quality assurance system was established: a subset of 
the study slides (ZN microscopy) were sent to QMRL in Brisbane for quality control. 
Slides were re-read in a blinded way, results compared to the ones delivered by PNG 
IMR and feedback was given on the quality of smears, staining and reading of the slides. 
In parallel, panel slides prepared by QMRL (unstained sputum smears with known 
amount of bacteria) were sent to PNG IMR, where these slides were stained and read 
and results sent back to QMRL for quality analysis. 
 
To be able to avoid false positive and false negative reads as a result of quality issues of 
staining solutions (for example due to debris, overheating or contamination), positive as 
well as negative control slides were prepared, stained and read with each new batch of 
staining solution.  
 
Decontamination solutions were freshly prepared on a regular basis and subsequently 
underwent a quality check by titration.  
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4.6 Database and data analysis 
Questionnaire and lab results data were entered into a Microsoft Access database and 
regular validity checks were performed. Statistical analysis was carried out using Stata 
12.1 (StataCorp, College Station, TX, USA). 
 
4.7 Ethics 
Ethical approval was obtained from the PNG IMR Institutional Review Board (IRB No. 
0913) and the PNG Medical Research Advisory Council (MRAC No. 10.02). In addition, 
the Ethikkommission beider Basel was informed of the study. Written informed consent 
was obtained from all participants prior to enrolment and all participants were free to 
reject sample collection and/or an interview at any time of the study. Names of 
participants were kept confidential throughout the whole study and not mentioned in 
reports.  
 
4.8 Research collaborators 
The presented research was a collaboration between the Swiss TPH and partners in 
Papua New Guinea and Australia, the roles of which are listed below: 
 
Swiss Tropical and Public Health Institute, Basel, Switzerland 
- Grant holder 
- Study design, study management, study implementation 
- Personnel, facilities 
 
PNG Institute of Medical Research, Goroka and Madang, Papua New Guinea  
- Study design, study management, study implementation 
- Personnel, facilities 
 
Queensland Mycobacterium Reference Laboratory, Brisbane, Australia 
- Culturing and drug susceptibility testing 
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Central Public Health Laboratory, Port Moresby, Papua New Guinea 
- Training of microscopist in the frame of the national TB program 
- Central registry of drug resistant TB cases 
 
Provincial Health Authorities of Goroka, Alotau and Madang, Papua New Guinea 
- Study approval 
- Providing access to health facilities 
 
Provincial Hospitals, Goroka, Alotau, Madang, Papua New Guinea 
- Patient management and treatment according to the national TB program 
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5.1 Abstract 
Background: Papua New Guinea (PNG) is considered a high tuberculosis burden 
country in the World Health Organization’s Western Pacific Region. These estimates are 
based on passive case detection only and it is unclear how accurate these estimates for 
PNG are. As a complementary approach to the routinely implemented passive case 
detection, active case detection (ACD) can lead to improved case detection rates, 
increased probability of cure and a reduction of the duration of possible transmission of 
tuberculosis. Here the potential role of ACD in PNG to obtain a better estimation of the 
real tuberculosis burden is discussed.  
Methods: An ACD survey was implemented in two provinces of PNG. Sputum samples 
were collected from adult patients reporting chronic productive cough during a house to 
house screening. Diagnosis of tuberculosis was based on the detection of acid fast bacilli 
by light microscopy and sputum smear positive samples were subsequently sent for 
culture and drug susceptibility testing. 
Results: Twenty four undetected pulmonary tuberculosis cases were found around 
Sausi in Madang Province, whereas around East-Cape in Milne Bay Province only a 
single additional case could be detected. Except one sample that turned out not to 
contain Mycobacterium tuberculosis, none of the samples grew in culture. Consequently, 
no drug susceptibility testing or genotyping was performed.  
Conclusion: ACD turned out to be a good tool to significantly increase the case detection 
rate in specific areas, but it proved unsuitable to investigate the genetic background of 
the bacteria. Major differences between sites were detected, influencing the suitability 
and usefulness of ACD as a complementary case detection tool. 
 
Key words 
Passive case detection, Milne Bay Province, Madang Province, drug resistance 
 
5.2 Background 
Papua New Guinea (PNG) is considered a high tuberculosis (TB) burden country in the 
World Health Organization’s Western Pacific Region (Viney et al. 2011; World Health 
Organization 2013b). For 2012, PNG reported 20,557 new and relapse cases, whilst in 
1990 only 2,497 cases had been reported (World Health Organization 2013b).  
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Particularly large increases were recorded for extrapulmonary and other smear-
negative cases or cases with unknown microscopy result. These reports are alarming 
because of the steep increase and because of the sheer number of cases the health 
system has to deal with. 
 
The estimates of the TB burden in PNG rely primarily on records of patients seeking care 
in formal health facilities and who were registered into the National TB Program (NTP). 
This strategy of passive case detection (PCD) is at the heart of all TB control programs 
(Luelmo 2004).  Considering the limited availability of laboratory diagnosis (World 
Health Organization 2013b), difficulty of diagnosing extrapulmonary TB and shortfalls 
in the health information system leading to often incomplete overall reporting (Cibulskis 
and Hiawalyer 2002), it is unclear how accurate the reported figures are. Reports of 
increasing drug resistance, with only little local data available, add to the complexity of 
the situation. No laboratory facility for culturing Mycobacterium tuberculosis (Mtb) exists 
within the country, and samples from suspected drug resistant TB cases need to be sent 
to the Queensland Mycobacterium Reference Laboratory in Australia. This makes it 
difficult for hospitals and even more for rural health centres to obtain timely laboratory 
confirmation of drug resistance, and rapid diagnosis and appropriate treatment are 
therefore difficult to achieve. Because of the difficult access to quality health services in 
many rural areas (World Health Organization and National Department of Health PNG 
2012) and the dramatic decline in health facility coverage (e.g. a reduction in the 
number of aid posts from 2,304 in 1990 to 1,506 in 1998) (Thomason et al. 2009) the TB 
figures reported for PNG might likely be an underestimation of the true TB burden.  
 
Active case detection (ACD) has been shown to be an effective tool to detect a significant 
number of undetected active tuberculosis (TB) cases among people in the community 
(Corbett et al. 2010; Sekandi et al. 2009; Yimer et al. 2009). Thus ACD can lead to 
improved case detection rates, increased probability of cure and a reduction of the 
duration of possible transmission of TB (Borgdorff et al. 2002; Luelmo 2004).  
Here we discuss the potential role of ACD in PNG based on active case detection surveys 
implemented in two provinces. Of particular interest were the questions whether ACD 
could be applied to obtain a better estimation of the true TB burden in PNG, of the level 
of drug resistance, and diversity of circulating Mtb strains.  
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5.3 Methods  
5.3.1 Study sites  
An active case detection survey was conducted around Sausi, Madang Province, between 
July 2010 and August 2010 and around East Cape, Milne Bay Province, between 
November 2010 and December 2010. In both locations, a sentinel surveillance site was 
set up for longitudinal disease surveillance in the frame of the evaluation of the National 
Malaria Control Program (Hetzel et al. 2014), which provided population data for the 
study. Both sites consisted of one health centre and all villages in its catchment area, 
which were under demographic surveillance. 
 
Sausi lies in the Usino Bundi District of Madang Province, about 170 m above sea level 
(Hetzel et al. 2014) and at the time of the study, the catchment area of the Sausi health 
centre covered 49 villages with 1,013 households and a total population of 4,992 people. 
East-Cape is located at the eastern-most tip of mainland PNG and belongs to the Alotau 
District of Milne Bay Province. The catchment area of the East-Cape health centre 
included 289 villages with 801 households and a population of 5,666 people. Both study 
sites comprised a variety of settings, such as villages in close proximity to the health 
centre as well as villages with restricted access to health services. Some villages around 
Sausi, for example, are located at a day long walking distance from the health centre and 
have no road access. East-Cape health centre, on the other hand, serves not only villages 
on mainland PNG accessible by road but also some small off-shore islands and villages 
along the mainland coast that can only be reached by boat (Figure 5.1). 
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Figure 5.1: Map of Papua New Guinea 
The map shows the locations of the two study sites and the respective catchment area around 
the health centre. Map designed using MapInfo Professional 7.0. 
 
5.3.2 Inclusion criteria and sample collection 
Within the catchment area of the respective health centres all households were screened 
for people with chronic productive cough for at least two weeks. Such household 
members aged 15 years or older (i.e. 3147 people around Sausi and 2185 around East-
Cape) who were at that time not taking any TB treatment, were invited to participate in 
the study. Patients reporting an episode of TB and taking TB treatment in the past (i.e. 
category II patients) were excluded from the study. Following written informed consent, 
enrolled patients were interviewed about signs and symptoms and about any history of 
TB in their family or among close contacts. Three sputum specimens were collected over 
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two consecutive days. All study participants were registered as TB suspects at the local 
health centre, as required by the national guidelines.  
 
5.3.3 Diagnosis and sample processing  
Collected sputum samples were stored in a mobile refrigerator at 4°C and transported 
on a regular basis to the nearest laboratory facility located in the respective provincial 
capital (Madang and Alotau). Of each sample, a direct smear was prepared and examined 
by conventional Ziehl-Neelson sputum microscopy by two independent microscopists. 
For quality control, a sub-sample of the collected sputa was also examined by 
fluorescent microscopy with slides stained according to the manufacturer’s protocol 
(Morse Stain; TB Fluorescent Stain Kit M, Becton, Dickinson and Company, USA). Active 
TB was defined as at least two smear positive samples per patient, following the 
National TB Program guidelines (National Department of Health et al. 2012). Results 
were reported to the health centre at which the patient was originally registered. TB 
positive patients were enrolled into the NTP and put on full first line treatment under 
the directly observed treatment short-course strategy (DOTS).  
 
The remainders of all three samples of smear positive patients were pooled and 
decontaminated by Petroff’s method (Petroff 1915).  All decontaminated samples were 
stored at -20°C until 15 – 20 samples were ready to be inoculated into Mycobacterium 
Growth Indicator Tubes (BACTECTM MGITTM 960 system; BD, Franklin Lakes, NJ, USA) 
which were then sent by express air freight to the Queensland Mycobacterium Reference 
Laboratory in Brisbane, Australia for culturing.   
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5.4 Results  
5.4.1 Sausi, Usino Bundi District, Madang Province 
During the active case detection survey around Sausi, 136 (4.3%) people with chronic 
cough could be identified among 3147 adult people screened. Of these, 114 household 
members fulfilled the inclusion criteria and were enrolled into the study (Table 5.1). The 
remaining people with chronic cough were excluded from the study, as they were either 
already on TB treatment, did not produce any sputum or refused to participate in the 
study. People with chronic cough identified to belong into category II – i.e. had 
previously taken TB treatment for a period of at least one month – were also excluded 
from the study, but were referred to the local health centre for further investigation. Of 
all the study participants, 21.1% (24/114) were diagnosed with active TB according to 
the above described criteria. For ten of these 24 samples, the smear positivity was 
confirmed by either a second, independent read of the slide or by an additional method 
(e.g. fluorescent microscopy). Table 5.1 describes basic characteristics of the study 
population. In comparison, from July 2009 until the onset of our study in July 2010, only 
one TB case fitting our inclusion criteria had been detected through passive case 
detection and recorded by the local health centre in the study site (Sausi health centre 
records). It is important to note, that the median age of people with chronic cough and 
active TB cases was higher compared to the general population. The peak of chronic 
coughers as well as of smear positive patients was in the age group 45 – 64 years 
(median age 50 years in chronic coughers and 48 years in TB positive cases) which in 
the screened population only accounted for about 16 – 20%.  
 
Unfortunately, none of the samples could be recovered in culture, except one that was 
determined to be a non-tuberculous mycobacterium - Mycobacterium gordonae. 
Consequentially, no drug susceptibility testing or genotyping could be performed.   
  
Table 5.1: Population characteristics of the screened population aged 15 years or older and the enrolled study patients with chronic cough 
    Sausi East-Cape 
    
Screened 
population 
n (%) 
Study patients  
(chronic cough) 
n (%) 
Smear positive  
patients 
n (%) 
Screened 
population 
n (%) 
Study patients  
(chronic cough) 
n (%) 
Smear positive  
patients 
n (%) 
Sex 
  Female 1438 (45.7) 53 (46.5) 12 (50.0) 1029 (47.1) 18 (40.0) 0 
  Male 1705 (54.2) 61 (53.5) 12 (50.0) 1136 (52.0) 27 (60.0) 1 (100) 
  missing 4 (0.1) 0 0 20 (0.9) 0 0 
Median age (IQR) 30 (22 - 45) 50 (38 - 60) 48 (32.5 - 57.5) 24 (19 - 54) 49 (35 - 60) 65 
Age groups 
  15 - 24 1014 (32.2) 11 (9.6) 3 (12.5) 636 (29.1) 5 (11.1) 0 
  25 - 34 824 (26.2) 12 (10.6) 3 (12.5) 457 (20.9) 6 (13.3) 0 
  35 - 44 518 (16.5) 12 (10.6) 2 (8.3) 404 (18.5) 7 (15.6) 0 
  45 - 54 338 (10.7) 29 (25.4) 8 (33.3) 269 (12.3) 9 (20.0) 0 
  55 - 64 189 (6.0) 29 (25.4) 4 (16.7) 158 (7.2) 10 (22.2) 0 
  > 64 79 (2.5) 18 (15.8) 4 (16.7) 112 (5.1) 8 (17.8) 1 (100) 
  missing 184 (5.9) 3 (2.6)  0 149 (6.9) 0 0 
Total 3147 114 24 2185 45 1 
IQR= Inter quartile range
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5.4.2 East-Cape, Alotau District, Milne Bay Province 
Around East-Cape, 64 (2.9%) people with chronic cough were identified among 2,185 
screened adult household members. Of those, 45 fulfilled all the inclusion criteria and 
gave written informed consent and were therefore enrolled into the study. Amongst 
these study participants, only one (2.2%) TB case was identified. During the period from 
January 2010 to November 2010, four cases fulfilling our enrolment criteria were 
recorded at East Cape health centre by PCD (East Cape health centre records).  
As already observed during the survey around Sausi, also the sample of the single TB 
case from around East-Cape detected by ACD could not be recovered in culture and no 
further analysis could be performed.  
 
5.5 Discussion 
Around Sausi, 1013 households with 3147 adult people were screened and 114 people 
who reported to have chronic cough and for whom the cause of the cough had not yet 
been identified, were enrolled into the study. Twenty four of these patients were 
subsequently diagnosed with pulmonary TB, revealing a high number of so far 
unidentified positive pulmonary tuberculosis cases, forming a hidden reservoir of 
possible TB transmission. Generally, the high number of people with chronic cough in 
the age group of 45 – 64 years represents a public health issue in that community that 
requires further investigation.  
 
The ACD survey was conducted at one point of time only, and possible changes in the 
prevalence of undetected cases in the community over time could therefore not be 
investigated. Since only one case fitting the enrolment criteria was detected at the health 
centre during the year preceding the ACD survey, the impact of such an approach on the 
case detection rate in that particular community becomes evident. It cannot be ruled out 
that additional TB cases from that area had been detected through PCD but were 
registered at a different health centre. Although the villages screened belong to the 
catchment area of the sampled health centre, other health centres exist in the proximity 
and might be more conveniently located for patients to go for diagnosis and treatment. 
As patients on treatment might not be coughing anymore, they would not have been 
detected by our study, as chronic cough was one of the inclusion criteria.  
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Many of the study patients reported to have had their cough for already over one year, 
demonstrating a delay in seeking health care. Patients might be used to their cough and 
not consider their symptoms as serious to seek health care and people might actually 
not be aware that chronic productive cough is a strong indicator for TB. The present 
study did not focus on social factors contributing to the health seeking behaviour of the 
community and as reports on traditional perceptions of responses to TB are partly 
contradictory (Maibani G. et al. 2010; Whittaker M. et al. 2009) it remains unclear 
whether it has an impact on the observed numbers. 
 
Around East-Cape, a smaller proportion of the community had reported chronic cough 
(2.9% of the screened adult population compared to 4.3% around Sausi). Furthermore, 
almost all pulmonary TB cases in the community had already been detected through 
passive case detection, suggesting that the TB program has been well implemented.  
 
Our findings clearly demonstrate discrepancies between different settings and underline 
the importance of the study. In areas were the NTP might not be working efficiently 
enough to detect the majority of cases, the community could benefit from a 
complementary ACD approach. On the other hand, increasing the case detection rate is 
only an effective strategy to reduce the TB burden if at the same time cure rates are 
remaining high (Luelmo 2004; Murray and Salomon 1998).  Increased case detection 
would also increase the amount of patients to be managed and treated, therefore putting 
an additional burden on the already often understaffed health centres, especially in 
settings where PCD is not well functioning. Active case detection should therefore only 
be considered if it can be conducted by an external, independent team and if the study is 
nevertheless well implemented within the NTP with clear role allocations.  
 
An additional factor impacting on treatment success includes the patients themselves. 
Patients need to be well aware of the benefit of being diagnosed early and treated 
against TB, as otherwise their motivation of treatment compliance is low (Luelmo 2004). 
During an active follow up of our study patients, several of the patients could not be 
located anymore, defaulted early during their treatment, or refused to further be part of 
the study. This behaviour might be the result of patients not having felt the need of 
seeking health care, but were diagnosed because of an arising opportunity through the 
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study. This could be addressed through directly involving the community by distributing 
lay informant questionnaires for ACD to village counsels (Odermatt et al. 2007). 
Although this would not relieve the health centre staff of the increasing workload, it 
would nevertheless increase awareness in the community, maybe resulting in a different 
health seeking behaviour in the future. 
 
Even though ACD is a useful strategy to improve the case detection rate, operational 
limitations did not allow obtaining better estimates on the real burden of TB. 
Extrapulmonary TB cases were not included, as other, more complex diagnostic 
methods are required than smear microscopy. Additionally, better estimates can only be 
obtained if access to records from all health facilities on registered TB cases through 
PCD can be guaranteed and if information about the health seeking behaviour of patients 
can be obtained. This was not possible in frame of the present study. ACD furthermore 
turned out not to be suitable for drug resistance and genotyping investigations. Even if 
samples could have been cultured and DNA obtained, neither one nor 24 cases would 
have been enough to draw a scientifically sound conclusion about the prevalence of DR 
in the respective provinces. The most likely explanation for no growth in culture is the 
low bacteraemia in the collected samples (72% had a bacterial count below 10/100 
fields), which may be a result of less advanced disease progression. In samples with a 
low bacterial count the decontamination procedure followed by freezing of the samples 
before inoculation might have been too harsh for the bacteria to survive. Another reason 
for the almost zero culture recovery could be false positives amongst the samples with 
no confirmation of AFB presence by an additional read or microscopic method. 
However, it is known that the agreement of several microscopists on AFB positivity 
decreases with decreasing number of bacteria in a sample (Toman 2004) and as also 
none of the confirmed positive samples grew in culture, this is nevertheless unlikely to 
be the sole explanation. 
 
5.6 Conclusion 
Numbers of people with chronic cough and undetected TB cases can vary strongly 
between settings. The presented study provides baseline data from two different sites 
and elicits factors to be considered and numbers of chronic cough and additional 
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pulmonary TB cases to be expected when planning such an approach in the future. ACD 
turned out to be unsuitable for investigating the bacterial genetic background, and 
operational limitations did not allow obtaining better estimates on the TB burden in the 
country. Nevertheless important insights about the role, ACD could play in PNG were 
gained. Case detection rates can significantly be improved through ACD, resulting – if 
treatment can be guaranteed - in a reduced duration of possible TB transmission in the 
community. However, an effort in finding undetected cases will automatically increase 
the need for diagnosis, patient management and supplies. An already overloaded health 
centre won’t be able to cope with the resulting additional workload, probably leading to 
a decrease in health service quality and cure rates. ACD should therefore only be 
considered if the case finding approach can properly be integrated into the NTP without 
overburdening the often already understaffed health centres.  
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6.1 Abstract 
Introduction: Papua New Guinea (PNG) is a high tuberculosis (TB) burden country of 
the WHO Western Pacific Region, but so far research on drug resistance and genotypes 
of Mycobacterium tuberculosis (Mtb) was only conducted in few different provinces in 
the country. The aim of the present study was to obtain baseline data on the level of 
drug resistance and the genotypic diversity of circulating Mtb in additional provinces 
and to investigate the differences between three specific sites across PNG. 
Results: Genotyping of Mtb could successfully be conducted of 147 strains, which could 
be classified into three main lineages of Mtb: lineage 4 (European-American lineage), 
lineage 2 (East-Asian lineage) and lineage 1 (Indo-Oceanic lineage). All three lineages 
were detected in all three sites, but the individual lineage compositions varied 
significantly between sites. In Madang lineage 4 was the most prevalent lineage (76.6%), 
whereas in Alotau lineage 2 was dominating (84.4%). In Goroka, a trend towards a 
higher prevalence of L2 (60.5%) was found. 
Overall, phenotypic drug susceptibility testing showed 10.8% resistance to at least one 
of the first-line drugs tested.  Multi-drug resistant TB was found in 2.8% of cases. The 
highest amount of multi-drug resistant TB was found in Alotau in Milne Bay Province 
(4.6%).  
Conclusion:  A significant number of DR TB infections are present over the country and 
multi-drug resistant TB has already spread to all three surveyed regions of PNG, 
highlighting the importance to monitor drug resistance and for making it a high priority 
for the National Control Program. The increased prevalence of the Beijing type of Mtb in 
Milne Bay Province and its known association with drug resistance, monitoring of the 
latter should especially be scaled up in that province, facilitating it for example by 
implementing the GeneXpert system also in Alotau.  
 
Keywords: Goroka, Madang, Alotau, spoligotyping, multi-drug resistance, pseudo-
Beijing  
 
6.2 Introduction 
The different strains of the Mycobacterium tuberculosis complex (MTBC) are extremely 
homogenous with little or no horizontal gene transfer (Hirsh et al. 2004; Supply et al. 
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2003). For a long time it was thought that only the human genetic background and 
environmental factors are driving the epidemiology of tuberculosis (TB) and that the 
genetic background of the bacteria is neglectable. Over the last decade with the complete 
genome of Mycobacterium tuberculosis (Mtb) becoming available (Cole et al. 1998), 
evidence for the impact of the bacterial genetic background on TB infection and disease 
has strongly increased (Coscolla and Gagneux 2010). A phylogeography of Mtb based on 
large sequence polymorphisms and confirmed by multi-locus sequence analysis could 
furthermore be established, showing an association between specific Mtb strains and a 
particular geographic region (Gagneux et al. 2006b; Hershberg et al. 2008). The different 
Mtb strains were grouped into 6 main lineages (and a 7th was recently added (Firdessa 
et al. 2013), and a higher genetic diversity for the human adapted MTBC strains than so 
far believed was revealed (Hershberg et al. 2008). Various studies investigated the 
impact of different lineages on the clinical presentation of the disease. Kong et al. (Kong 
et al. 2006) for example showed an association between extrapulmonary TB and the 
Beijing family of lineage 2 (L2). Infection with the same strain family has also been found 
to be associated with faster progression to disease (de Jong et al. 2008), drug resistance 
(DR) (Bifani et al. 1999; vanRie et al. 1999) and poor clinical outcome (Lan et al. 2003). 
Lineage 4 (L4) on the other hand, has been shown to correlate with pulmonary TB 
rather than extrapulmonary TB (Caws et al. 2008). In addition, few studies have 
analysed the impact of the genetic background of both, humans and bacteria on disease 
development (Caws et al. 2008; van Crevel et al. 2009). Van Crevel and colleagues found 
an association between the Beijing strain and two specific polymorphisms of the human 
SLC11A1 protein, a resistance associated macrophage protein (van Crevel et al. 2009). 
These findings of correlations between different human genetic polymorphisms with 
specific Mtb lineages support the idea of a longstanding host-pathogen co-evolution and 
the hypothesis that TB spread together with the human out-of-Africa migration (Comas 
et al. 2013; Gagneux 2012; Hershberg et al. 2008). To investigate the Mtb genetic 
diversity within and between different populations could therefore give important 
insights into the dynamics of TB disease and might help to inform national TB programs 
to develop better control strategies.  
 
Papua New Guinea (PNG) is a high TB burden country of the WHO Western Pacific 
Region, the region making up 19% of the global TB burden (global incidence: 8.6 million 
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in 2012) (World Health Organization 2013b). PNG had an estimated TB incidence rate of 
348/100’000 in 2012 and its multidrug resistance (MDR) estimate of 4.9% in new cases 
is higher than the estimated global average of 3.6% (WHO 2012; World Health 
Organization 2013b). Publications on drug resistant TB in PNG are rare, and data is 
mainly derived from patients from Western Province, diagnosed in Australia (Gilpin et 
al. 2008; Lumb et al. 2011; McBryde 2012; Simpson et al. 2011). Gilpin et al. for example 
reported an MDR-TB proportion of 25% (15/60) in patients from Western Province 
diagnosed between 2000 and 2006 (Gilpin et al. 2008). Only two publications on DR 
data from other provinces exist: Ballif et al. found that 5.2% of tested samples of adult 
patients from Madang were MDR-TB (Ballif et al. 2012b), and a recently published study 
from Kikori in Gulf Province of PNG reported even 9% of suspected MDR-TB (based on 
rifampicin resistance detected by Xpert® MTB/RIF) in the investigated population 
(Cross et al. 2014).  
 
PNG is known for its vast human genetic diversity and has been isolated from the 
outside world for a long time. PNG was populated through several waves of human 
migrations and people living in the Highlands represent the oldest population from the 
first migration wave about 50’000 years ago, and are thought to be related to Australian 
Aborigines (Main et al. 2001; Yoshida et al. 1995). The highlands region has furthermore 
only been ‘detected’ in 1930s (Laehy 1936) and was sparsely populated. Hence it would 
be expected that ancient lineages of M. tuberculosis (e.g. lineage 1 (Brosch et al. 2002)), 
believed to be adapted to low density populations (Portevin et al. 2011), would be found 
there, whilst the more modern lineages such as lineage 2 and lineage 4 would be 
expected at the coast. However, there is limited information on the TB situation and on 
DR available in PNG (chapter 2). As mentioned above, various lineages have been 
associated with different disease presentations and vary in their level of virulence 
(reviewed in (Coscolla and Gagneux 2010)). Since they have also been found to differ in 
their prevalence between different regions of the same country (e.g. in Indonesia 
(Parwati et al. 2008) or Taiwan (Chen et al. 2014)) it is important to also identify the 
circulating strains in various communities in PNG. From a previous study conducted in 
Madang province, we reported the presence of three of the seven so far known main 
lineages (Comas et al. 2013), with L4 being the most abundant one (74%), followed by 
L2 (25%) and with the lowest frequency (1%) lineage 1 (L1) (Ballif et al. 2012a). In a 
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different study where samples from patients from Western Province where analysed, 
25% of the 60 samples collected belonged to the Beijing family of L2 (Gilpin et al. 2008). 
The only additional study providing Mtb genotyping data from PNG was conducted in 
the Gulf Province and reported to have detected mainly strains of the Beijing family 
(Cross et al. 2014). However, apart from those few studies, to our knowledge no data on 
the Mtb population structure from other provinces of PNG existed so far. The aim of the 
present study was to obtain baseline data on the level of DR and the genotypic diversity 
of circulating Mtb in two additional provinces and to investigate the differences between 
three sites across PNG. 
 
6.3 Results and discussion 
6.3.1 Study population characteristics 
A total of 449 patients enrolled into our study were diagnosed positive with TB of any 
type. From 377 of these patients, sputum samples could be collected and from 212 of 
these Mtb were successfully grown in culture and drug susceptibility testing (DST) was 
performed. Details of population characteristics per study site are described in Table 
6.1.  
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Table 6.1: Characteristics of study population for each study site. 
    
Drug Susceptibility Testing Result available 
Total  TB 
positive 
(any type)  
Characteristics 
Goroka 
n= 56 (%) 
Alotau 
n= 66 (%) 
Madang 
n= 90 (%) 
Total 
n= 212 (%) 
All sites 
n= 449 (%) 
Sex           
  Male 32 (57.1) 28 (42.4) 43 (47.8) 103 (48.6) 221 (49.2) 
  Female 24 (42.9) 38 (57.6) 47 (52.2) 109 (51.4) 228 (50.8) 
Median age [IQR] 30 [25 - 40] 29 [24 - 42]  30 [24 - 40] 30  [24 - 40] 30 [25 - 42] 
Age group           
  
15-24:  
25-34:  
35-44:    
45-54:    
55-64:    
>64:        
missing:  
13 (23.2) 
19 (33.9) 
12 (21.5) 
7 (12.5) 
4 (7.1) 
0 
1 (1.8) 
19 (28.8) 
23 (34.9) 
9 (13.6) 
8 (12.1) 
4 (6.1) 
2 (3.0) 
1 (1.5) 
27 (30.0) 
31 (34.4) 
16 (17.8) 
9 (10.0) 
5 (5.6) 
1 (1.1) 
1 (1.1) 
59 (27.8) 
73 (34.4) 
37 (17.5) 
24 (11.3) 
13 (6.1) 
3 (1.4) 
3 (1.4) 
110 (24.5) 
157 (35.0) 
76 (16.9) 
51 (11.4) 
40 (8.9) 
11 (2.4) 
4 (0.9) 
Smear Result           
  smear pos. 55 (98.2) 62 (93.9) 90 (100) 207 (97.6) 280 (62.4) 
  smear neg. 1 (1.8) 4 (6.1) 0 5 (2.4) 116 (25.8) 
HIV           
  HIV+ 12 (21.4) 1 (1.5) 3 (3.3) 16 (7.5) 36 (8.0) 
  HIV- 23 (41.1) 12 (18.2) 43 (47.8) 78 (36.8) 140 (31.2) 
  HIV unknown 21 (37.5) 53 (80.3) 44 (48.9) 118 (55.7) 273 (60.8) 
Region of origin           
  
Highlands  
Coast 
Other country 
Unknown 
25 (44.6) 
4 (7.2) 
0 
27 (48.2) 
0 
23 (34.9) 
0 
43 (65.1) 
3 (3.3) 
84 (93.3) 
1 (1.1) 
2 (2.2) 
28 (13.2) 
111 (52.3) 
1 (0.5) 
72 (34.0) 
71 (15.8) 
171 (38.1) 
1 (0.2) 
206 (45.9) 
History of TB 
treatment           
  
No 
Yes 
Unknown 
50 (89.3) 
2 (3.6) 
4 (7.1) 
42 (63.6) 
5 (7.6) 
19 (28.8) 
75 (83.3) 
11 (12.2) 
4 (4.5) 
167 (78.8) 
18 (8.5) 
27 (12.7) 
355 (79.1) 
50 (11.4) 
44 (9.8) 
*Data of 212 samples for which drug susceptibility was tested compared to 449 enrolled 
patients diagnosed with any type of TB. IQR = interquartile range  
 
6.3.2 Genotyping 
Genotyping of Mtb could successfully be conducted of 147/212 samples. Of seven 
worldwide reported Mtb lineages (Comas et al. 2013; Gagneux et al. 2006b) three were 
detected in all three study sites. Overall lineage 4 (L4) was the most prevalent lineage 
with 75/147 isolates (51.0%), followed by lineage 2 (L2) with 67/147 isolates (45.6%) 
whilst lineage 1 (L1) was rare with 5/147 isolates (3.4%). Overall, this composition of 
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circulating lineages was similar as previously described for Madang [20] and reflects the 
reduced Mtb diversity within PNG compared to other countries of the region, e.g. 
Indonesia (Parwati et al. 2008) or New Zealand (Yen et al. 2013) where lineage 3 strains 
were also found. It remains to be speculated whether this reduced diversity seen in PNG 
could be a result of the relatively long isolation of the country from the outside world.  
 
When lineage compositions (shown in Figure 6.1) were compared between the study 
sites, statistically significant differences were observed (Fisher’s exact test (p < 0.001)). 
L1 was generally rare in all three sites, but was seen slightly more often in Goroka 
compared to the coastal sites (one case in Madang, one case in Alotau, but three cases in 
Goroka). L4 was the most abundant lineage in Madang (76.6%) similar to what has 
previously been described (Ballif et al. 2012a). In contrast, in Alotau L2 was the 
dominant lineage (84.4%). In Goroka, a trend towards a higher prevalence of L2 (60.5%) 
was found but was not as high as in Alotau.   
 
We further performed spoligotyping, the spoligo pattern with the corresponding 
families and frequencies being shown in Figure 6.2. Thirty different spoligo patterns 
belonging to nine different families were observed, including 14 orphans with 12 
different spoligo patterns. Orphans were strains with no matching entry in the SpolDB4 
database and are therefore considered as undefined. Whether these strains represent 
PNG specific Mtb strains remains to be confirmed. Whole genome sequencing and 
phylogenetic analysis of these orphan strains would be necessary to reveal the evolution 
of TB within PNG.  
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Figure 6.1: Mycobacterium tuberculosis lineage composition for 
each study site. 
Black bars = lineage 1 (Indo-Oceanic); dashed bars = lineage 2 (East-
Asian); white bars = lineage 4 (Euro-American) 
 
One of the L1 strains from Goroka exhibits an interesting spoligo pattern with only 
spacers 40-43 being present (sample No. 4 in Figure 6.2). Per definition this would 
define that strain to belong to the Beijing family of lineage 2 (Tsolaki et al. 2005; van 
Soolingen et al. 1995) but based on SNP-typing, the strain was assigned to lineage 1, 
therefore representing a “pseudo-Beijing” strain with convergent evolution leading to an 
independent deletion event in the direct repeat locus of MTBC, as has already been 
described for strains of lineage 3 (Fenner et al. 2011). 
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Figure 6.2: Spoligotypes for the observed lineages 
N=145; SIT= shared international type. 
 
All L4 samples belonging to the LAM family were exclusively found in Madang, also 
reflecting the different Mtb lineage composition in the spoligo data. All L2 samples 
belonged to the Beijing family and were subsequently subtyped into three different 
monophyletic groups which are sublineages defined by the presence or absence of 
specific regions of difference (RD) (Tsolaki et al. 2005). Over all three sites, one sample 
of 67 Beijing strains belonged to sublineage 1, here defined as having no deletion of 
RD181, RD150 or RD142. One sample belonged to sublineage 2 with RD181 deleted but 
RD150 and RD142 being present, but the majority of Beijing strains (63/65), including 
all Beijing strains from Alotau, belonged to sublineage 3 with RD180 and RD150 deleted. 
None of the samples had a deletion for RD142. Sublineage 3 is usually rare, hence the 
high frequency in our sample is surprising. Several studies have shown that sublineage 3 
Spoligotype Pattern Spoligo Family SIT n (%) Lineage
■■□■■■■■■■■■■■■■■■■□□■■■■■■■□□□□■□■■■■□■■■■ EAI2-MANI 1501 1 (0.69) 1
□□□□□□□□□□□□□□□□□□□□□□□□■■■■□□□□■□■■■■■■■■■ EAI5 1365 2 (1.38) 1
■■□■■■■■■■■■■■■■■■■□□■■■□□□□□□□□□□□□□□□■■■■ Orphan 2590 1 (0.69) 1
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■ Orphan --- 1 (0.69) 1
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing 1 62 (42.76) 2
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■□■■■■ Beijing 255 2 (1.38) 2
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■□■■□■ Beijing 1651 1 (0.69) 2
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■□□□■■■■ Beijing 1941 2 (1.38) 2
■■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□■□□□□■■■■■■■ H1 47 2 (1.38) 4
■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■■■■■■■ H3 50 2 (1.38) 4
■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■■□□□□■■■■■■■ LAM9 42 4 (2.76) 4
■■■■■■■■■■■■■■□□■■■■□□□□■■■■■■■■□□□□■■■■■■■ LAM9 1844 1 (0.69) 4
■■■■■■■■■□■■■■□■■■■■□□□□■■■■■■■■□□□□■■□■■■■ LAM9 --- 1 (0.69) 4
■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ T1 53 25 (19.23) 4
■■■■■■■■■■■■□□□□■■■■■■■■■■■■■■■■□□□□■■■■■■■ T1 102 4 (3.08) 4
■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■□■■■■ T1 245 1 (0.77) 4
■■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ T1 393 16 (12.31) 4
■■■■■■■■■□■■■□■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ T1 1475 1 (0.77) 4
■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ T2 52 1 (0.77) 4
■■■■■■■■■■■■■■■■■■□■■■□□■■■■■■■■□□□□■□□■■■■ T4-CEU1 39 2 (1.54) 4
■■■■■■■■□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■ Orphan 32 1 (0.69) 4
■■■■■■■■■■□□□□□□□□□□□□□□■□□□□□□■□□□□■■■■■■■ Orphan --- 3 (2.07) 4
■■■■■■■■■■■■□□□□■■■■■■■■■■■■■■■■□□□□■■■□■■■ Orphan --- 1 (0.69) 4
■■■■■■□■■■■■■□■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ Orphan --- 1 (0.69) 4
■■■■■■■■■■■■■□■■■■■■■■■□□□□■■■■■□□□□■■■■■■■ Orphan --- 1 (0.69) 4
■■■■□□□□■■■■■■□□■■■■■■■■■■■■■■■■□□□□■■■■■■■ Orphan --- 1 (0.69) 4
■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■□□□□□□□□■■■■■ Orphan --- 1 (0.69) 4
■■■■■■■□■□■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ Orphan --- 1 (0.69) 4
■■■■■■■■■■■■■□□□□■□□□■■■■■■■■■■■□□□□□□□□■■■ Orphan --- 1 (0.69) 4
■■□□□■■■■■■■□■■■■■■■□□□□■■■■■■■■□□□□■■■□■■■ Orphan --- 1 (0.69) 4
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has rapidly spread in Cape Town, South Africa during in the last decade, probably 
because of adaptation to the local host-population (Cowley et al. 2008; Hanekom et al. 
2007a; Hanekom et al. 2007b). Due to the lack of longitudinal data, it is not possible to 
draw a conclusion about the time of introduction or the duration of spread of this 
subtype in PNG, but except for two outliers, our subtyping data based on RDs implies a 
single introduction of the Beijing strain and a subsequent clonal expansion through PNG. 
Starting with this observation it would be important to follow up the distribution of this 
lineage in Madang but also in the whole country in the next 10 – 20 years to monitor if a 
shift to a higher prevalence of Beijing strains will be observed in the future.  
 
The reasons for the observed differences in lineage frequencies remain speculative. The 
three study sites differ in several aspects, e.g. Goroka in the Highlands had been much 
longer isolated from the outside world than the two coastal sites. The population in the 
Highlands are believed to be descendants of the oldest migration wave that populated 
the country (Main et al. 2001) and the slightly increased number of infections with the 
L1 strain in Goroka might signify this aspect.  
 
Other factors might also influence the lineage distribution. Goroka and Madang are 
connected to the country through the highlands highway, whilst Madang and Alotau 
have direct access to the island of PNG and beyond. Similarly, the host genetic 
background and environmental or circumstantial factors such as co-infections or age 
could well influence the lineage distribution. We therefore performed univariate and 
multivariate logistic regressions to test whether infection with an L2 strain (equals an 
infection with Beijing strain) was associated with other factors such as DR, HIV status, 
age and gender (Table 6.2). Samples not belonging to L2 were pooled for the analysis, 
consisting of five samples of L1 and 75 samples of L4. Univariate logistic regression 
confirmed the differences in lineage distribution between the study sites. These 
differences remained significant also when correcting for possible confounders in a 
multivariate regression.  
  
 
Table 6.2: Univariate and multivariate logistic regressions for the odds of an infection with a Beijing strain of lineage 2. 
Explanatory variable 
Lineage 2 
n= 67 (45.58%) 
Non-Lineage 2 
n= 80 (54.42%) 
Univariate regression:  
Associations with  
M. tuberculosis Lineage 2 
Multivariate regression:  
Associations with  
M. tuberculosis Lineage 2 
      crude OR (95% CI) p-value adj. OR (95% CI) p-value 
Study Site n (%) 
Goroka* 
Alotau 
Madang 
23 (34.33) 
27 (40.30) 
17 (25.37) 
15 (18.75) 
5   (6.25) 
60 (75.00) 
3.5 (1.11 - 11.18) 
0.2 (0.08 - 0.43) 
  0.033 
<0.001 
3.3 (1.0 - 10.8) 
0.2 (0.1 - 0.4) 
0.047 
<0.001 
Sex, n (%) 
Men* 
Women 
31 (46.27) 
36 (53.73) 
37 (46.25) 
43 (53.75) 1 (0.52 - 1.91) 0.99     
Age - median years [IQR] 30 [25 - 42] 29 [22 - 40] 1 (0.99 - 1.05) 0.13 1.0 (0.98 - 1.1) 0.218 
HIV status 
Negative* 
Positive 
19 (63.33) 
11 (36.67) 
44 (95.65) 
  2   (4.35) 12.74 (2.57 - 63.07) 0.002     
TB treatment history, n (%) 
No* 
Yes 
55 (91.67) 
15 (11.03) 
66 (86.84) 
10 (13.16) 0.60 (0.19 - 1.86) 0.38     
Drug resistance (any type) 
No* 
Yes 
54 (83.08) 
11 (16.92) 
72 (92.31) 
  6   (7.69) 2.44 (0.85 - 7.02) 0.097 2.5 (0.7 - 8.5) 0.153 
*reference category 
IQR= interquartile range; OR = odds ratio. A p-value <0.05 was considered statistically significant.
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Co-infection with HIV has several times been shown to be associated with infection with 
strains of the Beijing type (Brites and Gagneux 2012; Caws et al. 2006). We also found a 
significant association between HIV positivity and infection with an L2 strain (p=0.002), 
but due to sample size multivariate logistic regression could not be performed. 
However, HIV prevalence in PNG is still comparably low, in particular in Alotau (2.1% in 
Milne Bay Province (Alotau), 5.2% in Eastern Highlands Province (Goroka) and 2.8% in 
Madang Province) (National Department of Health 2010) and is therefore unlikely to 
play a major role in the distribution of lineages.  
 
It is important to note that all differences are between the frequencies of L2 and L4, 
whilst L1 played no major role, although we would have expected more ancient lineages 
(L1) in the highlands. L4 and L2 are not only the most prevalent Mtb lineages in PNG, but 
are also predominating globally (Gagneux et al. 2006b). Thus, our findings could support 
the notion of Hershberg and colleagues (Hershberg et al. 2008) that the lineage 
distribution between and within countries might become homogenized with increasing 
migration.  In other words, more virulent strains such as L4 and L2 might slowly replace 
the ancient lineages as has already been observed in Cameroon (Assam et al. 2013) and 
might have started in PNG.  
 
6.3.3 Drug resistance 
In total 23/212 (10.85%) samples were resistant to at least one of the drugs tested.  The 
details of the DR patterns and their frequency in each study site are shown in Table 6.3. 
Drug resistance of any type and MDR frequencies were highest in Alotau with 4.6% of 
MDR cases, but monoresistance was observed more often in Goroka (8.9%) and Madang 
(6.7%) compared to Alotau (4.6%). However, none of these differences were statistically 
significant (p=0.960). 
 
In order to confirm the phenotypical resistance of 16 DR samples for which DNA could 
be obtained (16/23), we determined mutations in ten genes known to be associated 
with resistance. Two pan-susceptible strains of patients with late sputum conversion 
were also included.  Sequence data were analysed and mutations observed are shown in 
Figure 6.3.  
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Table 6.3: Observed phenotypic drug resistance per study site. 
  
GKA 
n= (%) 
ALO 
n= (%) 
MAG 
n= (%) 
TOTAL 
n= (%) 
Pan-Susceptible 50 (89.3) 58 (87.8) 81 (90.0) 189 (89.2) 
Monoresistant 5 (8.9) 3 (4.6) 6 (6.7) 14 (6.6) 
  STR    1 3 3 7 
  INH    (0.1 mg/L) 2 0 1 3 
  INH    (0.4 mg/L) 0 0 1 1 
  RMP  2 0 1 3 
Polyresistant 0 2 (3.0) 1 (1.1) 3 (1.4) 
  STR + INH    0 1 1 2 
  STR + RMP  0 1 0 1 
MDR   1 (1.8) 3 (4.6) 2 (2.2) 6 (2.8) 
  INH  + RMP 0 0 1 1 
  STR  + INH  + RMP + EMB 1 0 0 1 
  STR  + INH  + RMP 0 2 0 2 
  STR  + INH  + RMP + ETH 0 1 0 1 
  INH + RMP + PZA  + ETH 0 0 1 1 
GKA = Goroka, ALO = Alotau, MAG = Madang, STR = Streptomycin, INH= Isoniazid, RMP = 
Rifampicin, EMB = Ethambutol, ETH = Ethionamide, PZA = Pyrazinamide. 
 
Streptomycin (STR) resistance has been shown to be associated with mutations in the 
rrs, rpsL or gidB gene (Okamoto et al. 2007; Zhang and Yew 2009). For two STR 
monoresistant samples only mutations in gidB were detected (samples 1 and 2 in Figure 
6.3). All observed mutations in that gene had also been observed in our previous study 
in Madang. The sole observation of the synonymous mutation A  G at codon 205 and 
the non-synonymous mutation A  C at codon 92 in L2 strains, suggests that these 
mutations might be lineage specific (Ballif et al. 2012b; Spies et al. 2008) with no 
mutations occurring in L4. In three samples, all belonging to L4, we found the A10P 
mutation. In contrast to our previous study where the A10P mutation was absent from 
21 pan-susceptible samples, we observed this mutation in one of the pan-susceptible 
samples (sample 17 in Figure 6.3), probably suggesting that this mutation plays no role 
in STR resistance. Whether the mutation V77G found here in one STR resistant strain - 
and yet only described from PNG - is involved in STR resistance (Ballif et al. 2012b) 
remains to be proven. 
 
Ninety-five per cent rifampicin (RMP) resistance conferring mutations occur in an 81bp 
core region of the so called rifampin resistance determining region (RRDR) 
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(Ramaswamy and Musser 1998). We found only one RMP monoresistant sample 
(sample 9 in Figure 6.3) which had no mutation in the amplified 849bp (including the 
RRDR) of the rpoB gene, confirming that RMP resistant strains without a typical 
mutation in the RRDR are not more common in our sample. This is of crucial importance 
for the PNG DR surveillance being based on Xpert® MTB/RIF (Cepheid) (National 
Department of Health et al. 2012) which determines RMP resistance only through 
detection of mutations in the 81bp core region (Hillemann et al. 2007). However, 31.3% 
(5/16) of strains were INH monoresistant or INH/STR polyresistant. INH resistance is a 
precursor to MDR-TB and is not detected by the Xpert® MTB/RIF, forming an additional 
challenge for the control of DR TB that should be addressed by the NTP in the future. 
 
All low level isoniazid (INH) resistant samples (resistant to a concentration of 0.1 mg/L 
INH) of our study showed a mutation in the inhA promoter region, whereas all high INH 
resistant samples (0.4 mg/L) showed a mutation at codon 315 of katG, including all MDR 
samples and one of the polyresistant strains with INH and STR resistance (sample 11 in 
Figure 6.3). No mutations were detected in the ahpC promoter region for any of the 
samples.  
 
Two MDR samples had no mutation in 850bp of katG sequenced, none in the ahpC 
promoter or the inhA promoter. One of these samples was also resistant to ethambutol 
(EMB) (sample 16 in Figure 6.3) and had also no mutation in the embB region including 
codon 306, which is mutated in up to 68% of clinical EMB resistant strains (Zhang and 
Yew 2009). For that sample the whole genome sequence was available (data not shown) 
and was used to screen for mutations outside the amplified regions of katG or embB.  
Screening revealed a 14bp deletion at position 2156047 to 2156060 (H37Rv reference, 
GeneBank AL123456) causing a truncation of katG through a frameshift, explaining the 
phenotypic high INH resistance of that sample. Outside of the sequenced embB region 
the non-synonymous mutation G406S was found which had already been described in 
several other studies suggesting its role in EMB resistance (Plinke et al. 2010; Safi et al. 
2013). For the second MDR sample without a katG mutation, no sequence data was 
available and the INH resistance conferring mutation could not be determined. It 
remains open whether a deletion in katG or mutations in other genes associated with 
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INH resistance, for example in kasA (Ramaswamy and Musser 1998) could be 
responsible for the INH resistance. 
 
No mutation was found in the amplified regions of gyrA but since for the only sample 
with phenotypic pyrazinamide resistance (Table 6.3) no DNA could be obtained, 
genotyping was not possible and hence the lack of DR associated mutations in pncA was 
expected.  
 
Possible associations with known risk factors for DR were tested using univariate 
logistic regressions (Table 6.4). Risk of being infected with a DR strain was 5.5 times 
higher for patients with a history of TB treatment and 2.4 times higher for patients 
infected with an L2 strain although the latter was not statistically significant (p= 0.097). 
To correct for possible confounders multivariate logistic regression analysis was 
conducted and the adjusted odds ratio (OR) for risk of being infected with a DR strain 
with a history of TB treatment decreased from 5.5 to 4.2 but remained significant 
(p=0.040). This association highlights the importance of constant access to treatment 
and compliance for the control of DR TB. Strengthening the DOTS strategy and 
increasing awareness of TB in the population is crucial also in PNG and needs to be 
maintained at a high level in order not to delay diagnosis and to prevent the possible 
spread of TB.  
 
Ballif et al. had found a significant association between an infection with a L2 strain and 
DR in Madang (p<0.010, OR= 5.2, CI (95%): 1.8 - 15.1) (Ballif et al. 2012a), however, in 
our current sample set from Madang only a borderline significant association was found 
after correction for previous TB treatment (p= 0.041, OR = 3.4, CI (95%): 1.0 – 11.2) 
(Table 6.4). To test whether the two sample sets from Madang differed significantly in 
the DR data, we compared the results of the DR and L2 analyses from both sample sets 
by a χ2 test of ORs, but no significant difference was found (χ2 = 0.747).   
  
 
Figure 6.3:  Overview of genes/gene regions sequenced and mutations observed. 
No mutations were found in ahpC, pncA and gyrA. Black squares: mutation detected at indicated position; white squares: no mutation found at indicated 
position; grey squares: no mutation found at expected site.  All positions indicate the amino acid change at the codon position, except for rrs gene where 
nucleotide position and change is indicated. 
katG embB
 No. Lineage Drug Resistance Phenotype S531L H526Y F584S S315T C -15 T T -8 C M306L A514C C517T K88K K43R A205A E92D V77G G65G A10P
1 4 STR MONORESISTANT
2 4 STR MONORESISTANT
3 4 STR MONORESISTANT
4 4 STR MONORESISTANT
5 2 INH MONORESISTANT (0.4 mg/L)
6 4 INH MONORESISTANT (0.1 mg/L)
7 2 INH MONORESISTANT (0.1 mg/L)
8 2 RMP MONORESISTANT
9 2 RMP MONORESISTANT
10 2 STR INH   POLYRESISTANT (0.1 mg/L)
11 2 STR INH   POLYRESISTANT (0.4 mg/L)
12 2 STR RMP POLYRESISTANT
13 4 MDR: INH, RMP
14 2 MDR: STR, INH, RMP
15 2 MDR: STR, INH, RMP
16 2 MDR: STR, INH, RMP, EMB
17 4 PAN SUSCEPTIBLE
18 2 PAN SUSCEPTIBLE
rpoB
inhA 
(promoter) rrs rpsL gidB
  
Table 6.4: Univariate and multivariate logistic regressions for the odds of drug resistance. 
Explanatory variable 
Pan-susceptible 
n= 189 (89.15%) 
Resistant 
n= 23 (10.85%) 
Univariate regression:  
Associations with DR 
Multivariate regression:  
Associations with DR 
      
crude OR  
(95% CI) p-value 
adj. OR  
(95% CI) p-value 
Study Site n (%) 
Goroka* 
Alotau 
Madang 
50 (26.46)  
58 (30.69) 
81 (42.86) 
6 (26.09) 
8 (34.78) 
9 (39.13) 
1.1 (0.4 - 3.5) 
0.9 (0.3 - 2.8) 
0.808 
0.890     
Sex, n (%) 
Men* 
Women 
92 (48.68)  
97 (51.32)  
11 (47.83) 
12 (52.17) 1.0 (0.4 - 2.5) 0.939     
Age - median years [IQR] 29 [24 - 40] 31 [25 - 50] 1.0 (1.0 - 1.1) 0.267     
HIV status 
Negative* 
Positive 
67 (83.75) 
13 (16.25) 
11 (78.57) 
3 (21.43) 1.4 (0.3 - 5.7) 0.636     
TB treatment history, n (%) 
No* 
Yes 
155 (92.26) 
13 (7.74) 
15 (71.43) 
6 (28.57) 5.5 (1.8 - 16.8) 0.003 4.2 (1.1 - 16.7) 0.040 
Lineage 2 
No* 
Yes 
72 (57.14) 
54 (42.86) 
6 (35.29) 
11 (64.71) 2.44 (0.85 - 7.02) 0.097 3.4 (1.0 - 11.2) 0.041 
*reference category 
IQR = interquartile range; DR = drug resistance; OR = odds ratio 
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Because of the small sample size we also only found a borderline significant association 
between multiple DR and L2 infection (p = 0.058; CI (95%) 0.9 – 68.4; OR= 8): there was 
an 8 times higher risk of being infected with a poly- or multidrug resistant strain when 
infected with an L2 strain compared to an infection with a strain of a different lineage 
(in this case L4 or L1). Since there is no biosafety level 3 laboratory in PNG, DST results 
from DR suspected patients have to be obtained from Australia, which is difficult under 
normal circumstances. Our studies provided the opportunity to send additional samples 
to Australia, and the higher MDR rate in Madang in the first study might be due to a 
collection bias at the beginning of the study when long time DR suspects might have 
been ‘pushed’ into the study to finally get confirmation.  
 
6.4 Conclusions 
Our data show that a significant number of DR TB infections are present across the 
country and that MDR TB has already spread to all three surveyed regions of PNG. No 
inferences can be made from this study for the whole country because of the small 
sample size and data being derived from only three major towns, but it highlights the 
importance to monitor DR in PNG, and for making it a high priority for the NTP.  
Although the reasons for the observed significant differences of the circulating Mtb 
strains between study sites are not yet understood, these differences might have a major 
impact on disease and transmission dynamics in different populations of PNG. Different 
control strategies for places with a different Mtb lineage composition are not available 
yet, i.e. the same control strategies apply for all provinces in PNG, namely to detect cases 
and treat them accordingly. However, by knowing about the increased prevalence of the 
Beijing type of Mtb in Milne Bay Province, and with the known association between this 
lineage and DR, monitoring of the latter should especially be scaled up in that province, 
as it could become a hot spot for DR and even MDR TB. The need for a GeneXpert system 
in places such as the Alotau Provincial Hospital is undisputed and should urgently be 
introduced to have more than just the one instrument located in the countries’ capital 
for the whole Southern Region of PNG (National Department of Health et al. 2012). 
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6.5 Methods 
6.5.1 Study sites and patient characteristics 
The study was conducted in three different sites across PNG, one site in each region of 
PNG: in Madang (MAG), Madang Province in the Momase Region; Goroka (GKA), Eastern 
Highlands Province (EHP), in the Highlands Region, and in Alotau (ALO), Milne Bay 
Province (MBP) in the Southern Region of PNG. In Madang, patients were enrolled into 
the study from November 2010 onwards. In Goroka, patient enrolment started in June 
2011 and Alotau was added as a study site in July 2011. In all three study sites 
enrolment was completed in July 2012. Three consecutive sputum samples were 
collected from adult TB suspect patients (15 years or older) with chronic productive 
cough who presented at any department of the provincial hospitals (Modilon Hospital, in 
Madang; Goroka Provincial Hospital in Goroka; Alotau Provincial Hospital and Gurney 
Health Centre in Alotau). Questionnaire based interviews were conducted to obtain 
socio-demographic and behavioural information of each patient. TB was diagnosed by 
either direct smear light microscopy (Ziehl-Neelson staining), fluorescent microscopy 
(Morse Stain; TB Fluorescent Stain Kit M, Becton, Dickinson and Company, USA), chest X-
ray (CXR), clinical examination or a combination of these methods. All TB positive study 
patients were automatically enrolled into the PNG National TB Program (NTP). 
Therefore, patient management, i.e. treatment and follow up procedures, was carried 
out according to the NTP guidelines (National Department of Health et al. 2012). For a 
subset of study patients the HIV status could be obtained from the NTP, which 
recommends HIV testing of TB positive patients. 
 
6.5.2 Sample processing and drug susceptibility testing 
Of all patients diagnosed with pulmonary TB, thoracic TB (for example milliary TB) or 
mixed pulmonary/extrapulmonary TB of which sputum samples were available, sputum 
samples were decontaminated according to Petroff’s method (Petroff 1915). 
Subsequently, these samples were inoculated into Mycobacterial Growth Indicator 
Tubes (BACTECTM MGITTM 960 system; BD, Franklin Lakes, NJ, USA) and sent to the 
Queensland Mycobacterium Reference Lab in Brisbane, Australia, for culture and drug 
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susceptibility testing (DST). DST was conducted as described previously (Ballif et al. 
2012a). 
 
6.5.3 Genotyping of Mycobacterium tuberculosis 
DNA was extracted from culture either by InstaGene Matrix (Bio-Rad, Hercules, CA, USA) 
following the manufacturer’s protocol, with one bacterial colony resuspended in 1 ml of 
dH2O as starting material, or by mixing 100 µl of Mtb inoculated into Dubos broth 
(prepared tubed medium for cultivation of mycobacteria; Becton, Dickinson and 
Company, Maryland, USA) with 100 µl distilled water and subsequent heat killing at 
90°C for 1 hour. The DNA was then used for molecular analyses.  
 
M. tuberculosis isolates were classified into the main phylogenetic lineages (Comas et al. 
2013) by a TaqMan real-time PCR assay using single nucleotide polymorphism (SNP) 
typing (Stucki et al. 2012). Lineages were further discriminated into families by 
spoligotyping (Kamerbeek et al. 1997). Information on the shared international type 
(SIT) and the spoligo family were obtained from SpolDB4 (Brudey et al. 2006). All 
Beijing strains were further sub-classified into monophyletic groups based on the 
presence or absence of the regions of difference (RDs) RD181, RD150 and RD142 as 
described by Tsolaki et al. (Tsolaki et al. 2005). PCR conditions and primers were used 
as previously described by Gagneux et al. (Gagneux et al. 2006b). 
 
6.5.4 Drug resistance genotyping 
Of all phenotypically drug resistant samples of which DNA could be obtained, DR 
associated regions of the following genes were amplified by PCR and sequenced by 
Macrogen (The Netherlands): katG, rpoB, ahpC (promoter), inhA (promoter), gidB, pncA, 
gyrA, rrs, rpsL, embB. Additionally, two fully susceptible samples of patients for whom 
smear conversion took longer than the usual 2 months were included. Primers and PCR 
conditions were used as previously described by Ballif et al. (Ballif et al. 2012b) with the 
following modifications.  For rpoB a new set of primers was designed: forward primer 
5’AYATCGACCACTTCGGYAACC3’, reverse primer 5’TCCTCGATGACGCCGCTTTCT3’ (Y 
=C/T). PCR was run with an annealing temperature (TA ) of 62°C, an elongation time (ET) 
of 60 seconds and 37 cycles,  leading to a product length of 849bp. For the inhA 
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promoter and katG amplification, primers remained the same as published but the TA 
was increased from 60°C to 65°C and the cycle number from 35 to 39 for inhA, and from 
64°C to 66°C and from 35 to 40 cycles for katG.  
 
6.5.5 Statistical analysis 
Statistical analysis was carried out with Stata 12.1 (StataCorp, College Station, TX, USA). 
Differences between study sites were assessed by cross-tabulation and significance 
testing using Fisher’s exact and χ2 testing. P-values <0.05 were considered statistically 
significant. Univariate logistic regressions were performed to assess associations of DR 
or L2 infection with known potential predictors or confounders.  Independent variables 
with a significance level of p<0.2 in the univariate analysis and a plausible causal link 
where further analysed in a multivariate logistic regression. Model selection for 
multivariate regressions was based on the AIC-criterion. The comparison of two 
different sample sets from the same study site was done with a χ2 test of odds ratios 
with χ2 > 3.84 considered to show a statistically significant difference (5% level). 
 
6.5.6 Ethical approval  
Ethical approval for this study was granted by the PNG IMR Institutional Review Board 
(IRB No. 0913) and the PNG Medical Research Advisory Council (MRAC No. 10.02). The 
Ethikkommission beider Basel (EKBB) has been informed and had approved the study. 
Written informed consent was obtained from all study participants.  
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7 Additional data on the genetic background of 
Mycobacterium tuberculosis  
7.1 Subtyping of lineage 1 and lineage 4 samples 
In chapter 6 we described the subtyping of lineage 2 (L2) samples based on regions of 
difference. For lineage 1 (L1) and lineage 4 (L4) samples, a single nucleotide 
polymorphism (SNP) based fluorescent microsphere assay was used for subtyping, 
further developed from an existing assay described by Stucki et al. (Stucki et al. 2012). 
With the help of phylogenetically informative SNPs, ten L4 and six L1 subtypes can be 
distinguished. The ten subtypes of lineage 4 used in that assay were X, Haarlem, Ghana, 
Ural, Vietnam, LAM, Iran, Uganda, Cameroon and PGG3, names being working definitions 
and not necessarily representing associations of the strains with the country or region of 
the subtype name (D. Stucki, personal communication). The six L1 sub-lineages were 
called L1.1, L1.2, L1.3, L1.4, L1.5 and L1.6 (Rutaihwa 2014).  
 
All of the five L1 strains could sucessfully be subtyped, but only three of them could be 
classified into one of the six sub-lineages: all three strains from Goroka belonged to the 
sub-lineage L1.1, also called the Philippines subtype of L1, but the two strains from the 
coastal sites remained undetermined, although they were confirmed L1 strains (Table 
7.1).  
 
The majority (84%) of the lineage 4 samples could not be amplified and could therefore 
not be assigned to any subtype (Table 7.1). As the DNA used was derived from heat 
inactivated specimens, quality problems of the DNA could be responsible for the large 
number of failures. They might contain PCR inhibitors or too little DNA, leading to 
borderline signals for several of the subtypes, not allowing classification. However, the 
same procedure was used for L1 samples, where the assay was sensitive enough to 
obtain specific signals for all five samples.  
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Table 7.1: Lineage 1 and lineage 2 subtyping results 
Lineage 1-subtypes 
  
Goroka 
n= 3 
Alotau 
n= 1 
Madang 
n= 1 
Total 
n= 5 (%) 
L1.1 Philippines 3 0 0 3 (60) 
Undefined 0 1 1 2 (40) 
Lineage 4 subtypes 
  
Goroka 
n= 12  
Alotau 
n= 4 
Madang 
n= 59 
Total 
n= 75 (%) 
Vietnam 1 1 1 3 (4.0) 
LAM 0 1 4 5 (6.6) 
Haarlem 1 0 1 2 (2.7) 
X 0 1 1 2 (2.7) 
Missing 10 1 52 63 (84.0) 
LAM = Latin American Mediterranean 
 
7.2 Phylogenies based on whole genome sequencing 
Aall five strains of L1, ten randomly selected L2 samples (10/67), and all Latin American 
Mediterranean (LAM) strains of L4 (7/75) were whole genome sequenced (WGS). Short 
read libraries were prepared according to the Nextera® XT DNA sample preparation kit 
(Illumina, California, USA) which were then paired-end sequenced (barcoded and 
multiplexed) on an Illumina MiSeq device (see chapter 4). Short reads were mapped to a 
hypothetical ancestral genome (Comas et al. 2010) with the Burrows-Wheeler 
Alignment tool (BWA 0.6.2) (Li and Durbin 2009), and bam files generated with 
SAMTools 0.1.18 (Li et al. 2009). Two of the LAM strains revealed insufficient sequence 
coverage and had to be excluded from further analysis. Phylogenetic trees were 
obtained using the model GTR implemented in RAxML with 1000 rapid inferences, 
followed by a thorough maximum-likelihood search (Stamatakis 2006) trough CIPRES 
(Miller et al. 2010). Maximum likelihood topologies of L1, L2 and L4 related strains are 
shown in Figures 7.1, 7.2 and 7.3. 
 
Spoligotyping had revealed that all lineage 2 samples in our sample set belong to the 
Beijing family of strains. Subsequent subtyping based on regions of difference (RD) 
further showed that almost all of these strains from all three study sites belong to the 
same monophyletic subtype, pointing to a founder effect: a single introduction of the 
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Beijing strain with a subsequent clonal expansion (chapter 6). The ten whole genome 
sequenced Beijing strains represent 15% of all the Beijing strains of our sample set: 
three strains each from Madang and Alotau and four strains from Goroka. In the 
phylogenetic tree formed with these ten WGS (Figure 7.1), nine of the ten strains form a 
cluster of closely related (but not identical) strains with a mean genetic distance of 41 
SNPs.  The strains are related to strains from China and Vietnam, but form a separate, 
PNG specific clade suggesting a certain degree of in-country evolution. Based on the 
results of the RD subtyping one can be confident that the other Beijing strains of our 
sample set would also fall into this cluster and that these WGS strains are therefore 
representative for the whole sample set. The only outlier in the tree is a case from 
Goroka, the only sample with RD181, RD150 and RD142 present (chapter 6). That strain 
intermingles with other strains from Asia, and indicates a rather recent introduction; 
however, the origin remains speculative. 
 
A more complex pattern of introduction and evolution than for L2 strains emerged for 
the LAM strains of L4 (Figure 7.2). The four isolates from Madang were forming a cluster 
of closely related strains with a difference of 14 to 70 SNPs between any of the four 
strains. An additional strain from Alotau, on the other hand, is found in a separate 
cluster with a difference of 200 to 441 SNPs to any of the four LAM strains from Madang, 
pointing to separate introductions of this strain family in the two provinces. No LAM 
strain was found in Goroka. It appears difficult to associate the two different clusters 
with a specific geographic area, as samples isolated from patients from various 
geographic regions cluster in several distinct clades.  
 
Two introductions can also be observed for L1. The five samples collected in the three 
sites in PNG form two distinct clusters: one cluster formed by the three isolates from 
Goroka and a second cluster by the two isolates from the coastal sites (Figure 7.3). The 
highlands samples are intermingled with strains originating from the Philippines and 
other South-East Asian countries, as already shown by the subtyping described in 
chapter 7.1. As reflected already in the SNP-based subtyping results (see chapter 7.1), 
the coastal L1 strains could not be classified into any of the sub-lineages of lineage 1. In 
the phylogenetic tree these coastal PNG L1 strains branch off early from the clade 
leading to sub-lineage L1.2, and suggesting a within PNG evolution. However, due to 
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restricted sample size it is not possible to draw a definite conclusion about the origin of 
these strains. 
 
In conclusion, although only few PNG samples were included in the phylogenetic studies, 
all three lineages exhibit a degree of PNG internal evolution, providing the basis for 
further studies on the evolution of TB in PNG.  For L4 no general inference can be made 
based on the analysis of the LAM family. Generally, more samples from several different 
places in PNG should be analysed to be able to further investigate the introduction and 
evolution of TB in PNG. 
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Figure 7.1: Maximum-likelihood topology of lineage 2 related strains (Beijing family). 
Support values at the nodes are bootstrap values relative to 1000 replicates. Some 
monophyletic groups were collapsed for convenience. Branch lengths are proportional 
to nucleotide substitutions. The Papua New Guinea cluster of samples contains nine 
closely related samples, three of each study site. Country names indicate the country of 
origin. PNG= Papua New Guinea; GKA= Goroka 
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Figure 7.2: Maximum-likelihood topology of lineage 4 related strains (Latin American 
Mediterranean family). 
Support values at the nodes are bootstrap values relative to 1000 replicates. Some 
monophyletic groups were collapsed for convenience. Branch lengths are proportional 
to nucleotide substitutions. Country names indicate the country of origin. PNG= Papua 
New Guinea 
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Figure 7.3: Maximum-likelihood topology of lineage 1 related strains. 
Support values at the nodes are bootstrap values relative to 1000 replicates. Some monophyletic 
groups were collapsed for convenience. Branch lengths are proportional to nucleotide 
substitutions. Stars indicate the SNP-position defining the subgroups L1.1 – L1.6. Country names 
indicate the country of origin. PNG= Papua New Guinea; MAG= Madang; GKA= Goroka; ALO= 
Alotau 
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8 Individual-level predictors of smear 
positivity in people with chronic cough living 
in Goroka, Papua New Guinea 
 
Behavioural factors such as smoking and excessive alcohol consumption, or co-
infections with HIV (Getahun et al. 2010) or helminths (Salgame et al. 2013), are only a 
few of the well-known risk factors for tuberculosis infection. Smokers for example, have 
a two times higher risk of getting infected with TB compared to non-smokers, as 
smoking not only mechanically damages the lung but also affects the immune response 
(Dye and Williams 2010). 
 
In the present study, patient interviews contained questions on personal characteristics, 
signs and symptoms accompanying the chronic cough (inclusion criteria: chronic 
productive cough for a minimum of two weeks), and potential risk factors for TB 
infection. This included questions on the duration of the cough, on smoking, alcohol 
consumption, and beetle nut (buai) chewing, as well as questions concerning the habit of 
lighting fire inside the house for cooking or heating. Furthermore, the HIV status was 
recorded, where available, and the presence of BCG scars was checked.  
 
In Goroka (as opposed to Alotau and Madang) patients with chronic productive cough 
were enrolled into the study before the diagnosis of tuberculosis (see chapter 4), thus 
allowing to investigate the association of specific background characteristics and risk 
factors with sputum smear positivity, a proxy of pulmonary TB.  For patients recruited 
in Goroka, we first assessed any association of age and sex with smear positivity. As both 
factors were not significantly associated with the outcome in the univariate regression, 
they were excluded from further analyses (Table 8.1). As a next step we then 
investigated if signs and symptoms common in TB patients were associated with smear 
positivity. Patient characteristics and the results of the logistic regression analyses are 
listed in Table 8.1. P-values <0.05 were considered statistically significant. Independent 
variables with a significance level of p<0.2 in the univariate analysis and a plausible 
causal link, were further included in a multivariate logistic regression model. 
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Table 8.1: Univariate logistic regression assessing associations between patient characteristics, 
signs/symptoms with smear positivity 
Explanatory  
variable 
Smear  
positive 
n= 80 (%) 
Smear  
negative 
n= 396 (%) 
Univariate 
regression: 
association with 
positive smear 
Multivariate 
regression: 
association with 
positive smear  
  
crude OR  
(95% CI) 
p-
value 
adj. OR   
(95% CI) 
p-
value 
Sex 
Male* 
Female 
45 (56.2) 
35 (43.8) 
216 (54.6) 
180 (45.5) 0.9 (0.6-1.5)  0.780     
Median age 
(IQR) 31.5 (25-45) 35 (26-50)         
Age groups 
15-24* 
25-34 
35-44 
45-54 
   > 55 
18 (23.1) 
26 (33.3) 
14 (17.9) 
12 (15.4) 
8 (10.3) 
83 (21.1) 
109 (27.6) 
66 (16.8) 
65 (16.5) 
71 (18.0) 
1.1 (0.6-2.1) 
1.0 (0.5-2.1) 
0.9 (0.4-1.9) 
0.5 (0.2-1.3)  
0.779 
0.955 
0.693 
0.150     
Chough 
duration 
< 3 weeks* 
> 3 weeks 
8 (11.3) 
179 (33.0) 
63 (88.7) 
363 (67.0) 4.0 (1.2-13.1)  0.022 
8.7  
(1.2-65.3) 0.035 
Cough up 
blood 
No* 
Yes 
52 (14.0) 
21 (21.9) 
319 (86.0) 
75 (78.1) 1.7 (1.0-3.0) 0.061 
1.4 
 (0.8-2.8) 0.272 
Breathing 
difficulties 
No* 
Yes 
15 (10.3) 
55 (17.9) 
130 (89.7) 
252 (82.1) 1.9 (1.0-3.5) 0.040 
1.7  
(0.8-3.5) 0.186 
Weight loss 
No* 
Yes 
2 (3.3) 
56 (19.1) 
58 (96.7) 
237 (80.9) 6.9 (1.6-28.9) 0.009 
5.5  
(1.3-23.6) 0.022 
Chest pain 
No* 
Yes 
23 (16.7) 
49 (15.2) 
115 (83.3) 
274 (84.8) 0.9 (0.5-1.5) 0.685     
Night sweats 
No* 
Yes 
25 (17.7) 
48 (15.2) 
116 (82.3) 
268 (84.8) 0.8 (0.5-1.4) 0.494     
*reference group 
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Several patients had reported to have a cough for several years already or even for 
their whole life. A cough for several years is highly unlikely to be due to TB, as a 
patient would not survive untreated active tuberculosis for such a long period. In 
these patients, it was impossible to determine the duration of the cough associated 
with the current TB episode. A patient reporting cough for 15 years, for example, 
could have had the TB associated cough for only few weeks, therefore biasing the 
analysis of the cough duration and the TB diagnosis. All patients reporting cough 
for longer than 3 weeks were therefore grouped and the analyses conducted with 
two groups of cough duration only. The univariate analysis revealed that cough 
duration of over 3 weeks as well as breathing difficulties and weight loss were 
significantly associated with smear positivity in this sample set (Table 8.1). When 
controlled for possible confounding in a multivariate logistic regression, only 
weight loss and chronic productive cough for more than 3 weeks remained 
significantly associated with smear positivity. This result confirms weight loss 
together with chronic productive cough to be strong predictors of pulmonary TB 
which should be considered during clinical examinations by health workers.  
 
Even though TB is known to be an important cause of haemoptysis (coughing 
blood), no significant association between haemoptysis and smear positivity could 
be found in our sample. One reason for this could be other aetiologies of 
haemoptysis in the study group, for example pneumonia, cystic fibrosis or 
bronchitis (Patel et al. 2014; Prasad et al. 2009; Santagati et al. 2014). It should 
also be considered that the outcome measure of this analysis was smear positivity 
in a population of patients with chronic productive cough, all of whom have an 
increased risk of pulmonary diseases; a comparison with healthy controls could 
not be performed. 
 
As a last step we investigated known risk factors for TB infection and their 
potential association with smear positivity. The risk factors included and the 
results of the univariate logistic regression analyses are listed in Table 8.2. None of 
the risk factors tested appeared to be significantly associated with smear 
positivity. A multivariate analysis confirmed these results. The reason for this 
might again be that our study population included only patients with chronic 
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cough. The analysis was therefore not investigating the association of these factors 
with a TB infection in the general population, but rather the association with active 
TB among sick individuals. To properly investigate risk factors of TB infection in 
the general population, a case control study comparing TB patients with healthy 
controls would have to be conducted.   
 
Table 8.2: Logistic regressions for the analysis of associations of common risk factors 
with smear positivity 
Explanatory  
variable 
Smear  
positive 
n= 80 (%) 
Smear  
negative 
n= 396 (%) 
Univariate regression: 
association with smear 
outcome 
  crude OR (95% CI) p-value 
Smoking 
No* 
Yes (currently/past) 
40 (14.7) 
33 (17.3) 
233 (85.4) 
158 (82.7) 1.2 (0.7 - 2.0) 0.445 
Chewing buai 
No* 
Yes (currently/past) 
35 (14.1) 
38 (17.7) 
214 (85.9) 
177 (82.3) 1.3 (0.8 - 2.2) 0.287 
Drinking alcohol 
No* 
Yes (currently/past) 
39 (14.4) 
34 (17.4) 
231 (85.6) 
161 (82.6) 1.3 (0.8 - 2.1) 0.382 
Fire inside the 
house 
No* 
Yes 
22 (13.7) 
51 (16.8) 
139 (86.3) 
252 (83.2) 1.3 (0.7 - 2.2) 0.373 
Close TB contact 
No* 
Yes 
40 (16.5) 
31 (15.3) 
203 (83.5) 
171 (84.7) 0.9 (0.6 - 1.5) 0.749 
Previous TB 
treatment 
No* 
Yes 
71 (17.0) 
2 (4.8) 
347 (83.0) 
40 (95.2) 0.2 (0.1 -1.0) 0.056 
BCG vaccinated 
No* 
Yes 
15 (13.0) 
52 (15.6) 
100 (87.0) 
282 (84.4) 1.2 (0.7 - 2.3) 0.513 
HIV status 
Negative* 
Positive 
29 (49.2) 
15 (45.5) 
30 (50.8) 
18 (54.5) 0.9 (0.4 - 2.0) 0.734 
*reference group; HIV= Human immunodeficiency virus; BCG= Bacille Calmette-Guérin; 
CI= confidence interval 
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9.1 Abstract 
Objective: To determine the proportion of non-tuberculous mycobacteria (NTM) in a 
sample of pulmonary tuberculosis patients from Papua New Guinea (PNG), diagnosed 
through acid fast bacilli microscopy. 
Methods: In the frame of a tuberculosis study conducted in PNG, Mycobacteria isolated 
from sputum and grown in culture were examined to distinguish between NTM and the 
Mycobacterium tuberculosis complex. 
Results: In 2.2% (5/227), the acid fast bacilli growing in culture were NTM only. Four 
different NTM species were detected: M. fortuitum, M. intracellulare, M. terrae and M. 
avium.  
Discussion: This is the first report showing the existence of NTM in three different 
populations in PNG. As NTM cannot be distinguished from M. tuberculosis through smear 
microscopy, the presence of NTM could lead to false positive diagnosis of tuberculosis. 
The prevalence of NTM and the implementation of a diagnostic test should be discussed 
for PNG in the future. 
 
9.2 Introduction 
Besides the Mycobacterium tuberculosis complex (MTBC), the genus Mycobacterium 
includes over 120 species of non-tuberculous Mycobacteria (NTM) (Tortoli 2003). Non-
tuberculous Mycobacteria can be found in the environment (such as water and soil), 
which is also the suspected source of occasional infection of humans with NTM. 
Asymptomatic infection as well as symptomatic disease can be caused by NTM (Griffith 
et al. 2007), including, amongst others, chronic pulmonary disease with symptoms also 
common for tuberculosis (TB): chronic cough (with or without sputum production), 
chest pain and weight loss (Gopinath and Singh 2010; Kendall et al. 2010). Different 
NTM have been associated with different disease presentations (Griffith et al. 2007). 
Pulmonary disease is common when infected with bacteria of the M. avium complex, for 
example. Also M. fortuitum is causing pulmonary disease, but more often affects the skin, 
soft tissue or bones (Griffith et al. 2007). Immunocompromised patients (e.g. HIV 
positive patients) are predisposed to NTM infection (Griffith et al. 2007), but also HIV-
negative patients with no predisposing conditions can be affected (Henry et al. 2004; 
Huang et al. 1999; Prince et al. 1989; Thomson 2010).  
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Standard first-line TB treatment drugs are less effective against NTM than against M. 
tuberculosis (Mtb) (Griffith et al. 2007; Mdluli et al. 1998), and relapses are common 
(Griffith et al. 2007). Isoniazid, for example has only little effect on M. avium (Mdluli et al. 
1998). Recommendations of treatment regimens depend on the NTM species, sometimes 
even including surgical removal of infected tissue beside treatment with antibiotics 
(Griffith et al. 2007; Root et al. 1999). 
 
Little data is available on the prevalence of NTM infections is available in TB high 
burden countries, but the incidence can nevertheless be substantial (Bensi et al. 2013). 
TB high burden countries tend to also be resource poor countries and the diagnosis of 
pulmonary TB is based on the microscopic detection of acid fast bacilli (AFB) in sputum 
samples. Smear microscopy cannot distinguish between NTM and MTBC, and false 
positive tuberculosis diagnosis cannot be ruled out. Exposure to NTM has been 
suggested to impact on the efficacy of the Bacille Calmette-Guérin vaccine (Poyntz et al. 
2014) and to exhibit cross-reactivity to tuberculin skin tests (TST), leading to increased 
difficulties in interpreting TST positive results and evaluating the protection through the 
only available vaccine against TB (Fine 1995; Rieder 1995). 
 
Very little information is available on NTM in Papua New Guinea (PNG). Data from a trial 
conducted in Karimui (Eastern Highlands Province) in the 1960s (Bagshawe A. et al. 
1989; Scott G.C. et al. 1966) as well as a  TST sensitivity study conducted in the 
Marawaka area of the Eastern Highlands of PNG by Brown et al. (Brown et al. 1981), 
found no evidence for environmental mycobacteria being present in this area. Therefore 
it was important to investigate the presence of NTM in sputum samples collected in the 
frame of a TB study conducted in three distinct sites across PNG (chapter 6). Molecular 
analysis of Mycobacteria identified in smear positive sputum samples and recovered in 
culture, was performed. Here we describe the NTM detected and provide baseline 
information on these bacteria in PNG. 
 
9.3 Methods 
In the frame of a tuberculosis passive case detection study conducted in three provincial 
hospitals in PNG (Goroka General Hospital, Eastern Highlands Province; Alotau 
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Provincial Hospital, Milne Bay Province; Modilon Hospital, Madang Province) sputum 
samples of suspected TB patients (15 years and older) were collected (chapter 6). Upon 
diagnosis of TB through acid fast bacilli Ziehl-Neelson microscopy or chest X-ray, 
sputum samples were sent to the Queensland Mycobacterium Reference Laboratory in 
Brisbane, Australia for culture and drug susceptibility testing. A repeat ZN smear was 
prepared on all culture positive isolates (n= 227) to confirm the presence of acid-fast 
organisms. An MPT64 test (SD Bioline/BD) was used to confirm the AFB as MTBC. 
Where the MTP64 was negative or the microscopic morphology of the AFB did not 
suggest the AFB were MTBC, the GenoType® Mycobacterium CM line probe assay (Hain 
LifeSciences, Nehren, Germany) was performed to identify the isolate as an NTM or 
MTBC. Both tests were conducted following the manufacturers’ protocols. 
 
9.4 Results 
NTM were detected in 4% (9/227) of sputum samples grown in culture. Five (2.2%) of 
these samples contained an NTM only, consisting of three isolates of M. fortuitum, one 
isolate of M. terrae and one isolate of M. intracellulare. Four (1.8%) isolates were 
identified as mixed cultures and contained both, bacteria of the MTBC and NTM: three 
cultures of MTBC and M. avium, and one culture of MTBC and M. intracellulare. All but 
one of the NTM infections were detected in women. All the patients with either a mixed 
infection or an NTM infection only, had reported productive cough for at least two 
weeks. Shortness of breath and fever was reported by four of the five patients with an 
NTM infection only. Weight loss, night sweats and chest pain were reported by three 
patients. One patient had reported no other symptoms than a productive cough.  
  
9.5 Discussion 
To our knowledge this is the first study describing the presence of NTM in PNG. Five 
(2.2%) of the 225 patients were infected with NTM only, which reveals a possibility of 
false positive TB cases. These general symptoms caused by NTM infections cannot be 
distinguished from symptoms observed in TB patients, and the appearances of the 
bacteria cannot be differentiated when examined by AFB Ziehl-Neelson light 
microscopy.   
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It is interesting that in our patient cohort all but one of the NTM isolates were found in 
female patients, the only isolate identified in a male was M. terrae. There are some NTM 
species which were more commonly isolated from females (Griffith et al. 2007; Iseman 
et al. 1991; Prince et al. 1989). Iseman et al. showed an increased prevalence of funnel 
chest (pectus excavatum) and abnormal narrowing of the thoracic dimension in female 
patients infected with NTM of the M. avium complex (Iseman et al. 1991) not seen in 
males. Also, the so called Lady Windermere syndrome, a specific pulmonary disorder 
caused by bacteria of the M. avium complex was only found in women (Reich and 
Johnson 1992). 
 
Compared to a recently published study from Nigeria where 15% of culture grown 
Mycobacteria isolated from presumptively diagnosed pulmonary TB patients were 
actually NTM (Aliyu et al. 2013), 2.2% in our study are low. However, reports on NTM 
from TB endemic countries are rare (Gopinath and Singh 2010) and it is generally 
difficult to directly compare our findings to studies from other countries. The study 
population was limited to pulmonary TB cases aged 15 years and above from three 
different sites within PNG and it is unclear whether inferences can be made to the rest of 
PNG. Nevertheless, compared to the few studies conducted in PNG in the 1960s and 
1980s (Bagshawe A. et al. 1989; Brown et al. 1981; Scott G.C. et al. 1966) where 
tuberculin skin testing did not provide evidence for NTM, the presented results proof 
the existence of NTM in the community and the possible impact on TB diagnosis in the 
country. While there remains the possibility that the presence of NTM in sputum 
specimens is due to environmental contamination rather than an infection, they can also 
lead to false positive TB diagnosis. As a consequence, the standard TB treatment would 
not be ideal, as different antibiotics than the ones used against TB are required to treat 
NTM (Griffith et al. 2007; Root et al. 1999), leading to an additional burden for the 
patient as well as the National TB Control Program. With an increasing burden of 
HIV/Aids, NTM might furthermore not only negatively impact on the diagnosis of TB, but 
also become an increasing source of disease, requiring different approaches concerning 
patient management and treatment. In PNG the diagnosis of multi-drug resistant (MDR) 
TB was for a long time based on the observation of repeated treatment failure despite 
compliance to treatment. Although since 2012 drug resistance surveillance based on 
Xpert® MTB/RIF has started in a few major cities (National TB Program Unit et al. 
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2011), it probably remains difficult for many health facilities to obtain a 
bacteriologically confirmed diagnosis of MDR TB. If the actual cause of treatment failure 
is not drug resistance, but a different bacterial infection, this would have a major impact 
on individual patient management, especially if the symptoms of the disease are similar 
to the ones of MDR TB.  This has for example been shown by a study from India, where 
17.6% of the suspected MDR pulmonary TB cases were actually NTM infections 
(Gopinath and Singh 2010).  
 
No NTM detection is yet performed in the frame of the National TB Control Program in 
PNG because no biosafety level three laboratory required for culturing Mycobacteria is 
available in the country. MDR TB suspected samples have to be shipped to the 
Queensland Mycobacterium Reference Laboratory in Brisbane, Australia. In-country 
bacterial culture would allow distinguishing TB from NTM infections much faster and at 
the same time improve the detection of drug resistance.  Until culturing becomes 
available within the country, PCR based assays amplifying the internal transcribed 
spacer region of 16-23S rRNA could be implemented at the Central Public Health 
Laboratory in Port Moresby to distinguish NTM from MTBC directly from clinical 
samples (Gopinath and Singh 2009).  
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10 General discussion  
The aim of the present studies was to contribute to the understanding of the TB 
epidemiology including drug resistance (DR) and the population structure of 
Mycobacterium tuberculosis (Mtb) in Papua New Guinea (PNG). For this purpose, the 
prevalence of undetected tuberculosis cases was investigated by active case detection in 
two sites in the country, and the proportion of drug resistance and the distribution of 
Mtb genotypes by passive case detection in three distinct sites. 
 
In this chapter, the main research findings are discussed. This is followed by a review of 
the limitations of the study design and its implementation. Finally, the impact of the 
findings for the respective provinces and the country as a whole are discussed and 
recommendations for future research on the topic are made.  
 
10.1 Drug resistance  
Data on DR TB in PNG is scarce. Even from the capital Port Moresby, which has the 
highest number of registered TB cases (1,065/100,000 in 2010) (PNG National 
Department of Health 2011), only little information on MDR TB is available. A report 
from 2010 only stated that, of over 30 confirmed MDR TB cases detected between 2008 
and 2010, most originated from Daru (Western Province) and Port Moresby (PNG 
National Department of Health 2010a; PNG National Department of Health 2010b). Our 
study provides DR data from three distinct sites across the country. Overall, 10.8% of 
the samples exhibited any form of DR, 2.8% MDR, 1.4% poly-resistance other than MDR, 
and 6.6% mono-resistance to any of the four first line drugs or streptomycin (chapter 6). 
Compared to 9% rifampicin (RMP) resistance (and therefore indicative MDR) found in 
Kikori, Gulf Province (Cross et al. 2014), the proportion of MDR in our sample set was 
low. Also in all three sites individually, the proportion of MDR TB was below the WHO 
estimate for PNG of 4.9% in new cases in 2012 (World Health Organization 2013b). 
However, this WHO estimate refers to category I cases (new cases) only, whereas in PNG 
(including this study) the distinction between category I and category II (previously 
treated) DR cases is often difficult. DR is often only confirmed after repeated treatment 
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failure and re-start of treatment, which turns a DR category I case automatically into a 
category II case, although in principle it is still the same and first episode of TB for that 
patient. A direct comparison of our results to separate estimates for each of these 
categories is therefore difficult. 
 
Compared to other countries in the South Pacific, the observed proportion of MDR TB is 
still relatively high, as for other countries in the region (e.g. Australia, Cambodia and 
Indonesia) the estimates lie below 2% (World Health Organization 2013b). Globally, 
4.9% MDR in new cases ranks around the average for the 22 high MDR TB burden 
countries, although these estimates range from 1.8% in South Africa to 23% in the 
Russian Federation (World Health Organization 2012). Interestingly, MDR estimates for 
all islands nations in the region that have not reported country wide data on DR TB are 
identical at 4.9%, reflecting the uncertainty of these estimates. The data presented here 
are a step towards filling this gap for PNG. They confirm the presence of a significant 
level of DR TB across the country, not only in Western Province, the so far identified hot 
spot (Gilpin et al. 2008; McBryde 2012; Simpson et al. 2011).  
 
In the present study, the highest percentage of drug resistance was found in Alotau 
(12.2%), the lowest in Madang (10%). However, the absolute differences are marginal 
and not statistically significant. After adjusting for history of TB treatment, DR was 
significantly associated with the Beijing strain family (p<0.041), confirming findings 
from previous studies in Madang, PNG (Ballif et al. 2012a), and from several other 
countries (Bifani et al. 1999; vanRie et al. 1999). In Alotau, there was hence a higher 
chance of a TB case being drug resistant than in Madang and Goroka. Providing DR 
monitoring and testing capacity in Alotau should therefore be a high priority.  
 
Except for RMP through Xpert® MTB/RIF (Xpert), monoresistance testing is generally 
inexistent in PNG. Data on monoresistance have only been reported by two studies 
(Ballif et al. 2012b; Simpson et al. 2011). In our sample, the highest proportion of mono-
drug resistance to INH, RMP or STR was found in Goroka (8.9%). On the other hand, no 
polyresistance and only one case of MDR TB was found there, suggesting a less advanced 
development of DR compared to Madang and Alotau. These findings emphasise the 
importance of not only investigating MDR. For sites like Goroka, where MDR still 
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appears to be rare, early detection of mono or polyresistance and accurate treatment 
could potentially prevent the development of MDR. Additionally, costs and the duration 
of treatment could be reduced by preventing sub-optimal treatment with no prospect of 
cure and by avoiding a full second-line regimen where not required. This would relieve 
both, the patient and the health system.  
 
To overcome these limitations, PNG should urgently establish facilities or procedures for 
reliable drug resistance monitoring throughout the country. The implementation of the 
GeneXpert system in each province would provide a partial solution, with the known 
limitations (e.g. except for RMP, mono-drug resistance cannot be detected).   
 
10.2 Mycobacterium tuberculosis strain diversity   
The present study is the first directly comparing differences in Mtb population 
structures between distinct sites in PNG. Besides our data and data from a previous 
study conducted in Madang (Ballif et al. 2012a), Mtb genotyping data exists from only 
two other provinces. Gilpin et al. (Gilpin et al. 2008) genotyped 15 MDR samples from 
patients from Western Province, all of which belonged to the Beijing strain family. These 
typed isolates represented 25% of the collected samples and the data therefore does not 
allow a conclusion about the Mtb genotype composition of the complete sample set 
(Gilpin et al. 2008). A recently published study from Kikori in Gulf Province of PNG 
showed that eight of nine genotyped samples were closely related to the Beijing family 
and one was related to the Haarlem family of L4 (Cross et al. 2014). Unfortunately, the 
MIRU-VNTR based phylogenetic tree constructed does not include sufficient details (i.e. 
no bootstrap values) to properly interpret the published data. Additionally, no patient or 
sample characteristics of the genotyped samples are provided, making it impossible to 
judge if the grown and genotyped strains were a random or a biased set of all the AFB 
positive samples sent for culture. Genotyping data of these two studies can therefore not 
directly be compared to our findings. 
 
Three of the seven human associated lineages of the Mycobacterium tuberculosis 
complex (MTBC) were found in our sample set: lineage 1 (L1), lineage 2 (L2), and 
lineage 4 (L4). No lineage 3 or M. africanum (lineages 5 and 6) isolates were found, and 
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also no infection with an animal associated MTBC strain (e.g. M. bovis) was detected in 
our study patients. These findings are consistent with results from previous studies in 
PNG (Ballif et al. 2012a; Cross et al. 2014; Gilpin et al. 2008). The Mtb lineage 
composition is similar to that of some other countries in the South Pacific (e.g. Kiribati), 
but also reflects a reduced diversity compared to others (e.g. Indonesia or New Zealand). 
In a study in Kiribati, also only lineages 1, 2 and 4 were found (Aleksic et al. 2013), 
whereas in Indonesia and New Zealand also lineage 3 was detected (Parwati et al. 2008; 
Yen et al. 2013). In Kiribati, the proportion of L2 and L4 (both accounting for 49.3% 
each) was much higher than that of L1 (1.4%) (Aleksic et al. 2013). Similar proportions 
were found in the present study, although here, L4 was the most frequent lineage 
(51.0%) followed by L2 (45.6%) and L1 (3.4%). These findings mirror the globally 
observed predominance of modern lineages (L2, L3, L4) over ancient ones (L1, L5, L6) 
(Gagneux and Small 2007). The successful spread of modern lineages has been 
associated with the fast expansion of the human population over the last decades, 
leading to a much higher population density and creating an environment favourable for 
a faster and easier transmission of MTBC in populations (Gagneux 2012; Portevin et al. 
2011; Wirth et al. 2008). A change towards a higher population density and an increase 
in genetic intermixture also happened in PNG in recent years. While especially the 
highlands remained isolated for a long time, two highways and daily domestic flights 
nowadays are connecting the different provinces of the country and the population 
growth is estimated at 2.8% annually (Australian Government Department of Foreign 
Affairs and Trade 2014). This might contribute to the Mtb lineage composition observed 
in our study. As TB is assumed to have expanded together with the human migration 
waves out of Africa around 70’000 years ago (Comas et al. 2013), a higher proportion of 
ancient strains of Mtb could have been expected to be found in the ‘older’ populations of 
the highlands compared to the ‘more recent’ arrived coastal populations. However, the 
statistically significant differences in the Mtb lineage composition between sites 
(p<0.001) were not mainly found between the coast and the highlands as expected, but 
rather between Madang and the two other sites. While in Madang L4 was the 
predominant lineage (76.6%) – confirming previous findings of Ballif et al. (Ballif et al. 
2012a) - Alotau had a significantly higher prevalence of L2 (84.4%). In Goroka, only a 
slightly higher number of L2 (60.5%) strains compared to L4 was found. Although all 
three lineages (L4, L2, L1) were found in all three study sites, L1 – belonging to the 
 128  10_General discussion 
ancient lineages – was only rarely found. Whether this results from a replacement by 
modern, more successful Mtb lineages (in this case L2 and L4) remains to be speculated. 
Such lineage replacement has been observed in Cameroon where the prevalence of 
modern Mtb lineages has been increasing in parallel to a decrease of previously 
dominant ancient lineages over the last four decades (Assam et al. 2013; Niobe-Eyangoh 
et al. 2003). However, it also cannot be ruled out that the low proportion of L1 in our 
sample set is due to the strain genetic background itself. It has been shown that L1 
strains exhibit a reduced transmissibility (Albanna et al. 2011) and a higher 
inflammatory response compared to modern lineages, which was suggested to be 
associated with a decrease in virulence (Portevin et al. 2011). Furthermore, an enhanced 
growth rate in macrophages was detected in modern lineages compared to ancient 
lineages (Reiling et al. 2013) potentially leading to a decreased culture recovery of the 
latter. A culture facility directly in the country without elaborate shipment could 
probably better address that question. 
 
The underlying reasons for the observed differences in lineage composition and sub-
typing data remain unclear and one can only speculate about the origin and the 
dynamics of Mtb in PNG. L4, also called the European-American lineage, for example 
might have been brought into the country during colonial times in the 19th century when 
many Europeans (Germans in the north and British in the south) settled in PNG. Various 
reports about the labour trade during that time describe an increasing number of 
“phthisis” in the expatriate population (Wigley S.C. 1972). Simultaneously, positive 
reaction to tuberculin skin tests increased steadily in the native population who had 
been working on plantations (Proust A.J.ed. 1991; Wigley S.C. 1972) (see chapter 2). 
Nevertheless, it cannot be ruled out that there was TB in New Guinea before the 19th 
century which then started to spread as a result of the changing external circumstances 
such as the labour trade, or it is possible that colonialists and missionaries introduced 
modern lineages leading to a spread of TB in PNG. The higher prevalence of specific 
lineages in a specific area (e.g. L4 in Madang) might also be linked to the host genetic 
background specific to the population of that area. Associations of specific lineages with 
geographical regions and human populations have been shown in the past (Gagneux et 
al. 2006b; Hirsh et al. 2004). However, the genetic background of study patients was not 
determined in the frame of the present study and this question cannot be answered.  
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Based on our findings from whole genome sequencing (chapter 7), L1 appears to have 
been introduced at least twice into PNG. A clear difference between isolates from the 
coast and the highlands could be observed. The L1 strains from the highlands are closely 
related to strains from the Philippines and other South-East Asian countries. The strains 
from the coast on the other hand share a common ancestor with strains from East-
Africa, but have branched off earlier than the highlands strains from their common 
ancestor. If this earlier branching off of coastal strains reflects within-PNG evolution 
remains to be investigated. More samples from different sites across PNG are required to 
answer the question about the origin of TB in PNG and to find a scientifically sound 
explanation for the differences of the Mtb composition observed between sites.  
 
The global origin of the Beijing strain family is suggested to be Central Asia (Mokrousov 
et al. 2005). From there it spread through East-Asia during the Neolithics (Comas et al. 
2013; Mokrousov et al. 2005), and most likely independently and rather recently further 
to the rest of the world. Already during colonial times at the end of the 19th century, 
Chinese immigrated into New Guinea, increasing in numbers after the independence of 
PNG in 1975 (Ichikawa 2006). MIRU-VNTR data indeed suggests an introduction of the 
Beijing strain into PNG from China/Southeast Asia rather than from Australia 
(Mokrousov 2012). This is supported by the WGS based phylogeny of ten of our Beijing 
samples and the LSP based subtyping of all Beijing strains (chapters 6 and 7). These 
strains appear to be closest related to strains from China and Vietnam. However, they 
are not intermingling with recent strains from Asia, but are forming a separate PNG 
cluster, suggesting a certain degree of in-country evolution. It remains unclear if a 
founder effect with subsequent clonal expansion or rather evolutionary selection of a 
specific sub-type of Beijing - as observed in Cape Town (Hanekom et al. 2007a; Hanekom 
et al. 2007b) - was the driving force of the observed Beijing population structure in PNG. 
 
10.3 Clinical considerations 
10.3.1 Risk factors  
It has been shown that the host and the Mtb genetic background influence disease 
diversity (Coscolla and Gagneux 2010). Environmental and behavioural factors also have 
to be taken into account in order to understand the TB epidemiology in a country, 
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especially in settings like PNG with a large cultural and host diversity. A variety of risk 
factors for TB infection are known (e.g. smoking (World Health Organization 2009a), or 
lighting fire inside the house (Ramachandran et al. 2011)) and might contribute to 
differences observed between study sites. Co-infections with HIV (Getahun et al. 2010), 
helminth infections (Salgame et al. 2013) or H. pylori infection (Perry et al. 2010) have 
been found to influence the course of an infection with Mtb and might contribute to the 
complexity also in PNG.  We analysed risk factors for TB infection in our Goroka sample 
set (chapter 8), but no statistically significant association between smear positivity and 
the investigated risk factors could be found. This could in part be a result of the sample 
consisting of people with chronic cough and thus lacking a healthy control population.  
 
In a second step, also signs and symptoms common for pulmonary TB were analysed in 
order to assess potential clinical predictors of infection. Weight loss and chronic 
productive cough for more than three weeks were significantly associated with smear 
positivity. These symptoms can therefore be used as an additional clinical indicator of 
active pulmonary TB which should be considered during clinical examinations by health 
workers.  
 
10.3.2 Non-tuberculous Mycobacteria  
The standard diagnostic procedure for TB in PNG, AFB smear microscopy, cannot 
discriminate between MTBC bacteria and non-tuberculous Mycobacteria (NTM). So far, 
no data exists on the prevalence and type of NTM present in PNG. In the frame of our 
study, sputum samples of patients diagnosed with TB were sent for culture to Brisbane, 
Australia. Besides allowing the performance of culture based DST, TB diagnosis based on 
AFB detection or chest X-ray could be confirmed and in parallel the proportion of NTM 
in our sample set could be determined (chapter 9). NTM were detected in 4% of sputum 
samples grown in culture, consisting of M. fortuitum, M. intracellulare, M. terrae and M. 
avium. Four of these (1.8%) were found in combination with Mtb (all samples containing 
M. avium and one sample with M. intracellulare), but 2.2% of patients diagnosed with 
pulmonary TB were actually infected with NTM and maybe not with Mtb. Depending on 
the NTM species, treatment regimens different to the TB combination treatment are 
recommended (Griffith et al. 2007). For an infection with M. fortuitum for example, a 
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daily dose of amikacin, cefoxitin plus probenecid for 2-6 weeks is recommended (Root et 
al. 1999). However, because of the lack of an in-country culture facility, NTM infections 
can currently not be distinguished from MTBC and consequently no specific treatment 
guidelines exist in PNG (Papua New Guinea Department of Health 2012). All our study 
patients with an NTM infection were therefore automatically put on TB first-line 
treatment for 6 months. Our results show that NTM infections causing lung disease 
mimicking pulmonary TB probably exist in PNG, an aspect that should be further 
investigated in the future. Xpert is not detecting NTM (partially explaining AFB positive 
Xpert negative results), again emphasising the need of an in-country culturing facility, as 
it would not only improve the diagnosis of TB and DR TB, but would also allow to 
investigate the burden of NTM infection and to establish treatment guidelines for 
pulmonary diseases caused by these pathogens.  
 
10.4 Methodological issues  
10.4.1 Sample size development and culture recovery 
A general limiting factor of the studies presented here was the limited number of TB 
positive samples obtained during both active and passive case detection. The relatively 
small sample size resulted in difficulties to perform certain analyses. For example it was 
not possible to investigate associations between specific DR conferring mutations and a 
particular Mtb lineage, as previously shown by Gagneux et al. (Gagneux et al. 2006a). 
 
As no data existed on the prevalence of undetected TB in the community, and with 
records of health centres being difficult to access, sample size calculation prior to the 
study had to rely on estimates and local anecdotal reports. Due to financial and logistical 
limitations, the studies focused on adults and pulmonary TB only, considered most 
important for transmission (Behr et al. 1999a). This consequently reduced the possible 
number of samples, and excluded in particular children who have been shown to 
contribute 36% of all TB cases in a recent study in Kikori, Gulf province (Cross et al. 
2014). 
 
Passive case detection (PCD) was conducted at provincial hospitals and patients seeking 
health care at lower level health facilities (health centres, aid posts and private clinics) 
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were not included in our study. Potential TB patients not seeking formal health care 
were also missed by the PCD approach. Active case detection (ACD) is considered a more 
useful strategy to identify undetected TB cases in the community (Corbett et al. 2010; 
Yimer et al. 2009) and could potentially have contributed to an increased sample size. As 
described in chapter 5, ACD was conducted in two sites and proved to be a useful 
approach to significantly increase the case detection rate in specific communities (24 
additional cases detected around Sausi, Madang province). On the other hand, ACD 
proved unsuitable to investigate the proportion of drug resistance or the genetic 
background of Mtb because of logistic and infrastructural challenges related to transport 
of samples. Overall, the absolute number of samples collected would not have 
significantly increased the sample size for molecular analyses. More importantly, we 
could demonstrate that the usefulness and feasibility of ACD varies between sites in PNG 
and it should only be considered as a complementary approach to PCD if it can be well 
integrated into the routine system while at the same time not overburdening staff of 
health centres which has been particularly emphasized by Luelmo (Luelmo 2004). ACD 
and PCD can usefully complement each other if well implemented into routine 
procedures.  
 
Sample collection is not the only factor impacting on the final sample size. From primary 
screening and enrolment of adult TB suspects to the final outcome of genotyped Mtb 
strains, the sample size was reduced drastically from 847 to 147. Apart from the logical 
reduction between enrolment to the diagnosis of TB (in Goroka and partially also in 
Alotau patients were enrolled prior to diagnosis), there was a substantial loss of samples 
during the process of culturing (Figure 10.1).  
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Figure 10.1: Flow chart of sample collection for genotyping. 
CXR= chest X ray; NTM= non-tuberculous mycobacteria; MTBC= 
Mycobacterium tuberculosis complex; DST= drug susceptibility testing; 
Swiss TPH = Swiss Tropical and Public Health Institute; QMRL= 
Queensland Reference Laboratory 
 
Only 67.2% (225/335) of all samples (including smear negative ones) sent for culture 
could be recovered. Successful culturing was significantly associated with bacterial 
count (see appendix 4): the higher the bacterial count the more likely bacteria grew in 
culture. For a positive determined 1+ sample (i.e. 10 bacteria per 100 fields) the chance 
to grow in culture was 17.6 times higher compared to a smear negative sample. When 
samples with lower counts were excluded culture recovery increased to 84.6% 
225
Samples grown in culture
4
Mixed infections
No consent
n= 89
936
Adult TB suspects screened
396
Patients with pulmonary TB
- 282 smear positive
- 114 smear negative/CXR + 
53 
Extra-pulmonary TB
335
Sent for culture
110
No growth
212
Samples with DST results
13
- 4 Non-viable sub-culture
- 5 NTM
- 4 Mixed MTBC/NTM
214
Dubos sent to SwissTPH
2 
No aliquot available
91
No growth/contamination
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DNA extracted at QRML
before dubos shipment
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TB positive cases (any form)
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Cups unavailable/leaking
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(203/240). In comparison, Cross and colleagues achieved a recovery rate of smear 
positive samples (≥ positive 1+) of only 34.6% (9/26) (Cross et al. 2014), clearly 
highlighting the technical bottle neck in these studies. 
 
There are several reasons for this bottle neck. Mycobacteria of the Mycobacterium 
tuberculosis complex (MTBC) are slow growing bacteria and each sputum also contains 
other, fast growing bacteria which can overgrow Mtb if not eliminated, rendering the 
culture contaminated and unusable for further investigations. Therefore, each sputum 
sample was chemically decontaminated and subsequently neutralized (see chapter 4 
and appendix 2). This decontamination process can nevertheless also become critical 
and might occasionally kill Mycobacteria in the sample. Consequently, this would lead to 
the sterilization of the sample, in particular for those with low initial bacteraemia, and 
no growth in culture. In general, occasional contamination of culture samples with non-
acid fast bacilli, the successful growth of a few scanty and even smear negative samples, 
represents a balanced decontamination process as specified by the European Centre for 
Disease Prevention ( 2011). Another reason for failure in bacterial growth could be 
freezing of decontaminated samples before inoculation and shipment, although Tessema 
et al. had shown no significant effect on culture recovery. However, scanty bacteria 
might still be affected (Tessema et al. 2011). Additionally, the shipping procedures of 
samples (shipment within the country and internationally to Australia) often under non-
favourable conditions may well have impacted on the survival of inoculates. This 
included several days in transit due to flight interruptions, customs issues, or negligence 
of airport and/or shipment company staff. Again, this emphasizes the need of culture 
facilities within the country, as it would not only decrease the time to diagnosis and 
appropriate treatment of DR TB, but would most likely also increase culture recovery 
and therefore the availability of results. 
 
In addition, a number of samples were lost between drug susceptibility testing (DST) in 
Australia and genotyping at Swiss TPH. QMRL transferred samples into Dubos broth and 
shipped to Swiss TPH, where they were transferred into Middlebrook 7H9 broth. In both 
laboratories a slower growth of PNG samples was observed when compared to other 
Mtb strains (personal communication R. Carter and J. Feldmann, respectively). This had 
probably also an impact on the bacterial growth rate or even on their survival. 
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10.4.2 Study site setup 
From Madang, more isolates were available for molecular analysis than from the other 
two sites. Differences in study site setups (see chapter 4) might have contributed to that 
difference. In Madang, the PNG IMR laboratory was established during a previous study 
(Ballif 2012) and the facility for TB diagnosis was run under a local agreement not only 
for research but also served as facility for the hospital providing a direct link to the NTP. 
There was also more staff available to assist in study procedures than in the other sites. 
This allowed processing of samples in time, confirmatory microscopy readings to be 
performed on a regular basis, and simultaneous enrolment of multiple patients.  
 
The Alotau Provincial Hospital laboratory facilities could be used for study purposes 
which provided good link to patient records, to microscopy results, and to sputum 
samples collected by hospital staff. Since only one PNG IMR staff member was 
responsible for interviews and sample processing, sample decontamination was often 
delayed, and samples had to be shipped to Goroka for further processing, potentially 
impacting on culture recovery.   
 
In Goroka, PNG IMR is located in close proximity to the hospital but the laboratories of 
IMR and the hospital are two independent entities. Access to sputum cups and records 
from the hospital was therefore more complicated than in Madang and Alotau. Due to 
the presence of the study investigator in Goroka, regular quality assurance and a quick 
response to operational issues was easier. It is noteworthy that in contrast to Madang 
and partly Alotau, patients in Goroka were enrolled before the diagnosis of TB. Analysis 
of risk factors associated with smear positivity was therefore only possible for Goroka 
(chapter 8).  
 
10.4.3 Transmission dynamics 
The present studies were not designed for household contact tracing to establish 
epidemiological links and to investigate the progression from latent infection to active 
disease. Therefore, genotyping methods had not been selected for discriminatory power 
to analyse the chain of transmission. For financial and logistical reasons it was not 
possible to conduct MIRU-VNTR or whole genome sequencing (WGS) on all samples. 
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However, the limited data available on whole genome sequencing of a sub-set of samples 
(chapter 7) suggested re-activation of latent TB rather than epidemiologically linked 
direct transmission. Clusters of closely related strains were found but the SNP 
differences between each single strain in a cluster where above the “outbreak-
threshold” of 12 SNPs (Walker et al. 2012). Nevertheless, recent transmission cannot be 
ruled out, as only a sub-set of samples has been sequenced. In our previous study in 
Madang (Ballif et al. 2012a), 44.4% of strains were found to be within a cluster, which 
might suggest recent transmission. However, as the cluster analysis was based on MIRU-
VNTR, there is a possibility that transmission was overestimated. WGS of all samples, 
including the ones from our previous study, could shed more light on the disease 
dynamics in PNG. 
 
10.5 Implications  
10.5.1 Provincial level 
With the increasing number of MDR TB cases and recently even XDR TB cases in PNG it 
is important for the NTP to determine hotspots of drug resistance to strategically 
position tools to diagnose and monitor DR TB. According to our data, Milne Bay is a 
province that would require better diagnostic capacity and improved monitoring of DR 
TB. Alotau was the study site with the highest proportion of any drug resistance (12.2%) 
and a large number of MDR TB cases (4.6%). In addition, 84.4% of all genotyped strains 
from Alotau belonged to the Beijing strain family, frequently associated with DR globally 
(Borrell and Gagneux 2009) and in PNG (this study and (Ballif et al. 2012b)).  Inter-
individual treatment regimens might become available in the future, but their 
implementation in resource-constrained countries with weak and already over-
burdened health systems might be difficult. A better understanding of the distribution of 
TB in general and DR TB in particular could ensure that additional infrastructure and 
diagnostic tools that cannot be provided country wide are targeted to where they are 
needed the most. We therefore propose to urgently supply provinces with a high DR 
prevalence such as Milne Bay Province with their own GeneXpert system, aiming at 
country wide coverage with each province having at least one of these systems in the 
future. This would make sample shipment to CPHL in Port Moresby (currently 
responsible for Milne Bay Province and others to test samples with Xpert (National TB 
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Program Unit et al. 2011)) obsolete.  The delay in diagnosing DR and starting second-
line treatment could be reduced, resulting in a decreased risk of MDR transmission and 
better cure rates. Furthermore, accurate calculations of required second-line treatment 
could be made to ensure an uninterrupted drug supply.  
 
10.5.2 Regional/global level 
Lumb et al. reported that 6/21 MDR TB cases diagnosed in Queensland, Australia, in 
2008, and 11/31 in 2009, were patients from PNG (Lumb et al. 2011) and the first cases 
of XDR TB from PNG were diagnosed and put on treatment in Australia (McBryde 2012). 
Supporting the PNG National TB Control Program with information on DR hotspots 
could therefore not only help to improve the control of TB within the country, but would 
also have an impact on neighbouring countries such as Australia.  
 
A complex system of the bacterial and host genetic background in combination with 
environmental and social factors determine the TB epidemiology in a country (Comas 
and Gagneux 2011; Coscolla and Gagneux 2010; Dye et al. 2011). Clinical strains from 
various countries and populations are required to further investigate host-pathogen 
interactions and the evolution of Mtb around the globe. In addition, such samples are 
required for the potential development of new diagnostic methods, drugs and vaccines, 
which could be strain-specific. The present study can therefore contribute to a global 
collection of information on Mtb genotypes and drug resistance, which so far did not 
include PNG (Gagneux and Small 2007).  
 
10.6 Outlook 
While baseline DR and Mtb population structure data is becoming available from 
different provinces of PNG, no country wide data is available to date. Especially from the 
highlands and isolated areas not much data is available yet. For example, it is unknown if 
in very remote and isolated areas of PNG TB is present at all. On the other hand, also 
from the largest and most densely populated urban centre Port Moresby only limited 
data on DR and no information on Mtb strain diversity are publicly available. 
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Comprehensive data on DR, the Mtb population structure and the host genetics from 
across the country would provide an opportunity to investigate the molecular 
characteristics driving DR TB in PNG. A country wide health centre-based study aimed at 
filling this data gap appears operationally difficult and very cost intense. A more feasible 
approach would be to conduct a longitudinal study at provincial hospitals, where 
sputum samples for DR analysis and Mtb genotyping could be collected in the frame of 
routine passive case detection. The National Department of Health  has started to roll-
out a GeneXpert-based drug resistance surveillance system as part of the passive case 
detection, but limited to a few main cities of the country (National Department of Health 
et al. 2012). Where available, this system could be used for drug resistance monitoring. 
However, as for further molecular analyses DST and DNA extraction of all samples (and 
not only of those RMP resistant) would be required, a parallel system of culture based 
DST would need to be established. With such an approach, the investigation of 
operational aspects and molecular epidemiology could be combined.   
 
Sampling at provincial hospitals would be restricted to patients seeking care at the 
hospital, but would nevertheless provide comparable data from across the country. 
Using hospitals as the basis of a longitunial study (as opposed to rural health facilities) 
could provide the comfort of essential infrastructure and an opportunity for extending 
the investigations to more complex clinical presentations such as extrapulmonary TB 
and TB in children.  
 
The development of drug resistance or changes in the Mtb lineage composition over 
time - as observed in other countries (Assam et al. 2013; Cowley et al. 2008; Hanekom et 
al. 2007a; Hanekom et al. 2007b; Niobe-Eyangoh et al. 2003) - could for example be 
investigated. Household contact tracing and investigations on the exposure history of 
patients should be included for analyses of the chain of transmission. Furthermore, 
including human leukocyte antigen (HLA) typing to evaluate the host genetic 
background could improve the understanding of host-pathogen interactions, which 
could shed light onto the evolution of Mtb in the country and could potentially explain 
the observed differences of the Mtb population structure in different areas of PNG.  
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Last but not least, the GeneXpert system based DR surveillance of the National 
Department of Health could be evaluated. How feasible is it for hospitals to use and 
maintain the GeneXpert system (e.g. Daru Hospital)? How feasible is it for hospitals with 
no such system (e.g. Alotau Provincial Hospital) to ship samples to the respective 
referral laboratory for diagnosis of DR? Addressing these and other similar questions 
could help to find gaps in the system and to determine the best adapted approach for DR 
monitoring and surveillance in PNG. 
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Appendix 1: Flow charts laboratory procedures 
Active Case Detection 
 
  
Collect sputum samples and
Keep them at 4°C 
(car/gas fridge/esky).
Centrifugation + re-dissolving in supernatant
archive
NaOH-H3PO4 Decontamination
Shipment to Hospital (TB lab) by car
(Mondays and Thursdays)
A (day 1) B (day 2) C (day 2)
Sputum pool
500ul
DNA extraction  
(IMR GKA, 
PNG)
MTBDR assay
500ul
MGIT
(RefLab, 
Brisbane)
DNA extraction
from culture
Genotyping
IMR GKA, PNG
1.5 ml
Result to
sentinel site
AFB 
microscopy
Direct AFB smear + 
fluorescent microscopy
Pool all 3 sputum samples 
of one patient
Additional AFB slide
after decontamination
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Passive Case Detection 
 
 
Collect sputum samples
Keep them at 4°C 
Centrifugation + re-dissolving in 3 ml supernatant
archive
NaOH-H3PO4 Decontamination
A (day 1) B (day 2) C (day 2)
Sputum pool
500ul
DNA extraction  
(IMR GKA, 
PNG)
MTBDR assay
500ul
MGIT
(RefLab, 
Brisbane)
DNA extraction
from culture
Genotyping
IMR GKA, PNG
1.5 ml
Result to
sentinel site
AFB 
microscopy
Direct AFB 
smear microscopy
Pool all 3 sputum samples
of one patient
Additional AFB slide
After decontamination
Direct fluorescent
microscopy
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Appendix 2: Laboratory standard operational 
procedures  
1. Reagents preparation  
1.1 Sodium hydroxide 4% (NaOH) 
Ingredients: 
• Sodium hydroxide      40g   
• Bromothymol blue solution (0.4%W/V)*  1.5ml 
• Sterile distilled water     1L 
  
* Bromothymol blue solution: 
• Bromothymol blue MP Biomedical 150524 0.8g 
• Ethanol      200ml 
Protect from light! Wrap the bottle with aluminum foil! 
 
Remarks: Sodium hydroxide granules may absorb moisture. Keep the bottle lid tightly 
sealed with parafilm! 
 
Preparation: 
1. Add the bromothymol blue solution to the sterile distilled water 
2. Mix well  
3. Add the sodium hydroxide to the bromothymol blue solution and mix well 
until the NaOH pellets are resolved  
4. When all the pellets are resolved and the solution has cooled down to room 
temperature, check the quality of the prepared solution (see below) 
 
Hazards: 
Sodium hydroxide: Highly corrosive; avoid eye, skin and vapour contact 
Alcohol: flammable 
Shelf life: The prepared solution may be stored for up to 3 months at room temperature. 
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1.1.1 Quality control  
Materials: 
• Standard phosphoric acid  
• 4% sodium hydroxide to be tested 
• 50 ml Falcon tube 
• Pipette filler/bulb 
• 5 ml, 10 ml graduated pipettes (re-use) 
• 50 ml beaker (re-use) 
 
Procedure: 
1. Mix the reagents by gentle agitation 
2. Decant 15ml of the NaOH solution to be validated into the 50ml Falcon tube 
3. Decant 30ml of standard phosphoric acid into the glass beaker 
4. Withdraw 9ml of standard phosphoric acid and add to the Falcon tube. Mix. 
Indicator colour should be light blue. If yellow, the batch FAILS! 
5. Withdraw a further 3ml of standard phosphoric acid and add drop wise to the 
falcon tube until the colour changes to a pale green. This should occur around 
1ml. Note the volume added and record the result on the media QC sheet (see 
annex), e.g. 9ml +1ml =10ml as final result 
6. Rinse containers with tap water and dry with paper towel 
Acceptance criteria: Titration volume = 10ml +/- 2ml 
 
1.2 Phosphoric acid 1M 
Ingredients: 
• Orthophosphoric acid    75ml 
• Bromothymol blue solution (0.4%W/V)  1.5ml 
• Sterile distilled water                923.5ml 
 
Preparation: 
1. Add the bromothymol blue solution to approximately 800ml sterile distilled 
water. 
2. Mix well to dissolve 
3. Add the orthophosphoric acid to the bromothymol blue solution and mix well 
4. Check the quality of the prepared solution  
 
Wrap bottle with aluminium foil to protect it from light! 
 
Hazards: 
Orthophosphoric acid: highly corrosive, avoid eye, skin and vapor contact 
Alcohol: flammable 
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Shelf life 
The prepared solution may be stored for up to 3 months at room temperature 
 
1.2.1 Quality control  
Material: 
• Standard 4% sodium hydroxide (the standard must be allowed to adjust to room 
temperature before use) 
• Phosphoric acid to be tested 
• 50 ml Falcon tube 
• Pipette filler/bulb 
• 5 ml, 10 ml graduated pipettes (re-use) 
• 50 ml beaker (re-use) 
 
Procedure: 
1. Mix the phosphoric acid to be validated by gentle agitation 
2. From bottle decant 15ml phosphoric acid solution into a 50ml falcon tube 
3. Decant 30ml of standard sodium hydroxide into a glass beaker. Withdraw 
2x10ml of standard and add to the falcon tube. Mix. Indicator colour should 
remain yellow. If blue, the batch FAILS! 
4. Withdraw a further 5ml of standard sodium hydroxide and add drop wise to 
the Falcon tube until the colour changes to a pale green. This should occur 
around 2ml. Note the volume added in the quality and record the result on the 
media QC sheet (see annex), e.g. 20ml +2ml =22ml as final result 
5. Rinse containers with tap water and dry with paper towel 
 
Acceptance criteria: Titration volume = 22ml +/- 2ml 
 
1.3 Carbol fuchsin Solution  
(Source: Pathology Queensland) 
Purpose: Primary staining solution in Ziehl-Neelson (ZN) Stain. 
Material:  
Basic fuchsin BDH 340325K  24 g 
Ethanol 400 ml 
Phenol  180 g 
Sterile distilled water 400 ml 
Sterile distilled water 4x1800 ml 
 
Preparation: 
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1. Weigh phenol into a 500ml beaker and add approx. 100ml dH2O. 
2. Mix the phenol water mixture and add to the basic fuchsin. 
NOTE: put the whole bottle basic fuchsin in at once to avoid pink staining. 
3. Allow to stand in a warm water bath (45-55°C) for at least 2 hours. 
4. Add 400mL of ethanol 
5. Allow to stand overnight in a warm water bath. Store under the bench until 
required for use.  
6. When ready to dilute measure the 1800ml of RO water into 2L bottles with a 
stirrer in each bottle and place in the water bath to warm.  
7. Place the stain concentrate in the water bath at the same time and allow to 
arm.  
8. Add 245ml of the concentrate to the RO water, mix and leave in warm water 
bath at (45-55°C) for at least 2 hours.  
9. Remove the bottle from the water bath and mix well using a magnetic 
plate and stirrer until the solution reaches room temperature. Let stand for up 
to 1 month to allow debris to settle on the bottom of the bottle  
10. Dispense in 400ml volumes into 500ml sterile bottles (avoid debris). 
11. Label and number bottles 1 through to 5 as poured including the expiry date. 
 
Hazards:  
Alcohol: flammable. 
Basic fuchsin: Low to Moderate toxicity avoid eye, skin contact and dust 
inhalation possible carcinogen. Clean up spills with a sodium sulphite solution.  
Phenol: causes burns, toxic in contact with skin and if swallowed. 
 
Shelf life:  
The prepared solution may be stored for up to 3 months at room temperature. 
 
1.3.1 Quality control:  
ZN QC slide stained each week with routine slides. 
 
Source:  
(Master 1992) 
 
2. Sputum processing 
Sputum samples have to be kept at 4°C before decontamination; Decontamination has to 
be done at the latest 4 days after sample collection. 
 
2.1 Sample decontamination 
Before decontamination, make sure that the direct smears and the smears for 
fluorescent microscopy have been prepared (see below). 
 
1. Pool cups A, B and C of the patient into a pre-labelled 70 ml sample cup 
2. Transfer about 0.5ml of the sputum pool into a 15ml falcon tube. Put aside for  
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3. Decontaminate the sputum pool with NaOH-H3PO4 as follows: 
 
a. Add about an equal volume of 4% NaOH to the sputum pool  
b. Shake vigorously by shaking and vortexing.  
NOTE: The mucous/purulent material needs to be completely liquefied during this 
process, no clumps or anything solid should be visible anymore after mixing. If not 
liquefied, more NaOH 4% needs to be added.  
 
c. Let the sample stand for 30 min, shaking periodically (vortex) 
d. After incubation neutralize the sample by adding 1M H3PO4 (containing 
bromothymol blue): Swirl gently while slowly adding the acid. Continue to 
add acid until the sample turns greenish/yellowish (= pH 7; double check 
with pH paper, the colour indicator might not work properly due to 
fading). 
e. Transfer the digested sample into a 10ml screw cap tube. Discard patient 
container 
f. Seal the 10 ml tube with parafilm to make them aerosol tight 
g. Load centrifuge buckets (still insight the biosafety cabinet!) 
h. Centrifuge the sample at 3300rpm 20 min 
i. With a transfer pipette remove supernatant, leave 3 ml residual liquid  
j. Vortex to re-suspend the pellet 
 
4. Aliquot the decontaminated sputum for all the following procedures: 
 
a. 1.5 ml into a 2 ml cryovial, labelled with YJ patient ID, age, gender, 
initials, date of decontamination, and “ARCHIVE” 
b. 500 ul into a 1.5 ml screw cap tube (red lid), labelled with YJ 
patient ID, age, gender, initials, date of decontamination, and 
“HAIN” 
c. 500 ul into a screw cap tube (red lid), labelled with YJ patient ID, 
age, gender, initials, date of decontamination, and “for MGIT” 
 
2.2 Bleach processing  
(Adapted from (Angeby et al. 2000)) 
1.  Add equal amount of household bleach (NaOCl) to the 1 ml sputum pool set 
2.  aside before decontamination  
3.  Shake vigorously (vortex or shake) 
4.  Let the sample incubate for 15min 
5.  Double the amount of liquid in the tube by adding dH2O 
6.  Centrifuge samples at 3300rpm 20 min 
7.  Remove supernatant, only leave few drops and the pellet 
8.  Resolve the pellet in these residual drops  
9.  Store the tubes at 4°C for smearing 
 
2.3 MGIT inoculation 
MGIT (Mycobacteria Growth Indicator Tube) contains a liquid growth medium, which 
allows mycobacteria to grow more rapidly than in other types of medium, especially 
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solid. Before inoculating the tube with decontaminated sputum, a complement mixture 
is added. It contains nutrients and antibiotics, which prevent the growth from other 
bacteria. 
In order to save complement mixture (it can only be used for 7 days once opened and 
mixed) the inoculation is only done once a month and only if there are at least 10 
samples (one bottle of complement mixture lasts for 10-15 samples). 
All smear positive samples and samples smear negative but from patients with strong 
clinical symptoms are inoculated into MGIT:  
Label the MGIT tubes with the date of the inoculation, the sample ID, the initials of the 
patient, sex and age of the patient  
 
1. Prepare the complement mixture by pouring the OADC (liquid, brown bottle) 
to the PANTA (powder, transparent bottle), and mix until dissolved.  
2. Check that the MGITs are not defect and open them 
3. Pipette 800 µl of the complement mix into each MGIT. Use a fresh pipette tip 
for each MGIT to avoid contamination! 
4. Close the MGITs (keep only one tube open at the time for inoculation) 
5. Inoculate the MGITs with 500 µl of decontaminated sputum (well suspended 
in the residual liquid). Make sure a different pipette tip is used for each 
sample! 
6. Gently mix by inverting the MGIT 5 times 
7. Discard remaining complement mixture  
8. Prepare shipment to Brisbane via TNT  
 
3. Microscopy 
3.1 Sample appearance 
Before preparing the direct smear, the appearance of the sputum samples needs to be 
checked and entered into the sample handling form. Saliva samples cannot be used for 
diagnosis and another sample needs to be collected.  
If a sample is not labelled properly and it cannot be assigned to a specific patient, the 
sample has to be discarded without processing. 
A good quality sample is either mucous or purulent or both. If the sample has a saliva 
portion and a purulent portion, the latter has to be used to prepare the smear. A saliva 
smear will be washed off during staining procedure and does usually not contain 
mycobacteria. Therefore, saliva smears do not allow performing a proper diagnosis. 
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Figure 1: Sputum sample types. A. purulent sample; B. mucous/purulent sample; C. 
purulent sample in saliva; Source: adapted from documents obtained from the 
Mycobacterium Reference Laboratory, Pathology Queensland, Health Services Support 
Agency  
The following slides have to be prepared for each patient: 
- A direct smear for AFB of each sample (A, B, C) 
- A direct smear for Fluorescent microscopy of each sample (A, B, C) 
- A bleach treated smear (one slide smeared from pool of cups A, B + C) 
- An after decontamination smear (one slide of the decontaminated sample pool) 
 
3.2 Smearing 
The quality of a smear is very important. The better the smear is, the easier the reading 
will be. A smear should be centred on the slide (Figure 1). It should not be too thin or 
thick. Mucous or purulent material has to be used to prepare the smear.  
The bacteria are “hiding” in the mucous part of the sample. Therefore, the mucous 
material has to be broken up while smearing. This can be done by using the 
ragged/splintered end of a broken wooden applicator stick for smearing, rather than the 
smooth end. 
 
 
Figure 2: The sputum smear should be centred on the slide, so that a=b, c=d 
 
3.2.1 Direct smear 
1. Take a sterile wooden applicator stick and break it into half 
2. Dip the ragged end of the stick into the freshly collected, untreated sputum 
sample and try to pick up purulent/mucous material (only about a drop) 
3. Smear it over the slide in small circles, starting in the centre and slowly moving 
outside, increasing the smear area like this 
4. Let the smear dry on the heating plate 
 
B
A
C D
a
c
b
d
Saliva 
Purulent 
material 
A B C 
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3.2.2 Smear after decontamination 
1. Take a sterile wooden applicator stick  
2. Dip it into the pooled, decontaminated sputum sample and try to pick up 
purulent/mucous material (only about a drop) 
3. Smear it over the slide in small circles 
4. Let the smear dry on the heating plate 
 
 3.2.3 Smear after bleach treatment 
1. Take a sterile wooden applicator stick and break it into half 
2. Dip the ragged end into the pellet of the bleach treated sputum sample and try to 
pick up purulent/mucous material (only about a drop) 
3. Smear it over the slide in small circles 
4. Let the smear dry on the heating plate 
 
3.3 Staining 
3.3.1 Acid fast bacilli Ziehl-Neelson staining 
(used for direct smears, bleach smears and after decontamination smears) 
1. Put the staining solution into a water bath or an incubator (70°C) before starting 
2. Put the smeared microscopy slides onto the staining rack, smear facing up, label 
facing towards you 
3. Flood the slides with carbol fuchsin. Apply the staining solution on the top corner 
of the slide and let it slowly spread over the slide in order not to flush away the 
smear (Figure 2). 
 
 
 
 
 
Figure 3: Application of carbol fuchsin for slide staining 
 
4. Incubate the slides at room temperature (RT) for 10min. 
5. Rinse the slides with dH2O 
6. Flood the slides with acid alcohol 
7. Rinse the slides strait away with dH2O 
8. Flood the slides again with acid alcohol 
9. Incubate the slides at room temperature for 2min. 
10. Rinse the slides with dH2O 
11. Flood the slides with Methylene blue (counter staining) 
12. Incubate for 2min. at RT 
13. Rinse the slides with dH2O 
14. Let the slides air dry at RT in a staining rack 
Apply carbol 
fuchsin here 
and let it flow 
down the slide 
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3.3.2 Fluorescent microscopy, auramine staining method  
(Commercial kit: fluorescent stain kit M, Becton, Dickinson, USA) 
Fluorescent staining fades very quickly. If slides are stained with Auramine, they need to 
be read the same day! 
Staining procedure:  
 
1. Place slides on staining rack and flood with TB Auramine M (primary stain) for 
15min. 
2. Wash gently in running water  
3. Decolorize with TB Decolorizer TM for 30-60 sec. 
4. Wash slides gently in running water 
5. Counterstain with TB Potassium Permanganate for 2min 
6. Wash gently in running water 
7. Air dry the slides 
 
3.3.3 Quality control of staining 
The quality of staining can be checked by staining control slides (compare 3.3.5). As the 
result of these control slides is known, they can be used to detect contamination of 
staining solution:  
 
- If the negative control slide turns out to be positive, the staining solution could be 
contaminated and has therefore to be discarded 
 
- If the positive control slide turns out to be negative, the staining is not working 
and has to be prepared freshly again.  
 
Once a week, a negative and a positive control slide have to be stained during a routine 
staining of diagnostic slides. Furthermore, if a new staining solution was prepared, 
control slides need to be stained during the first round of staining with the new solution. 
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Appendix 3: Primer tables 
Drug resistance typing primers 
Gene 
Product  
length Direction Primer sequence (5' - 3') 
AT 
(°C) Source 
rpoB Rv0667 
847    (Mtb) 
1539 (NTM) Reverse TCCTCGATGACGCCGCTTTCT 62 
adapted 
from [1] 
rpoB Rv0667 
847    (Mtb) 
1539 (NTM) Reverse TCR GAG ATC TTG CGC TTC TGS 62 
adapted 
from [1] 
rpoB Rv0667 
847    (Mtb) 
1539 (NTM) Forward AYA TCG ACC ACT TCG GYA ACC 62 
adapted 
from [1] 
inhA  
prom. Rv1484 478 Forward GGCACGTACACGTCTTTATGTA 65 [2] 
inhA  
prom. Rv1484 478 Reverse GGTGCTCTTCTACCGCCGTGAA 65 [2] 
KatG Rv1908c 850 Forward CCAGCGGCCCAAGGTATC 66 [1] 
KatG Rv1908c 850 Reverse GCTGTGGCCGGTCAAGAAGAAGTA 66 [1] 
embB Rv3795 260 Forward CGGCATGCGCCGGCTGATTC 65 [3] 
embB Rv3795 260 Reverse TCCACAGACTGGCGTCGCTG 65 [3] 
ahpC Rv2428 236 Forward ACCACTGCTTTGCCGCCACC 64 [4] 
ahpC Rv2428 236 Reverse CCGATGAGAGCGGTGAGCTG 64 [4] 
gyrA Rv0006 320 Forward CAGCTACATCGACTATGCG 58 [5] 
gyrA Rv0006 320 Reverse GGCTTCGGTGTACCTCATC 58 [1] 
gidB Rv3919c 793 Forward CGAGAGCGGAGAATGTTTCAC 60 [1] 
gidB Rv3919c 793 Reverse CTGGCCCGACCTTACGAGC 60 [1] 
rpsL Rv0682 333 Forward CGTGAAAGCGCCCAAGATAG 60 [1] 
rpsL Rv0682 333 Reverse GAACCGCGGATGATCTTGTAG 60 [1] 
rrs MTB000019 238 Forward GATGACGGCCTTCGGGTTGT 60 [6] 
rrs MTB000019 238 Reverse TCTAGTCTGCCCGTATCGCC 60 [6] 
rrs MTB000019 245 Forward GTAGTCCACGCCGTAAACGG 60 [6] 
rrs MTB000019 245 Reverse CACACAGGCCACAAGGGAAC 60 [6] 
rrs MTB000019 547 Forward CGTTCCCTTGTGGCCTGTG 60 [1] 
rrs MTB000019 547 Reverse GGCGTTTTCGTGGTGCTCC 60 [1] 
pncA Rv2043c 652 Forward GGCTGCCGCGTCGGTAGG 62 [1] 
pncA Rv2043c 652 Reverse GCCGCCAACAGTTCATCCC 62 [1] 
References: [1]= Ballif et al. 2012; [2]= Gagneux et al. 2006a; [3]= Victor et al. 1999; 
[4]= Homolka et al. 2010; [5]= Feuerriegel et al. 2009; [6]= Brossier et al. 2010; 
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Lineage 2 sub-typing primers 
Region of 
Difference 
Affected 
ORFs 
Product 
length (bp) 
H37Rv 
Product 
length (bp) 
deleted Direction Primer sequence (5' - 3') 
AT  
(°C) 
RD_181 
Rv2262c- 
Rv2263 1712 1001 Forward CGCAACGGCCGCGGTGAACTCT 62 
RD_181 
Rv2262c- 
Rv2263 1712 1001 Reverse CGGGCGGCTGCGGGAACCTT 62 
RD_150 
Rv1671- 
Rv1674c 3266 779 Forward TGTGGCGTGGCTCGGCAAATAG 64 
RD_150 
Rv1671- 
Rv1674c 3266 779 Reverse CGGGACGGCAAACGGGTGAT 64 
RD_142 
Rv1189- 
Rv1192 3634 783 Forward TCCGCGACGACGAACAACGAC 64 
RD_142 
Rv1189- 
Rv1192 3634 783 Reverse TCACTTCCATTTCCAGCGGCAACT 64 
Source: adapted from (Gagneux et al. 2006b) 
 
 
 
Appendix 4: Additional data 
Univariate regression to assess the association of bacterial count with culture outcome 
AFB count 
Culture outcome 
 
Association with  
culture outcome   
(growth/no growth) 
No growth 
n (%) 
Growth 
n (%) 
OR  
(95% CI) p-value 
Negative* 48 (43.6) 6 (2.7)     
Scanty  25 (22.7) 16 (7.1) 5.12 (1.8 - 14.7) 0.002 
Pos 1+ 20 (18.2) 44 (19.6) 17.6 (6.5 - 47.8) < 0.001 
Pos 2+ 4 (3.6) 47 (20.9) 94.0 (24.9 - 354.5) < 0.001 
Pos 3+ 13 (11.8) 112 (49.8) 68.9 (24.7 - 192.0) < 0.001 
Total 110 (32.8) 225 (67.2)     
*Reference category; AFB= acid fast bacilli; OR= odds ratio; CI= confidence interval 
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Abstract
Background: Monitoring drug resistance in Mycobacterium tuberculosis is essential to curb the spread of
tuberculosis (TB). Unfortunately, drug susceptibility testing is currently not available in Papua New Guinea (PNG) and
that impairs TB control in this country. We report for the first time M. tuberculosis mutations associated with
resistance to first and second-line anti-TB drugs in Madang, PNG. A molecular cluster analysis was performed to
identify M. tuberculosis transmission in that region.
Results: Phenotypic drug susceptibility tests showed 15.7% resistance to at least one drug and 5.2% multidrug
resistant (MDR) TB. Rifampicin resistant strains had the rpoB mutations D516F, D516Y or S531L; Isoniazid resistant
strains had the mutations katG S315T or inhA promoter C15T; Streptomycin resistant strains had the mutations rpsL
K43R, K88Q, K88R), rrs A514C or gidB V77G. The molecular cluster analysis indicated evidence for transmission of
resistant strain.
Conclusions: We observed a substantial rate of MDR-TB in the Madang area of PNG associated with mutations in
specific genes. A close monitoring of drug resistance is therefore urgently required, particularly in the presence of
drug-resistant M. tuberculosis transmission. In the absence of phenotypic drug susceptibility testing in PNG,
molecular assays for drug resistance monitoring would be of advantage.
Keywords: Mycobacterium tuberculosis, Papua New Guinea, Drug resistance, Mutations
Background
Mycobacterium tuberculosis drug resistance is a global
concern. In Papua New Guinea (PNG), the estimated tu-
berculosis (TB) incidence rate is 303/100000 population,
with 5% multidrug resistant TB (MDR-TB) among new
cases [1]. Culture-based drug susceptibility testing (DST)
requires infrastructures often too sophisticated for
resource-constrained settings. Detecting resistance-
associated mutations is a faster alternative, as shown by
Genotype MTBDRplus (Hain Life science) [2] or Xpert
MTB/RIF (Cepheid) [3]. To monitor drug resistance mo-
lecularly, the distribution of drug resistance-conferring
mutations in a given setting needs to be known, and
such data is currently missing for PNG. We report
mutations associated with drug resistance among TB
isolates in the Madang area of PNG and provide evi-
dence for transmission of drug-resistant M. tuberculosis.
Results and discussion
The patient characteristics and detailed M. tuberculosis
genotypes were reported elsewhere [4]. In brief, 60
patients were recruited in the frame of a pilot study in
2005-2007 and 201 in the frame of a treatment cohort
study in 2009-2010. History of previous TB treatment
was reported in 16.9% (31/201) of the 2009-2010
patients, for whom data was collected. Molecular ana-
lyses were performed on the DNA from 173 successfully
grown isolates and phenotypic DST was obtained for
172 isolates. From the six previously described M.
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tuberculosis lineages [5], we observed 133/173 (76.9%)
Euro-American (Lineage 4), 39/173 (22.5%) East-Asian
(Lineage 2, includes Beijing genotype), and 1/173 (0.6%)
Indo-Oceanic (Lineage 1).
Overall, 27/172 (15.7%) isolates were resistant to ≥1
drug: 15/172 (8.7%) monoresistant, 3/172 (1.8%) polyre-
sistant and 9/172 (5.2%) MDR. A total of 10/172 (5.8%)
strains were Rifampicin (RIF) resistant, 21/172 (12.2%)
Isoniazid (INH) resistant (13 low-level [0.1 mg/L], 8
high-level [0.4 mg/L]), 9/172 (5.2%) Streptomycin (STR)
resistant, and 4/172 (2.3%) Ethionamide (ETH) resistant.
Among resistant isolates, the genes harboring drug re-
sistance associated mutations were sequenced. The
observed mutations in katG, inhA promoter, ahpC pro-
moter, rpoB, embB, pncA, rpsL, rrs, gidB, and gyrA are
listed in Figure 1.
INH resistant isolates harbored mutations in katG
(codon S315T) or inhA promoter (nucleotide C15T). All
isolates with katG S315T were resistant to 0.4 mg/L
INH except one, which was sensitive to this concentra-
tion of INH. On the other hand, all isolates with inhA
promoter mutation were sensitive at this drug concen-
tration (but resistant at 0.1 mg/L), thus confirming the
association between inhA promoter mutations and low-
level INH resistance [6]. Among all 6/9 MDR-TB isolates
with either katG or inhA promoter mutations, all had
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1 RIF monoresistant    
tnatsiseronomHNI2
tnatsiseronomHNI3
tnatsiseronomHNI4
tnatsiseronomHNI5
tnatsiseronomHNI6
tnatsiseronomHNI7
tnatsiseronomHNI8
tnatsiseronomHNI9
tnatsiseronomHNI01
11 STR monoresistant        
12 STR monoresistant         
13 STR monoresistant          
14 STR monoresistant              
15 PZA monoresistant              
16 INH + STR polyresistant     
17 INH + STR polyresistant     
18 INH + STR polyresistant     
19 RIF + INH MDR 
20 RIF + INH MDR 
21 RIF + INH MDR 
RDMHNI+FIR22
RDMHNI+FIR32
24 RIF + INH + ETH MDR   
25 RIF + INH + ETH MDR   
26 RIF + INH + ETH + STR MDR         
27 RIF + INH + ETH + STR + PAS MDR  
Figure 1 List of all mutations observed in each of the 27 strains resistant to at least one drug. The polymorphisms are indicated at codon
positions, except for rrs gene. RIF: Rifampin; INH: Isoniazid; STR: Streptomycin; PZA: Pyrazinamide; ETH: Ethionamide; PAS: p-aminosalicylic acid; MDR:
Multidrug resistant.
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the katG S315T mutation, except one with an inhA pro-
moter mutation. This only MDR-TB case with an inhA
promoter mutation belonged to the four MDR-TB cases,
which were additionally ETH resistant. Mutations in
inhA promoter have been shown to cause INH and ETH
cross-resistance and were thereby associated with higher
risks of extensively drug resistant TB [7].
Eight INH resistant strains (38.1%) had no katG or
inhA promoter mutation. Only 850 bp of katG were
sequenced and mutations may therefore have been
missed. However, katG mutations outside this region are
rarer [6,8,9]. Alternatively, these strains might harbor
mutation(s) in the >20 other genes reported as poten-
tially associated with INH resistance (genes iniA or x for
example) [8].
We did not observe any ahpC promoter mutation,
thought to compensate the reduced catalase-peroxidase
activity resulting from katG mutations [10,11]. Because
the INH resistance-conferring mutations observed here,
i.e. katG S315T and inhA promoter C15T, are known to
be associated with a low fitness cost [11], they might not
require compensation.
All RIF resistant isolates harbored mutations in rpoB
at codons D516F, D516Y or S531L except one, which
did not have any mutation in the 600pb rpoB fragment
sequenced. DST was repeated for this case, confirming
the MDR phenotype. Furthermore, common rpoB, katG
and inhA promoter mutations were excluded by Geno-
type MTBDRplus. Nevertheless, it has been estimated
that mutations in the RIF resistance determining region
(81-bp region in rpoB) account only for 95% of RIF re-
sistance [6] and therefore other mechanisms cannot be
excluded. Mutation S531L has been linked to high-level
RIF resistance [12], whereas D516Y was associated with
low-level resistance [13-15]. Mutation D516F has only
been reported in Kazakhstan [16] and may also cause
low-level resistance. Low-level RIF resistance has been
little considered, but could influence treatment, espe-
cially knowing that phenotypic DST outcomes may differ
from the actual efficacy of the anti-TB drugs in patients
[17].
STR resistant isolates harbored mutations in rpsL
(codons K43R, K88Q, K88R) and rrs (nucleotide
A514C), as previously reported [18,19]. One isolate was
mutated at codon V77G in gidB, a mutation which was
not reported before. One STR resistant isolate did not
present any mutation in any of these genes.
Mutations in gidB have been associated with low-level
STR resistance [20,21], but were also reported in sensi-
tive strains [22]. In this study, gidB mutations A10P,
L16R, E92D, and A205A were observed among strains
resistant to other drugs than STR. We further explored
gidB mutations in whole genomes of 21 pan-susceptible
strains representative of the six defined M. tuberculosis
lineages [23]. Mutation gidB V77G, which we observed
in one STR resistant isolate from PNG, could not be
found in any of the 21 pan-susceptible strains. This mu-
tation could therefore indeed be involved in drug resist-
ance or could be a transitory polymorphism in the
population. The mutation A10P observed in one STR
sensitive isolate was not found in any of the 21 pan-
susceptible genomes. Mutations L16R was observed in
genome sequences from Lineage 4 strains (Euro-Ameri-
can lineage) and E92D in Lineage 2 strains (East-Asian
lineage). This supports the recent observation that gidB
L16R occurred in LAM strains (i.e. Lineage 4), whereas
gidB E92D occurred in Beijing strains [24]. A205A
appeared mutated in all strains not belonging to Lineage
4, therefore indicating that this mutation, identified by
comparison to H37Rv, is a Lineage 4 mutation. Observa-
tions from the 21 pan-susceptible genomes suggest that
most gidB mutations rather reflect M. tuberculosis
lineage evolution than drug resistance.
Clusters were defined for strains sharing identical spo-
ligotype and 24 locus mycobacterial interspersed repeti-
tive unit variable number of tandem repeats (MIRU-
VNTR) patterns. Among isolates with complete patterns,
72/162 (44.4%) were clustered. Despite potential fitness
costs associated with resistance-conferring mutations
[25], the proportion of clustered strains was not signifi-
cantly different among drug-sensitive (60/137, 43.8%)
and drug-resistant (12/25, 48.0%) isolates of M.
tuberculosis.
To distinguish between primary resistance and
acquired resistance, clustered isolates sharing identical
drug resistance-conferring mutations were considered.
Five of the 12 (41.7%) drug-resistant isolates involved in
molecular clusters shared their drug resistance-
conferring mutations with other isolates in the same
cluster, thus strongly suggesting patient-to-patient
transmission.
Conclusions
This study provides so far missing data about drug
resistance-conferring mutations in M. tuberculosis iso-
lates from Madang in PNG. Monitoring drug resistance
is essential to prevent the spread of resistant bacteria, es-
pecially in diseases requiring lengthy treatments such as
TB. Our data suggests that not all present drug resist-
ance associated mutations may be detected by molecular
tests, which mainly focus on a subset of polymorphisms
only. However, given the complex implementation of
culture-based DST in resource-constrained settings,
PNG may be well suited for an accelerated roll-out of
molecular drug resistance testing in order to better
tackle the emergence and the transmission of drug-
resistant M. tuberculosis strains.
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Methods
Study site and patient characteristics
In 2005-2007, a pilot study was conducted in Madang
(PNG) at the Modillion Hospital, which is the main
point of care in Madang province. In April 2009, a co-
hort study was initiated in the same hospital and two
smaller health centers in close vicinity to Madang town.
Patients above 14 years were included if having micro-
scopically confirmed pulmonary TB or other clinical evi-
dence suggesting smear-negative TB. Treatment and
follow-up were planed according to the directly observed
treatment, short-course (DOTS) program. Demographic
and clinical data were available for all patients, except
those recruited during the 2005-2007 pilot study.
Sample processing
Sputum samples were examined by light microscopy
after Ziehl-Neelsen staining. Decontamination was con-
ducted according to Petroff ’s method [26]. DST was per-
formed by proportion method [27] at the Queensland
Mycobacterial Reference Laboratory in Australia using
BACTEC™ MGIT™ 960 (Beckton Dickinson, USA) and
the following drug concentrations: RIF (1.0 μg/mL), INH
(0.1 and 0.4 μg/mL), Ethambutol (5.0 μg/mL), Pyrazina-
mide (100 μg/mL), Streptomycin (1.0 μg/mL), Amikacin
(1.0 μg/mL), Kanamycin (5.0 μg/mL), Ofloxacin (2.0 μg/
mL), Capreomycin (2.5 μg/mL), ETH (5.0 μg/mL), p-
Aminosalicylic acid (4.0 μg/mL), and Cycloserine
(50.0 μg/mL). Isolates resistant to one drug were cate-
gorized as monoresistant, isolates resistant to at least
INH and RIF were categorized as MDR and isolates re-
sistant to at least one drug but not MDR were consid-
ered polyresistant. DNA was extracted from cultures
using Instigate Matrix (Bio-Rad, USA) and sent to the
Swiss Tropical and Public Health Institute for molecular
analyses.
Strain genotyping
Spoligotyping and 24 locus MIRU-VNTR were used to
define strain clusters as previously described [28,29].
The online MIRU-VNTRplus platform was used for
cluster identification (www.miru-vntrplus.org [30]).
Clusters were defined for strains sharing identical spoli-
gotype and 24 locus MIRU-VNTR patterns. Strains were
assigned to one of the six previously described lineages
by real-time PCR identification of specific single nucleo-
tide polymorphisms (SNPs) [5,31-33].
Drug resistance mutations
The following genes (or gene regions) were sequenced
to capture drug resistance conferring SNPs: rpoB, katG,
inhA promoter, ahpC promoter, embB, pncA, rpsL, rrs,
gidB, and gyrA (see Additional file 1: Table S1 for pri-
mers and PCR conditions). Sequencing was performed
by Macrogen (The Netherlands). Observed mutations
were compared to the online Tuberculosis Drug Resist-
ance Mutation Database (TBDream, www.tbdreamdb.
com [8]).
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SETT ING :  Madang and surroundings, Papua New 
Guinea (PNG).
OBJECT IVE :  To characterise the genetic diversity and 
drug susceptibility of Mycobacterium tuberculosis iso-
lates collected in Madang and surroundings.
DES IGN :  M. tuberculosis was isolated from sputum 
samples from active pulmonary tuberculosis cases. Drug 
resistance profiles were obtained by drug susceptibility 
testing. M. tuberculosis lineages were identified by sin-
gle nucleotide polymorphisms and sub-typing was per-
formed by spoligotyping. Spoligotyping and 24 locus 
mycobacterial interspersed repetitive units-variable num-
ber of tandem repeats were combined to identify clus-
tered isolates.
RESULTS :  The 173 M. tuberculosis isolates collected 
belonged predominantly to the Euro-American lineage 
(Lineage 4) and the East-Asian lineage (Lineage 2). 
Multidrug-resistant M. tuberculosis were observed in 
5.2% of isolates. Lineage 2 M. tuberculosis, which in-
cludes the ‘Beijing’ genotype, was significantly associated 
with any drug resistance (OR 5.2, 95%CI 1.8–15.1). 
Cluster analyses showed 44% molecularly clustered iso-
lates, suggesting transmission of M. tuberculosis in the 
community, including transmission of primary drug-
r esistant M. tuberculosis.
CONCLUS ION :  These data provide the first insight into 
the molecular characteristics of M. tuberculosis in the 
Madang area of PNG, and indicate substantial drug re-
sistance with evidence of ongoing transmission.
KEY  WORDS :  resistance; genotype; lineage; transmis-
sion; spoligotyping
TUBERCULOSIS (TB) in Papua New Guinea (PNG) 
is of concern, with an estimated incidence >10 times 
higher than in other Paci! c Island countries.1,2 In 
2010, the World Health Organization (WHO) esti-
mated that the yearly TB incidence in PNG was 303 
per 100 000 population, and the prevalence of multi-
drug-resistant TB (MDR-TB, de! ned as resistance to 
at least rifampicin [RMP] and isoniazid [INH]) in 
new cases was estimated at 5%.3 However, due to 
limited access to health care and poor record keeping 
in rural PNG, those numbers are likely to have been 
underestimated. 
Previous studies in the PNG Western Province 
showed 25% MDR-TB among patients seeking care 
in Australian territories across the border.4,5 Unfortu-
nately, facilities for Mycobacterium tuberculosis cul-
ture and drug susceptibility testing (DST) are lacking 
S U MM A R Y
in PNG. However, a collaborative agreement with the 
Queensland Mycobacterium Reference Laboratory 
in Australia allows samples collected in the Madang 
region to be sent to Australia for culture and DST.
M. tuberculosis harbours higher genetic diversity 
than previously thought.6,7 On the basis of phylo-
genetic markers, such as large sequence polymorphisms 
or single nucleotide polymorphisms (SNPs), six phylo-
genetic lineages of M. tuberculosis have been de! ned.6–9 
Each of these is closely associated with speci! c geo-
graphic regions, and preferentially infects persons 
originating from these regions.6,9 Within SNP-de! ned 
lineages, further genotypic resolution can be obtained 
by spoligotyping.10 Spoligotyping combined with 
myco bacterial interspersed repetitive units-variable 
number of tandem repeats (MIRU-VNTR)11 can be 
used to de! ne clusters of strains that share identical 
molecular pro! les indicating recent transmission.12,13 
Evidence that M. tuberculosis genotypes might in" u-
ence disease development is increasing.14 In particular, 
MB and PH contributed equally to this article. SG and HPB are co-
senior authors.
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the association between Beijing strains (Lineage 2) 
and drug resistance has often been reported.15,16
The diversity of M. tuberculosis in PNG remains 
largely unexplored. Such data are necessary to better 
understand underlying differences in M. tuberculosis 
infections and study M. tuberculosis transmission 
dynamics in the region. The present study provides 
the ! rst data on drug resistance and genetic diversity 
of M. tuberculosis strains collected in Madang and 
its surroundings. 
MATERIAL AND METHODS
Study setting and patient characteristics
Madang Town is located on the north coast of PNG, 
with a population of about 27 000 in 2005 (Madang 
Province population = 365 000). From 2005 to 2007, 
a pilot study was conducted at Modilon General 
Hospital, the main hospital of Madang Province, fol-
lowed by a treatment cohort study initiated in April 
2009 at the same hospital plus two rural health cen-
tres located nearby. 
All microscopically con! rmed pulmonary TB pa-
tients aged ⩾15 years attending for a TB consultation 
were eligible, as were those with other clinical evi-
dence suggestive of TB. Patient treatment and follow-
up procedures were carried out according to the Na-
tional TB Programme, which in Madang Province is 
run under the DOTS strategy. Demographic and clin-
ical data were prospectively collected from the initia-
tion of the treatment cohort study in April 2009. 
Samples from the pilot study were included in the 
molecular analyses; however, no corresponding pa-
tient demographic or clinical data were available for 
these.
HIV status was assessed by Determine® HIV-1/2 
(Inverness Medical Innovations, Brisbane, QLD, Aus-
tralia) and con! rmed by ImmunoComb® HIV 1&2 
TriSpot Ag-Ab (Orgenics, Yavne, Israel). 
Sample collection and processing
In the TB laboratory of Madang, all sputum samples 
collected from pulmonary TB patients were exam-
ined by light and " uorescence microscopy. Samples 
were decontaminated according to Petroff’s method.17 
Centrifuged pellets were transferred into Mycobacte-
rial Growth Indicator Tubes (BACTEC™ MGIT™ 
960 system; BD, Franklin Lakes, NJ, USA) and trans-
ported to the Queensland Mycobacterium Reference 
Laboratory in Australia for culture and DST. DNA 
was extracted from cultured strains with InstaGene 
Matrix (Bio-Rad, Hercules, CA, USA) and sent to the 
Swiss Tropical and Public Health Institute, Basel, 
Switzerland, for molecular analyses.
Genotyping analyses
M. tuberculosis lineages were identi! ed by real-time 
polymerase chain reaction targeting lineage-speci! c 
SNPs (Applied Biosystems, Carlsbad, CA, USA), as 
described previously.6,7,18,19 
Sub-lineage differences were identi! ed using spoli-
gotyping.10 Speci! c shared international type (SIT) 
and spoligotype families were obtained from SpolDB4 
(www.pasteur-guadeloupe.fr:8081/SITVITDemo/
i ndex.jsp).20 Spoligotypes not reported in SpolDB4 
database were designated as orphans.
MIRU-VNTR was performed at 24 loci as previ-
ously described11 in collaboration with the Research 
Center, Borstel, in Germany. Clusters were de! ned 
as strains sharing identical spoligotype and MIRU-
VNTR patterns, and were used as a proxy to evalu-
ate M. tuberculosis transmission. MIRU-VNTRplus 
(www.miru-vntrplus.org)21 was used to match spo-
ligotypes and MIRU-VNTR patterns. Incomplete 
MIRU-VNTR patterns were excluded from the clus-
ter analysis.
Drug resistance
DST was performed using the proportion method22 
and the MGIT™ 960 system, with the following 
drug concentrations: RMP (1.0 μg/ml), INH (0.1 and 
0.4 μg/ml), ethambutol (5.0 μg/ml), pyrazinamide 
(100 μg/ml), streptomycin (1.0 μg/ml), amikacin 
(1.0 μg/ml), kanamycin (5.0 μg/ml), o" oxacin (2.0 μg/
ml), capreomycin (2.5 μg/ml), ethionamide (5.0 μg/
ml), para-aminosalicylic acid (4.0 μg/ml) and cyclo-
serine (50.0 μg/m). Isolates resistant to one drug were 
considered monoresistant, isolates resistant to at least 
INH and RMP were considered MDR, and isolates 
resistant to at least one drug but not MDR were con-
sidered polyresistant. 
Statistical analyses
χ2 or Fisher’s exact tests were used to assess differ-
ences in categorical variables, and Mann-Whitney 
U tests for continuous variables. Odds ratios were 
obtained from univariate logistic regressions. Statisti-
cal analyses were performed using Stata 10.1 (Stata-
Corp, College Station, TX, USA).
Ethical approval
The PNG Institute for Medical Research Review 
Board and the PNG National Medical Research Ad-
visory Council’s Ethics Committee approved the 
study protocol. The Ethikkommission beider Basel in 
Switzerland was informed about the study. Written 
informed consent was obtained from all patients.
RESULTS
Patient characteristics and sample set
In a pilot study, 60 patients with pulmonary TB were 
enrolled from 2005 to 2007. From April 2009 to Octo-
ber 2010, 201 patients were recruited into a treatment 
cohort study, during which detailed demographic and 
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clinical data were collected. Table 1 depicts the pa-
tient characteristics at enrolment. 
All DST and molecular analyses were performed 
on 60 isolates from the pilot study plus 118 from 
the 2009–2010 treatment cohort study. Five (2.8%) 
isolates were excluded because of mixed infections, 
as indicated by the presence of two alleles at >1/24 
MIRU-VNTR loci. A total of 173 isolates were in-
cluded for subsequent analysis. 
Strain genotypes
SNP-based lineage typing showed that 133/173 
(76.9%) isolates belonged to the Euro-American lin-
eage (Lineage 4), 39 (22.5%) to the East-Asian lineage 
(Lineage 2, includes Beijing genotype), and 1 (0.6%) to 
the Indo-Oceanic lineage (Lineage 1). No patient char-
acteristic was signi! cantly associated with Lineage 2 
as opposed to Lineage 4 M. tuberculosis (Table 2).
Within lineages, isolates were sub-divided by spo-
ligotyping. Among the 173 strains spoligotyped, 34 
different patterns were observed, with 19 (11.0%) iso-
lates belonging to 14 different orphan spoligotypes 
(see Figure for the list of spoligotypes observed). 
The three most prevalent spoligotypes were SIT 393 
(39/173, 22.5%), SIT 1 (38/173, 22.0%) and SIT 53 
(26/173, 15.0%). Within Lineage 4, the most frequent 
spoligotype families were T1 (87/133, 65.4%), LAM 
(11/133, 8.3%) and X1 (10/133, 7.5%). Orphans 
within Lineage 4 accounted for 18/133 (13.5%). 
Within Lineage 2, the main spoligotype family was 
SIT 1, i.e., the Beijing genotype (38/39, 97.4%); one 
orphan spoligotype was found in this lineage (2.6%). 
The single Lineage 1 isolate (Indo-Oceanic lineage) 
belonged to the EAI family.
The lineage distribution among samples from 
the 2005–2007 pilot study and samples collected in 
Table 1 Socio-demographic, clinical and laboratory characteristics of patients recruited 
between April 2009 and October 2010 (n = 201)
Characteristic
All 
(n = 201)
n (%)
DNA sample 
available
(n = 118, 58.7%)
n (%)
DNA sample 
not available
(n = 83, 41.3%)
n (%)
Sex
 Male
 Female
102 (50.8)
 99 (49.2)
68 (57.6)
50 (42.4)
34 (41.0)
49 (59.0)
Age, years, median [IQR] 28 [21–37] 26 [20.5–32.5] 32 [22–45]
Age group, years
 15–24
 25–34
 35–44
 ⩾45
 Unknown
 70 (34.9)
 67 (33.3)
 28 (13.9)
 34 (16.9)
  2 (1.0)
48 (40.7)
43 (36.4)
15 (12.7)
10 (8.5)
 2 (1.7)
22 (26.5)
24 (28.9)
13 (15.7)
24 (28.9)
 0
Province of origin
 Madang
 East Sepik
 Other
 Unknown
 86 (42.8)
 49 (24.4)
 42 (20.9)
 24 (11.9)
48 (40.7)
29 (24.6)
23 (19.5)
18 (15.2)
38 (45.8)
20 (24.1)
19 (22.9)
 6 (7.2)
Education
 No education
 Primary education
 Higher education
 36 (17.9)
110 (54.7)
 55 (27.4)
15 (12.7)
73 (61.9)
30 (25.4)
21 (25.3)
37 (44.6)
25 (30.1)
HIV 
 Positive
 Negative
 Unknown
 12 (6.0)
162 (80.6)
 27 (13.4)
 5 (4.2)
97 (82.2)
16 (13.6)
 7 (8.4)
65 (78.3)
11 (13.3)
BMI, median [IQR] 18.5 [16.3–21.1] 17.4 [15.9–21.4] 19.6 [16.8–21.4]
Smoking
 Yes
 No
 88 (43.8)
113 (56.2)
56 (47.5)
62 (52.5)
32 (38.5)
51 (61.5)
Sputum smear result
 Negative
 Scanty
 1+
 2+
 3+
 Unknown
 13 (6.5)
 34 (16.9)
 32 (15.9)
 16 (8.0)
103 (51.2)
  3 (1.5)
 5 (4.2)
10 (8.5)
11 (9.3)
15 (12.7)
76 (64.4)
 1 (0.9)
 8 (9.6)
24 (28.9)
21 (25.3)
 1 (1.2)
27 (32.6)
 2 (2.4)
History of previous TB treatment 
 Yes
 No
 Unknown
 34 (16.9)
129 (64.2)
 38 (18.9)
16 (13.6)
74 (62.7)
28 (23.7)
18 (21.7)
55 (66.3)
10 (12.0)
IQR = interquartile range; HIV = human immunodeficiency virus; BMI = body mass index; TB = tuberculosis.
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2009–2010 did not differ signi! cantly. Regarding the 
spoligotype prevalence, SIT 1 and SIT 119 were more 
frequent in 2009–2010 than in 2005–2007 (SIT 1: 
24.8% vs. 16.7% and SIT 119: 8.9% vs. 0%), whereas 
SIT 102, SIT 42 and SIT 53 were less frequent in 
2009–2010 than in 2005–2007 (SIT 102: 7.1% vs. 
13.3%, SIT 42: 4.4% vs. 8.3%, and SIT 53: 10.6% 
vs. 23.3%). 
Drug resistance
DST was successfully conducted for 172/173 of the 
isolates. Of these, 27 (15.7%) were resistant to at 
Table 2 Univariate logistic regression for the risk of infection caused by M. tuberculosis 
Lineage 2 strains (n = 112)
Explanatory variable
Lineage 4
(n = 84, 75%)
n (%)
Lineage 2
(n = 28, 25%)
n (%)
Associations with 
M. tuberculosis Lineage 2
OR (95%CI) P value
Sex
 Female*
 Male
32 (38.1)
52 (61.9)
15 (53.6)
13 (46.4) 0.5 (0.2–1.3) 0.15
Age, years, median [IQR] 26 [20–31] 28 [21–34] 1.0 [0.9–1.1] 0.79
PNG province of origin
 Madang
 East Sepik
 Other*
37 (48.7)
23 (30.3)
16 (21.0)
10 (52.6)
 4 (21.1)
 5 (26.3)
0.9 (0.3–2.9)
0.6 (0.1–2.4)
0.82
0.43
HIV 
 Negative*
 Positive
70 (94.6)
 4 (5.4)
23 (95.8)
 1 (4.2) 0.8 (0.1–7.2) 0.81
Negative sputum at enrolment 
 No*
 Yes
80 (96.4)
 3 (3.6)
26 (92.9)
 2 (7.1)
2.1 (0.3–13.0)
0.45
* Reference category. 
OR = odds ratio; CI = confidence interval; IQR = interquartile range; PNG = Papua New Guinea; HIV = human 
immunodeficiency virus.
Figure Spoligotypes for the three observed lineages (n = 173). SIT = shared international type.
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least one drug, and the remaining 84.3% were pan-
susceptible. Table 3 shows the different combinations 
of drug resistance. INH monoresistance was seen in 
nine (5.2%) patients and RMP monoresistance was 
seen in one (0.6%). MDR-TB occurred in nine (5.2%) 
patients, and no extensively drug-resistant TB was ob-
served. Neither the prevalence of resistance to at least 
one drug nor the prevalence of MDR-TB differed 
signi! cantly among samples from the 2005–2007 pi-
lot study and from the 2009–2010 treatment cohort 
study. 
Univariate logistic regressions were performed to 
estimate risk factors associated with drug-resistant 
M. tuberculosis among patients from the 2009–2010 
study for whom characteristics were available (Ta-
ble 4). Lineage 2 isolates (East-Asian lineage) showed 
a statistically signi! cant association with resistance 
to any drug (OR 5.2, 95%CI 1.8–15.1).
Transmission clusters
MIRU-VNTR typing at 24 loci was complete for 
162/173 (93.6%) isolates, and was used together 
with spoligotyping to de! ne molecularly clustered 
M. tuberculosis isolates, indicating recent transmis-
sion. Of 162 isolates genotyped using both meth-
ods, 72 (44.4%) were in molecular clusters. In total, 
24 different clusters comprising 2–7 isolates were ob-
served (median 2 isolates/cluster), 6 (25%) of which 
involved drug-resistant isolates. The remaining 18 clus-
ters involved pan-susceptible isolates only. The pro-
portion of drug resistance was not signi! cantly dif-
ferent in clustered (12/72, 16.7%) vs. non-clustered 
(13/90, 14.4%) isolates. Similarly, MDR isolates were 
equally distributed between clustered (4/72, 4.4%) 
and non-clustered isolates (4/90, 5.6%). Table 5 de-
scribes risk factors associated with M. tuberculosis 
strain clustering. The proportion of clusters did not 
signi! cantly differ between patients from the 2005–
2007 pilot study and patients recruited in 2009–2010 
(respectively 36.7% and 49.0%).
DISCUSSION
Little is known about TB in PNG. In particular, data on 
drug resistance are scarce, and PNG remains a ‘white 
Table 3 Drug resistance patterns observed among non 
pan-susceptible isolates (n = 27)
Resistance type, n
Lineage 4 
(%)
(n = 12)
Lineage 2 
(%)
(n = 15)
Total
(%)
(n = 27)
Monoresistant, 15
 RMP
 INH
 SM
 PZA
0
6 (50.0)
2 (16.7)
1 (8.3)
1 (6.7)
3 (20.0)
2 (13.3)
0
1 (3.7)
9 (33.3)
4 (14.8)
1 (3.7)
Polyresistant, 3
 INH+SM 0 3 (13.3) 3 (11.1)
MDR, 9
 RMP+INH
 RMP+INH+ETH
 RMP+INH+SM+ETH
 RMP+INH+SM+ETH+PAS
0
2 (16.7)
0
1 (8.3)
5 (30.0)
0
1 (6.7)
0
5 (18.6)
2 (7.4)
1 (3.7)
1 (3.7)
RMP = rifampicin; INH = isoniazid; SM = streptomycin; PZA = pyrazin-
amide; MDR = multidrug-resistant; ETH = ethionamide; PAS = p-amino 
salicylic acid.
Table 4 Univariate logistic regression for the risk of resistance to at least one anti-tuberculosis 
drug (n = 112)
Explanatory variable
Pan-susceptible
(n = 94, 83.9%)
n (%)
Resistant
(n = 18, 16.1%)
n (%)
Associations with 
resistance to ⩾1 drug
OR (95%CI) P value
Sex 
 Female*
 Male
38 (40.4)
56 (59.6)
 9 (50.0)
 9 (50.0) 0.7 (0.2–1.9)   0.45
Age, years, median [IQR] 25 [20–30] 29 [24–35] 1.0 [1.0–1.1]   0.05
PNG province of origin
 Madang
 East Sepik
 Other*
41 (49.4)
26 (31.3)
16 (19.3)
 5 (41.7)
 2 (16.6)
 5 (41.7)
0.4 (0.1–1.5)
0.2 (0.04–1.4)
  0.18
  0.12
History of previous TB treatment
 No*
 Yes
61 (83.6)
12 (16.4)
 9 (75.0)
 3 (25.0) 1.7 (0.4–7.2)   0.48
HIV
 Negative*
 Positive
78 (95.1)
 4 (4.9)
15 (93.8)
 1 (6.2)
1.3 (0.1–12.2)
  0.82
Strain lineage
 Lineage 4*
 Lineage 2
75 (80.7)
18 (19.3)
 8 (44.4)
10 (55.6) 5.2 (1.8–15.1) <0.01
Negative sputum at enrolment
 No*
 Yes
88 (94.6)
 5 (5.4)
18 (100)
 0 Not defined
* Reference category. 
OR = odds ratio; CI = confidence interval; IQR = interquartile range; PNG = Papua New Guinea; TB = tuberculosis; 
HIV = human immunodeficiency virus.
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spot’ on the map of M. tuberculosis phylogeographic 
diversity.7 In the present report, we investigated M. tu-
berculosis isolates from pulmonary TB patients in 
Madang and surroundings. DST showed that 15.7% 
of the strains were resistant to at least one drug and 
5.2% strains were MDR. Strains collected in this re-
gion belonged predominantly to Lineages 4 (Euro-
American lineage) and 2 (East-Asian lineage). 
The proportion of MDR-TB strains reported here 
was lower than the 25% previously observed in the 
Western Province,4,5 although there, a bias towards 
sicker individuals seeking treatment in the nearby 
Austra lians territories cannot be excluded. In the ab-
sence of DST facilities in the country, no national sur-
veillance data are available for comparison. Apart 
from drug resistance, HIV is another factor impact-
ing on TB burden, more particularly in Africa.23,24 In 
PNG, the WHO estimated an HIV prevalence in the 
general population of 0.9% in 2009, and that among 
TB patients 3.8% were HIV co-infected, although 
most TB patients are not tested for HIV.1,25 In this 
study, HIV testing was performed routinely and 
12/201 (6.9%) TB patients were HIV-positive. 
Great human genetic diversity can be found in 
PNG, and more generally in Melanesia, partly be-
cause of the countries’ topology and the remoteness 
of many communities, particularly in the islands’ in-
teriors.26 Considering that M. tuberculosis appears to 
have co-evolved with human populations for millen-
nia,6 particular or novel M. tuberculosis lineages 
could be expected in PNG. However, in the sample 
set reported here, mainly Lineage 4 and Lineage 2 
were observed. The large proportion of Lineage 4 
M. tuberculosis strains suggests that the appearance 
of TB in PNG may be associated with the arrival of 
Europeans and Australians in the past centuries. 
M. tuberculosis genotypic data from other regions in 
the country would provide useful information to bet-
ter understand the emergence of TB in PNG. It would 
be interesting to see whether the same M. tuberculo-
sis genotypes are found in highland vs. coastal re-
gions of PNG. Human genetic differences between 
these communities were identi! ed by mitochondrial 
DNA analyses, illustrating the more ancient origin of 
highland populations.27 This difference could possi-
bly also be re" ected in the infecting M. tuberculosis 
populations.
Comparing the genetic diversity of M. tuberculosis 
in PNG with observations from surrounding coun-
tries would be highly informative; unfortunately, we 
know of no such data in any other Melanesian coun-
try. Only Gilpin et al. reported the genotypes of MDR 
strains collected in the PNG Western Province.4 Using 
17-locus MIRU-VNTR and insertion sequence (IS) 
6110 restriction fragment length polymorphism, they 
showed that all MDR strains belonged to the Beijing 
genotype. 
The proportion of orphan spoligotypes (11%) also 
revealed that not all the M. tuberculosis genotypes 
observed in the Madang region had been previously 
reported, and it would be interesting to see whether 
these ! ngerprints are observed in other regions of 
PNG, or in countries nearby. 
We observed that 38.5% of Lineage 2 strains (East-
Asian lineage) were resistant to at least one drug, in 
contrast with 9.1% among Lineage 4 strains (Euro-
American lineage). The association of Beijing strains 
with drug resistance has been reported repeatedly.16,28,29 
Table 5 Univariate logistic regression for the risk factors associated with molecularly clustered 
M. tuberculosis strains (n = 162)
Explanatory variable
Non-clustered
(n = 90, 55.6%)
n (%)
Clustered
(n = 72, 44.4%)
n (%)
Associations 
with molecularly 
clustered strains
OR (95%CI) P value
Sex
 Women*
 Men
18 (34.6)
34 (65.4)
26 (52.0)
24 (48.0) 0.5 (0.2–1.1) 0.08
Age, years, median [IQR] 26 [20–30] 26 [21–34] 1.0 [1.0–1.1] 0.42
PNG province of origin
 Madang
 East Sepik
 Other*
21 (43.8)
16 (33.3)
11 (22.9)
22 (57.8)
 8 (21.1)
 8 (21.1)
1.4 (0.5–4.3)
0.7 (0.2–2.4)
0.51
0.56
HIV 
 Negative*
 Positive
44 (95.7)
 2 (4.3)
39 (92.9)
 3 (7.1) 1.7 (0.3–10.7) 0.58
Reported previous TB medication
 No*
 Yes
34 (79.1)
 9 (20.9)
28 (84.9)
 5 (15.1) 0.7 (0.2–2.2) 0.52
Strain lineage
 Lineage 4*
 Lineage 2
42 (82.4)
 9 (17.6)
35 (70.0)
15 (30.0) 2.0 (0.8–5.1) 0.15
* Reference category. 
OR = odds ratio; CI = confidence interval; IQR = interquartile range; PNG = Papua New Guinea; HIV = human 
immunodeficiency virus; TB = tuberculosis.
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Furthermore, Beijing strains were more frequently 
observed in younger patients in Viet Nam;30 however, 
in the present study no age difference was observed.
The potential effect of mixed M. tuberculosis infec-
tions has not often been considered in epidemiologi-
cal studies. Moreover, being able to detect this phe-
nomenon depends on the genotyping methods.31,32 If 
they are not speci! cally sought, mixed M. tuberculo-
sis infections often remain undetected. In this study, 
! ve (2.8%) multiple infections were de! ned on the 
basis of mixed MIRU-VNTR patterns at ⩾2 loci, as 
previously proposed.12 Mixed signals at only one 
MIRU-VNTR locus (3/178 cases) were allowed as 
potential within-host strain diversity. 
Molecular clusters can be used as a proxy to esti-
mate recent M. tuberculosis transmission. In this set-
ting, transmission seemed high, with 44.4% of strains 
in clusters. Although little information is available 
about transmission in surrounding countries, fre-
quent transmission was also observed in Taiwan, 
with 61.6% clustered strains.18 However, the inter-
pretation of M. tuberculosis transmission based on 
molecular clusters should be made with caution. On 
the one hand, transmission may be overestimated, 
given that spoligotyping cannot discriminate varia-
tion among Beijing strains, and that the discrimina-
tion power of 24-locus MIRU-VNTR for Lineage 2 
sub-typing has also been questioned.32 Moreover, po-
tential chains of transmission should ideally be vali-
dated by contact tracing to con! rm true epidemio-
logical links. Such data were not available in our 
study and would be dif! cult to collect retrospectively. 
However, it is possible that transmission was under-
estimated, as only a proportion of TB patients in the 
Madang region were recruited into this study, and 
over a limited time period. Consequently, some geno-
types observed as unique may in fact also have resulted 
from recent transmission, although other patients in-
fected with the same strain were not represented in 
the study population.
In summary, this report provides baseline informa-
tion about M. tuberculosis strains circulating in the 
Madang region of PNG. Despite the limited number 
of patients included, the M. tuberculosis isolates ana-
lysed indicate substantial drug resistance, and suggest 
that TB in this region was at least in part introduced 
by European (lineage 4) and Asian (lineage 2) immi-
grants. Furthermore, the cluster analyses suggest on-
going M. tuberculosis transmission, including trans-
mission of drug-resistant strains. There is an urgent 
need to establish capacity for diagnosing and treating 
drug-resistant TB in PNG.
Acknowledgements
The authors thank all the study participants whose samples were 
used for analyses. They are indebted to the team working at the tu-
berculosis laboratory in Madang, in particular K Millan, B Warigi, 
P Javur, L Luke and H Pangoa, without whom this work could not 
have been performed. They also thank the team of the Mycobacte-
riology Laboratory at the University of Zurich for supporting 
parts of the spoligotyping and providing helpful advice, in particu-
lar E C Böttger, C Ritter and U Friedel. This work was supported 
by the Swiss National Science Foundation (North-South Program, 
grant number IZ70Z0_123988), partially subsidised by a grant 
from the Stanley Thomas Johnson Foundation, and the Medicor 
Foundation, Lichtenstein.
References
 1 World Health Organization. Tuberculosis control in the West-
ern Paci! c Region: 2010 report. Geneva, Switzerland: WHO, 
2011. http://www.wpro.who.int/publications/PUB_97892906 
15224/en/ Accessed April 2012.
 2 Viney K, O’Connor J, Wiegandt A. The epidemiology of tuber-
culosis in Paci! c Island countries and territories: 2000–2007. 
Asia Pac J Public Health 2011; 23: 86–99. 
 3 World Health Organization. Tuberculosis country pro! le: 
Papua New Guinea. Geneva, Switzerland: WHO, 2012. https://
extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_
HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountry
Pro! le&ISO2=PG&outtype=html Accessed April 2012.
 4 Gilpin C M, Simpson G, Vincent S, et al. Evidence of primary 
transmission of multidrug-resistant tuberculosis in the Western 
Province of Papua New Guinea. Med J Aust 2008; 188: 148–
152. 
 5 Simpson G, Coulter C, Weston J, et al. Resistance patterns of 
multidrug-resistant tuberculosis in Western Province, Papua 
New Guinea. Int J Tuberc Lung Dis 2011; 15: 551–552. 
 6 Gagneux S, DeRiemer K, Van T, et al. Variable host-pathogen 
compatibility in Mycobacterium tuberculosis. Proc Natl Acad 
Sci USA 2006; 103: 2869–2873. 
 7 Hershberg R, Lipatov M, Small P M, et al. High functional di-
versity in Mycobacterium tuberculosis driven by genetic drift 
and human demography. PLoS Biol 2008; 6: e311. 
 8 Gagneux S, Small P M. Global phylogeography of Mycobac-
terium tuberculosis and implications for tuberculosis product 
development. Lancet Infect Dis 2007; 7: 328–337. 
 9 Reed M B, Pichler V K, McIntosh F, et al. Major Mycobac-
terium tuberculosis lineages associate with patient country of 
origin. J Clin Microbiol 2009; 47: 1119–1128. 
 10 Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection 
and strain differentiation of Mycobacterium tuberculosis for 
diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907–
914. 
 11 Supply P, Allix C, Lesjean S, et al. Proposal for standardization 
of optimized mycobacterial interspersed repetitive unit-variable-
number tandem repeat typing of Mycobacterium tuberculosis. 
J Clin Microbiol 2006; 44: 4498–4510. 
 12 Allix-Béguec C, Fauville-Dufaux M, Supply P. Three-year 
population-based evaluation of standardized mycobacterial in-
terspersed repetitive unit-variable number tandem repeat typ-
ing of Mycobacterium tuberculosis. J Clin Microbiol 2008; 46: 
1398–1406. 
 13 Oelemann M C, Diel R, Vatin V, et al. Assessment of an op-
timized mycobacterial interspersed repetitive unit-variable-
number tandem repeat typing system combined with spoligo-
typing for population-based molecular epidemiology studies of 
tuberculosis. J Clin Microbiol 2007; 45: 691–697. 
 14 Coscolla M, Gagneux S. Does M. tuberculosis genomic diver-
sity explain disease diversity? Drug Discov Today Dis Mech 
2010; 7: e43–e59. 
 15 Glynn J R, Whiteley J, Bifani P J, Kremer K, van Soolingen D. 
Worldwide occurrence of Beijing/W strains of Mycobacterium 
tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: 
843–849. 
 16 Borrell S, Gagneux S. Infectiousness, reproductive ! tness and 
TB  in  Papua  New  Guinea 1107
evolution of drug-resistant Mycobacterium tuberculosis. Int J 
Tuberc Lung Dis 2009; 13: 1456–1466. 
 17 Petroff S A. A new and rapid method for the isolation and cul-
tivation of tubercle bacilli directly from the sputum and feces. 
J Exp Med 1915; 21: 38–42. 
 18 Comas I, Homolka S, Niemann S, Gagneux S. Genotyping of 
genetically monomorphic bacteria: DNA sequencing in Myco-
bacterium tuberculosis highlights the limitations of current 
methodologies. PLoS ONE 2009; 4: e7815. 
 19 Fenner L, Malla B, Ninet B, et al. “Pseudo-Beijing”: evidence for 
convergent evolution in the direct repeat region of Mycobacte-
rium tuberculosis. PLoS ONE 2011; 6(9): e24737.
 20 Brudey K, Driscoll J R, Rigouts L, et al. Mycobacterium tubercu-
losis complex genetic diversity: mining the fourth international 
spoligotyping database (SpolDB4) for classi! cation, popula-
tion genetics and epidemiology. BMC Microbiol 2006; 6: 23. 
 21 Allix-Béguec C, Harmsen D, Weniger T, Supply P, Niemann S. 
Evaluation and strategy for use of MIRU-VNTRplus, a multi-
functional database for online analysis of genotyping data and 
phylogenetic identi! cation of Mycobacterium tuberculosis 
complex isolates. J Clin Microbiol 2008; 46: 2692–2699. 
 22 Canetti G, Fox W, Khomenko A, Mahler H T, et al. Advances 
in techniques of testing mycobacterial drug sensitivity, and the 
use of sensitivity tests in tuberculosis control programmes. Bull 
World Health Organ 1969; 41: 21–43. 
 23 Kwan C K, Ernst J D. HIV and tuberculosis: a deadly human 
syndemic. Clin Microbiol Rev 2011; 24: 351–376. 
 24 Brites D, Gagneux S. Old and new selective pressures on Myco-
bacterium tuberculosis. Infect Genet Evol 2012; 12: 678–685.
 25 Joint United Nations Programme on HIV/AIDS. UNAIDS re-
port on the global AIDS epidemic, 2010. Geneva, Switzer-
land: WHO, 2008. Geneva, Switzerland: UNAIDS, 2010. http://
www.unaids.org/en/media/unaids/contentassets/documents/
unaidspublication/2010/20101123_globalreport_en.pdf Ac-
cessed April 2012.
 26 Friedlaender J S, Friedlaender F R, Reed F A, et al. The genetic 
structure of Paci! c Islanders. PLoS Genet 2008; 4: e19. 
 27 Stoneking M, Jorde L B, Bhatia K, Wilson A C. Geographic 
variation in human mitochondrial DNA from Papua New 
Guinea. Genetics 1990; 124: 717–733. 
 28 Thwaites G, Caws M, Chau T T H, et al. Relationship between 
Mycobacterium tuberculosis genotype and the clinical phenotype 
of pulmonary and meningeal tuberculosis. J Clin Microbiol 
2008; 46: 1363–1368. 
 29 Parwati I, van Crevel R, van Soolingen D. Possible underlying 
mechanisms for successful emergence of the Mycobacterium 
tuberculosis Beijing genotype strains. Lancet Infect Dis 2010; 
10: 103–111. 
 30 Anh D D, Borgdorff M W, Van L N, et al. Mycobacterium tu-
berculosis Beijing genotype emerging in Vietnam. Emerging 
Infect Dis 2000; 6: 302–305. 
 31 Sergeev R, Colijn C, Cohen T. Models to understand the 
p opulation-level impact of mixed strain M. tuberculosis infec-
tions. J Theor Biol 2011; 280: 88–100. 
 32 Cohen T, Wilson D, Wallengren K, Samuel E Y, Murray M. 
Mixed-strain Mycobacterium tuberculosis infections among 
patients dying in a hospital in KwaZulu-Natal, South Africa. 
J Clin Microbiol 2011; 49: 385–388. 
 33 Hsu A-H, Lin C-B, Lee Y-S, et al. Molecular epidemiology of 
multidrug-resistant Mycobacterium tuberculosis in Eastern Tai-
wan. Int J Tuberc Lung Dis 2010; 14: 924–926. 
TB  in  Papua  New  Guinea i
CONTEXTE  :   Madang et environs, Papouasie, Nouvelle 
Guinée (PNG).
OBJECT I F  :   Caractériser la diversité génétique et la sen-
sibilité aux médicaments d’isolats de Mycobacterium 
tuberculosis collectés à Madang et dans les environs.
SCHÉMA :   M. tuberculosis a été isolé dans des échan-
tillons de crachat venant de cas de tuberculose pulmo-
naire active. Les profils de résistance aux médicaments 
ont été établis par des tests de sensibilité. Les lignées de 
M. tuberculosis ont été identifiées par des polymorphis-
mes nucléotidiques uniques et le sous-typage s’est fait 
par spoligotypage. Le spoligotypage et typage par nom-
bre variable de répétitions en tandem dans les unités ré-
pétitives mycobactériennes sur 24 loci ont été combinés 
pour identifier les isolats en grappe.
RÉSULTATS  :   Les 173 isolats de M. tuberculosis collec-
tés appartenaient principalement à la lignée Euro-
Américaine (Lignée 4) et à la lignée de l’Est-Asiatique 
(Lignée 2). On a observé 5,2% de souches multirési-
stantes. La lignée 2 de M. tuberculosis (qui inclut le gé-
notype Beijing) était en association significative avec 
n’importe quelle résistance aux médicaments (OR 5,2 ; 
IC95% 1,8–15,1). Les analyses de grappes ont montré 
que 44% des isolats étaient en grappes moléculaires, 
ce qui suggère que des souches de M. tuberculosis sont 
transmises dans la communauté, y compris des souches 
avec une résistance primaire.   
CONCLUS ION  :   Ces observations donnent une première 
vision des caractéristiques moléculaires de M. tubercu-
losis dans la région de Madang en PNG et signalent une 
résistance substantielle aux médicaments ainsi que l’exi-
stence de transmission.
MARCO DE  REFERENC IA :   La zona metropolitana de 
Madang en Papúa Nueva Guinea (PNG).
OBJET IVO :   Caracterizar la diversidad genética y la sen-
sibilidad a los medicamentos de los aislados clínicos de 
Mycobacterium tuberculosis recogidos en Madang y 
sus alrededores.
MÉTODO:   Las cepas de M. tuberculosis se aislaron de 
muestras de esputo de pacientes con tuberculosis pul-
monar activa. Se obtuvieron los perfiles de farmacorre-
sistencia mediante pruebas de sensibilidad. Se determi-
naron los linajes de M. tuberculosis estudiando los 
polimorfismos de nucleótido sencillo y se estableció la 
subtipificación con la técnica del espoligotipado (geno-
tipificación con secuencias que reconocen las secuencias 
espaciadoras de la región de repetidos directos). Se de-
tectaron además los aislados agrupados en conglomera-
dos mediante el espoligotipado y la genotipificación con 
marcadores para 24 locus de secuencias micobacteria-
nas intercaladas repetidas.
RESULTADOS :   Los 173 aislados de M. tuberculosis reco-
gidos pertenecían en su mayoría al linaje euroamericano 
(linaje 4) y al asiático oriental (linaje 2). Se observaron 
cepas multidrogorresistentes en 5,2% de los aislados. El 
linaje 2 de M. tuberculosis (que comprende el genotipo 
‘Beijing’) se asoció de manera significativa con la presen-
cia de algún tipo de farmacorresistencia (OR 5,2; IC95% 
1,8–15,1). El análisis molecular puso de manifiesto la 
agrupación en conglomerados de 44% de los aislados, 
lo cual es indicativo de una transmisión activa en la co-
munidad, incluida la transmisión de cepas de M. tuber-
culosis portadoras de farmacorresistencia primaria.
CONCLUS IÓN :   Estos resultados ofrecen un primer aná-
lisis de las características moleculares de las cepas de 
M. tuberculosis de la zona metropolitana de Madang en 
PNG y sugieren un índice considerable de resistencia a 
los medicamentos, con datos indicativos de transmisión 
activa.
R É S U M É
R E S U M E N
